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ABSTRACT	
The recent announcement of the first successful Phase III clinical trial of a RNA 
interference (RNAi)-based therapeutic is a major achievement in the field. Synthetic 
RNAi therapeutic oligonucleotides are either first cleaved by Dicer or incorporate 
directly into the Argonaute-2 RNA-induced silencing complex (AGO2-RISC) and 
directs the protein complex to homologous RNA. Cleavage of target RNA occurs 
opposite bases 10-11 when counting from the 5’ end of the hybridized siRNA guide 
strand. The capture and identification of these cleaved products by 5’ Rapid 
Amplification of cDNA Ends and Sanger sequencing remains the gold standard for 
confirming Argonaute-2 mediated RNAi cleavage.  
 
Next Generation Sequencing of 5’ RACE has brought new insights into the biological 
activity of RNAi-based oligonucleotides. This work currently represents the largest 
undertaking using RACE-Seq to investigate AGO2-RISC-mediated activity. RACE-
Seq reported the expected RISC-cleaved product for each of the oligonucleotides 
investigated. Additionally, RACE-Seq analysis revealed that some of the 
oligonucleotides could be processed into multiple active siRNA molecules. Analysis 
of the activity of a Dicer substrate siRNA targeting transthyretin revealed that this 
molecule by-passed Dicer processing but still induced RNAi activity. In examining 
RACE-Seq peak profiles, an on-target mechanism of action (MOA) for up to four 
active siRNA derived from siRNA19 is proposed. The shRNA19 RACE-Seq assay 
predicted that this hairpin molecule probably exists as two distinct forms, one with a 
7-nucleotide loop and the other with a 5-nucleotide loop.  
 
The project also focused on optimising the library preparation, data filtering and data 
presentation for RACE-Seq. A simplified, low computation data analysis pipeline was 
designed and used to align the filtered dataset to a reference sequence and to count 
the 5’ ends. RACE-Seq is presented as a suitable solution for investigating, 
discriminating and quantifying specific RNA cleavage events and visualizing 
evidence for an on-target MOA of RNAi based oligonucleotide therapeutics.  
 
 
 
 
 
 
	 II	
ACKNOWLEDGEMENTS	
This PhD has been a truly fantastic experience and it would not have been possible 
without the support and guidance that I have received from many people.  
 
I would like to thank my supervisory team. To Dr John Murphy, for taking the helm 
and getting me through the final year of my PhD. Your continuous support, help and 
advice has been invaluable. To Dr Anatoliy Markiv, for your insightful nuggets which 
steered me on a straighter path.  
 
Thank you to Dr Sterghios Moschos, for the opportunity to undertake this PhD 
project, for your support and care. I am also grateful to Dr Nadége Presneau for her 
support, encouragement and helpful discussions.  
 
A very special thank you to Dr Pamela Greenwell, for her tireless support and 
encouragement, and for the many helpful discussions and advise in molecular biology 
and qPCR, and for sharing her wisdom and time. I would also like to thank Karima 
Brimah for her friendship, continued support and assistance both pre-PhD and over 
the last four years.  
 
I gratefully acknowledge the funding received for my PhD from University of 
Westminster PhD scholarship programme.  
 
To my PhD cohort and office colleagues, both past and present, thank you for being 
on this journey with me. Thanks for the cake and other treats, the cheery hellos, fist-
bumps and chats in the corridors, you really have been an immense support. To Jolene, 
Faye, Emma, Kavit, Brad, Artun, and Nasrin thanks for being there. 
 
To my two other musketeers, Hima and Moyin, thank you for your continued support 
and encouragement, for the hot chocolate breaks, the late-night dinners and the just 
checking-on-you-texts. I couldn’t have stayed sane without you.  
 
To my nephews, Corban and Lazarus, thank you for putting up with my continued 
absence. To my dear friends Jane and Quinton, and to Ravelle, Kewan and Cayden, 
thank you for being my second family and for holding me in your heart and for feeding 
me!   
 
And finally, to my mother. Thank you for being such a fantastic inspiration and for 
your unconditional love and support.  
 
 
	 III	
 
 
 
 
 
Declaration  
 
 
 
 
I declare that all the material presented in this thesis, is wholly my own work, unless 
otherwise referenced or acknowledged. The document has not been submitted for 
qualifications at any other academic institution.  
 
 
Louise Usher 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 IV	
PUBLICATIONS	
 
Moschos, Sterghios A., Louise Usher, and Mark A. Lindsay. "Clinical potential of 
oligonucleotide-based therapeutics in the respiratory system." Pharmacology & 
therapeutics 169 (2017): 83-103. 
 
Theotokis, Pantazis I., Louise Usher, Christopher K. Kortschak, Ed Schwalbe, and 
Sterghios A. Moschos. "Profiling the Mismatch Tolerance of Argonaute 2 through 
Deep Sequencing of Sliced Polymorphic Viral RNAs." Molecular Therapy-Nucleic 
Acids 9 (2017): 22-33. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 V	
ACKNOWLEDGEMENT	OF	
CONTRIBUTION	
 
I would like to acknowledge the contributions made to my PhD by Chris Kortschak 
and Pantazis Theotokis. Chris coded and developed the first RACE-Seq analysis 
programme that I initially used to analyse my data. Pantazis coded and built the final 
pipeline (RACE-SEQ-lite) that I eventually used to analyze my data. Thank you both 
for putting up with my repeated queries on using the pipelines. I’d also like to thank 
Damjan Temelkovski for installing the Linux packages.   
 
  
	 VI	
TABLE	OF	CONTENTS	
Abstract	................................................................................................................	I	
Acknowledgements	..............................................................................................	II	
Publications	.........................................................................................................	IV	
Acknowledgement	of	contribution	.......................................................................	V	
Table	of	contents	.................................................................................................	VI	
List	of	Tables	.......................................................................................................	XI	
List	of	Figures	.....................................................................................................	XII	
Abbreviations	....................................................................................................	XV	
1	 Introduction	..................................................................................................	1	
1.1	 RNA	interference:	Biology	and	mechanism	of	action	.......................................	1	
1.1.1	 Dicer:	structure	and	function	implications	for	siRNA	.......................................	5	
1.1.2	 Human	Argonaute	2:	Structure	and	function	...................................................	6	
1.2	 Targeting	disease:	RNAi	therapeutics	in	the	clinic	...........................................	9	
1.2.1	 Hepatitis	Virus	C:	Disease	and	molecular	biology	...........................................	10	
1.2.2	 HCV	as	a	target	and	modulator	of	RNAi.	........................................................	11	
1.2.3	 TT-034,	a	DNA-directed	RNAi	therapeutic	......................................................	12	
1.2.4	 HCV	replicon	reporter	cell	lines	......................................................................	14	
1.3	 Assays	confirming	RNAi	activity	....................................................................	14	
1.3.1	 Assays	for	direct	confirmation	of	RNAi	activity	..............................................	15	
1.3.2	 Confirmation	of	RISC	cleavage	using	RACE-Seq	..............................................	17	
1.4	 Next	Generation	Sequencing:	Ion	Torrent	PGM	.............................................	18	
1.4.1	 NGS	sample	preparation	and	emulsion	PCR	for	Ion	Torrent	Sequencing	.......	19	
1.4.2	 Ion	Torrent	semiconductor	sequencing	technology	.......................................	24	
1.4.3	 On-system	data	processing	and	analysis	........................................................	25	
1.5	 A	brief	overview	of	Illumina	Sequencing	Technology	.....................................	25	
1.6	 Aims	of	the	project	.......................................................................................	28	
1.7	 Work	presented	in	this	thesis	........................................................................	28	
	 VII	
2	 Methods	and	Materials	...............................................................................	29	
2.1	 RNAi-based	bioactive	oligonucleotides	.........................................................	29	
2.2	 Rational	design	of	a	siRNA	targeting	Transthyretin	........................................	29	
2.3	 Design	and	synthesis	of	a	Dicer	Substrate	siRNA	targeting	Transthyretin	......	31	
2.4	 Primer	design	................................................................................................	32	
2.5	 Cell	culture	and	Bioassays	.............................................................................	33	
2.5.1	 Routine	cell	maintenance	...............................................................................	33	
2.5.2	 Cell	revival	and	plating	....................................................................................	34	
2.5.3	 Cell	counting	...................................................................................................	34	
2.5.4	 Cell	storage	.....................................................................................................	35	
2.6	 RNAi	knockdown	assays	................................................................................	35	
2.6.1	 Dose	response	assays	.....................................................................................	35	
2.6.2	 Knockdown	of	HCV	replicon	for	collection	of	RNA	for	RACE-Seq	...................	37	
2.6.3	 Knockdown	of	Transthyretin	for	collection	of	RNA	for	RACE-Seq	..................	37	
2.6.4	 Cell	viability	assay	...........................................................................................	38	
2.6.5	 Luciferase	reporter	assay	................................................................................	38	
2.6.6	 Generating	cDNA	templates	for	qPCR	............................................................	39	
2.6.7	 Validation	of	primer	amplification	efficiency	.................................................	40	
2.6.8	 Relative	gene	expression	by	the	2-∆∆CT	Method	..............................................	40	
2.7	 RNA	extraction	and	purification	....................................................................	41	
2.7.1	 Collection	of	cells	from	96	well	plates	............................................................	41	
2.7.2	 RNA	extraction	using	the	PureLinK	RNA	Extraction	Kit	...................................	41	
2.7.3	 Extraction	of	RNA	by	TRIzol®	method	.............................................................	41	
2.8	 Assessment	of	nucleic	acids	..........................................................................	43	
2.8.1	 NanoDrop	quantification	(DNA	and	RNA)	......................................................	43	
2.8.2	 Qubit	quantification	.......................................................................................	43	
2.9	 RNA	Ligase-Mediated	Rapid	Amplification	of	cDNA	Ends	(RLM	RACE)	...........	43	
2.9.1	 PCR	amplification	............................................................................................	45	
2.9.2	 Agarose	gel	electrophoresis	...........................................................................	45	
2.9.3	 Gel	extraction	.................................................................................................	46	
2.10	 Ion	PGM	library	preparation	.........................................................................	46	
2.10.1	 AMPure	bead	clean	(amplicons	>100	bp)	..................................................	46	
2.10.2	 AxyPrep	Mag	PCR	clean	(amplicons	<100	bp)	............................................	46	
	 VIII	
2.10.3	 5’	RACE	library	preparation	using	NEBNext	Library	Prep	Set	.....................	47	
2.10.4	 Library	size	selection	using	the	Labchip	XT	instrument	..............................	47	
2.10.5	 Library	size	selection	using	the	Size	Select	2%	E-gel	system	......................	48	
2.10.6	 Gel	extraction	and	purification	of	NGS	libraries	.........................................	48	
2.10.7	 DNA	fragment	analysis	...............................................................................	49	
2.11	 Preparation	and	sequencing	of	NGS	samples	.................................................	49	
2.11.1	 Emulsion	PCR	and	enrichment	...................................................................	49	
2.11.2	 Quality	assessment	of	templated	ISP	.........................................................	50	
2.11.3	 Preparation	of	sequencing	reaction	and	chip	loading	................................	51	
2.12	 RACE-Seq	data	analysis	.................................................................................	51	
2.12.1	 Filtering	of	RACE-Seq	datasets	...................................................................	52	
2.12.2	 Data	presentation	......................................................................................	55	
2.12.3	 Generating	hybridization	images	for	RNAi	bioactives	................................	55	
2.12.4	 Analysis	of	unaligned	data	..........................................................................	55	
3	 Transitioning	RACE-Seq	to	the	Ion	Torrent	PGM	..........................................	56	
3.1	 Introduction	..................................................................................................	56	
3.2	 Results	..........................................................................................................	60	
3.2.1	 Growth	and	cell	morphology	of	Huh7/con1b	cells	in	culture	.........................	60	
3.2.2	 Validation	of	lower	detection	limit	for	luciferase	reporter	cell	line	...............	62	
3.2.3	 Potent	RNAi	by	siRNA22	and	shRNA22	...........................................................	63	
3.2.4	 RNA	extraction,	5’	RLM	RACE	assays	and	NGS	library	preparation	................	66	
3.2.5	 Size	selection	as	a	critical	component	of	library	preparation	.........................	72	
3.2.6	 RACE-Seq	data	analysis	...................................................................................	74	
3.2.7	 Interpretation	of	RACE-Seq	peak	profiles	.......................................................	77	
3.2.8	 Analysis	of	unaligned	data	..............................................................................	77	
3.3	 Discussion	.....................................................................................................	80	
4	 An	improved	method	for	preparing	RACE-Seq	libraries	...............................	83	
4.1	 Introduction	..................................................................................................	83	
4.2	 Results	..........................................................................................................	87	
4.2.1	 RNAi	activity	assays	........................................................................................	87	
4.2.2	 Long	amplicon	RACE-Seq	................................................................................	90	
4.2.3	 Multiplex	sequencing	on	the	Ion	Torrent	PGM	............................................	100	
	 IX	
4.3	 Discussion	...................................................................................................	103	
5	 RACE-Seq	predicts	the	mature	siRNA	sequence	processed	from	Dicer.	......	106	
5.1	 Introduction	................................................................................................	106	
5.2	 Results	........................................................................................................	108	
5.2.1	 Primer	efficiency	validation	..........................................................................	108	
5.2.2	 Targeted	knockdown	of	TTR	mRNA	expression	in	Huh7/con1b	cells	...........	112	
5.2.3	 Validation	of	RACE-Seq	libraries	by	fragment	analysis	.................................	112	
5.2.4	 RACE-Seq	data	analysis	.................................................................................	116	
5.2.5	 RACE-Seq	confirms	the	expected	cleavage	product	for	siRNA-TTR	..............	119	
5.2.6	 RACE-Seq	identifies	the	sequence	of	the	active	guide	strand	processed	out	of	
Dicer	for	DsiRNA-TTR	.................................................................................................	119	
5.2.7	 RACE-Seq	predicts	that	the	unprocessed	DsiRNA-TTR	is	itself	a	substrate	for	
AGO2-RISC	.................................................................................................................	120	
5.3	 Discussion	...................................................................................................	123	
6	 RACE-Seq	reports	the	active	siRNA	sequence	............................................	126	
6.1	 Introduction	................................................................................................	126	
6.2	 Results	........................................................................................................	126	
6.2.1	 Data	output	per	sample	and	read	depth	......................................................	126	
6.2.2	 RACE-Seq	confirms	the	expected	cleavage	site	for	siRNA22	........................	129	
6.2.3	 RACE-Seq	confirms	the	expected	cleavage	site	for	shRNA22	.......................	131	
6.2.4	 RACE-Seq	confirms	the	expected	cleavage	site	for	siRNA6	and	identifies	the	
trigger	guide	strand	sequence	after	Dicer	cleavage	of	shRNA6	................................	131	
6.2.5	 RACE-Seq	reports	two	active	siRNAs	processed	from	shRNA19	...................	139	
6.2.6	 RACE-Seq	reports	multiple	active	siRNA	species	from	siRNA19	...................	140	
6.3	 Discussion	...................................................................................................	145	
7	 Additional	findings	from	RACE-Seq	assays	and	RACE-Seq	data	analysis	.....	148	
7.1	 Introduction	................................................................................................	148	
7.2	 Results	........................................................................................................	149	
7.2.1	 RLM	RACE	assays	for	non-target	control	samples	........................................	149	
7.2.2	 Read	quality	analysis	of	adapter+20-nt	filtered	datasets	.............................	150	
7.2.3	 Analysis	and	insights	from	failed	TTR	RACE-Seq	datasets	............................	157	
7.3	 Discussion	...................................................................................................	161	
	 X	
8	 Conclusions	and	Future	work	....................................................................	163	
References	.......................................................................................................	166	
 
 
 
 
  
	 XI	
LIST	OF	TABLES		
Table 2.1   Bioactive oligonucleotides targeting against HCV replicon genome ..... 29	
Table 2.2   GeneRacer RNA adapter sequence ......................................................... 32	
Table 2.3   RACE-Seq primers used in this thesis .................................................... 33	
Table 2.4   Command line code used for filtering RACE-Seq datasets .................... 54	
Table 2.5   Command line code for adapter+20-nt filtering of RACE-Seq data ...... 54	
Table 3.1 Nucleic acid quantification at different stages of RACE-Seq sample 
preparation. ....................................................................................................... 68	
Table 3.2   RACE-Seq data analysis for siRNA22 and shRNA22 (legacy assays) .. 76	
Table 4.1   Concentration of RNAi analogue vs luciferase knockdown achieved. .. 90	
Table 4.2   Assessment of RNA for 5' RML-RACE ................................................. 93	
Table 4.3   Quantification of DNA input to RACE-Seq library preparation ............ 94	
Table 4.5   Ion Torrent PGM data output for RACE-Seq samples ......................... 102	
Table 5.1   Reporting of amplification efficiency for TTR and GAPDH ............... 109	
Table 5.2   Nucleic acid quantification for 5’RML-RACE and RACE-Seq ........... 114	
Table 5.3   RACE-Seq read analysis using filtering to retain long length reads .... 117	
Table 5.4   Read analysis for RACE-Seq siRNA-TTR and DsiRNA-TTR ............ 118	
Table 5.5   Table indicating the percent aligned reads for siRNA-TTR and DsiRNA-
TTR from RACE-Seq assays .......................................................................... 122	
Table 6.1   Read statistics for siRNA6, siRNA19 and siRNA22. ........................... 128	
Table 6.2   Read statistics for shRNA6, shRNA19 and shRNA22. ........................ 129	
Table 6.3   Percent aligned reads for siRNA22 and shRNA22 RACE-Seq assays 133	
Table 6.4   Percent aligned reads for siRNA6 and shRNA6 RACE-Seq assays .... 134	
Table 6.5   Percent aligned reads for siRNA19 and shRNA19 RACE-Seq assays 135	
Table 7.1   RACE-Seq read analysis of failed TTR sample ................................... 159	
Table 7.2 Table indicating the percentage of aligned reads for siRNA-TTR and 
DsiRNA-TTR failed RACE-Seq samples. ...................................................... 160	
 
 
	 XII	
LIST	OF	FIGURES		
Figure 1.1    MicroRNA processing and RNA interference in mammals. .................. 4	
Figure 1.2   Elucidation of Dicer architecture. ............................................................ 8	
Figure 1.3   Schematic of siRNA guide strand hybridization and target cleavage. .... 9	
Figure 1.4  Diagrammatic representation of a DNA-directed RNAi-based drug 
TT-034 that targets three positions of the HCV genome. ................................. 13	
Figure 1.5   Schematic illustration of HCV I389/NS3-3’/LucUbineo-ET subgenomic 
replicon. ............................................................................................................ 13	
Figure 1.6   Diagram of RNA ligase-mediated Rapid Amplification of cDNA Ends 
(RLM RACE) vs molecular probe detection of 5’ RACE products. ................ 17	
Figure 1.7 Workflow of library preparation for the Ion Torrent Sequencing 
Technology. ...................................................................................................... 22	
Figure 1.8  Illustration of Emulsion PCR reaction utilised in Ion Torrent library 
preparation. ....................................................................................................... 23	
Figure 1.9  Illustration of the Ion Torrent Semiconductor chip based sequencing 
technology. ........................................................................................................ 24	
Figure 1.10  Outline of Illumina sequencing process. .............................................. 27	
Figure 2.1   Criteria for selection of siRNA-TTR. .................................................... 31	
Figure 3.1   Schematic representation of the Legacy RACE-Seq assay. .................. 59	
Figure 3.2  Morphology of Huh7/con1b cells maintaining an HCV replicon under 
G418 selection. ................................................................................................. 61	
Figure 3.3 Luminescent signal (RLUs) vs fold dilution across a dynamic range 
spanning 5-folds of magnitude. ......................................................................... 62	
Figure 3.4   Potency of siRNA22 and shRNA22 in the Huh7/Con1b cell line. ........ 64	
Figure 3.5   Suppressive activity of RNAi analogues. .............................................. 65	
Figure 3.6   5’ RACE-PCR analysis on 3% agarose gel. .......................................... 68	
Figure 3.7  Failed library preparation using Platinum Taq Polymerase and Ion Plus 
Fragment Library Preparation kit. ..................................................................... 69	
Figure 3.8  Full outline of RACE-Seq library preparation, sequencing and data 
analysis workflow. ............................................................................................ 70	
	 XIII	
Figure 3.9   Successful RACE-Seq library preparation using Q5 DNA polymerase 
PCR mix and the NEBNext Library Prep Set for Ion Torrent. ......................... 71	
Figure 3.10   Impact of LabChip size selection on isolation of desired fragment size 
for RACE-Seq library preparation. ................................................................... 73	
Figure 3.11   Illustration to indicate how the RNA adapter sequence is output in both 
the forward and reverse complement directions. .............................................. 74	
Figure 3.12   Ion Torrent PGM summary of data for legacy RACE-Seq assays. ..... 76	
Figure 3.13 Novel 5’ ends identified by RACE-Seq legacy assay on Ion Torrent   
PGM. ................................................................................................................. 78	
Figure 3.14  Analysis of unaligned reads for siRNA22 RACE-Seq and shRNA22. 79	
Figure 4.1    Illustration of long amplicon RLM RACE assay. ................................ 85	
Figure 4.2   Work flow of RACE-Seq assay for time point 1 and time point 2. ....... 86	
Figure 4.3 Dose response analysis for siRNA6 vs shRNA6 and siRNA19 vs 
shRNA19. ......................................................................................................... 88	
Figure 4.4   Viability assay for RACE-Seq knockdown experiments. ..................... 89	
Figure 4.5   Agarose gel analysis of all RLM RACE samples. ................................ 95	
Figure 4.6   Fragment analysis for siRNA22 and shRNA22 RACE-Seq samples. .. 97	
Figure 4.7   Fragment analysis for siRNA6 and shRNA6 RACE-Seq samples. ...... 98	
Figure 4.8   Fragment analysis for siRNA19 and shRNA19 RACE-Seq samples. .. 99	
Figure 4.9   ISP density map for Ion Torrent PGM sequencing chips. ................... 101	
Figure 5.1   Determining amplification efficiency by calibration curve analysis. .. 110	
Figure 5.2   Melt curve analysis of PCR efficiency reaction. ................................. 111	
Figure 5.3  Relative TTR mRNA levels after siRNA-TTR treatment and DsiRNA-
TTR treatment in a hepatocellular cell line, stably expressing HCV replicon 
RNA. ............................................................................................................... 112	
Figure 5.4   Visualisation of 5’RML-RACE amplicons and RACE-Seq libraries post 
E-gel size selection. ........................................................................................ 115	
Figure 5.5  Data analysis strategy for filtering RACE-Seq datasets to generate the 
adapter+20-nucleotide short filtered datasets. ................................................ 118	
Figure 5.6   RACE-Seq result for siRNA-TTR. ...................................................... 121	
Figure 5.7   RACE-Seq identifies the siRNA guide strand of DsiRNA-TTR ........ 121	
	 XIV	
Figure 6.1   RACE-Seq detection of 5' end peaks for siRNA-mediated cleavage of 
HCV replicon RNA presented as percentage of total aligned reads. .............. 137	
Figure 6.2  Illustration of duplex siRNA Illustration of predicted and RACE-Seq 
observed cleavage positions for three siRNAs targeting the sense strand of HCV 
replicon genome. ............................................................................................. 138	
Figure 6.3  RACE-Seq detection of 5' end peaks for siRNA-mediated cleavage of 
HCV replicon RNA presented as percentage of total aligned reads. .............. 143	
Figure 6.4   Illustration of shRNAs and RACE-Seq observed cleavage positions. 144	
Figure 7.1   RACE-Seq library preparation for non-transfected control samples. . 150	
 Figure 7.2  FASTQC analysis of RACE-Seq samples for site 22 samples for siRNA22 
and shRNA22 samples .................................................................................... 153	
Figure 7.3   Per base quality plot for two different read lengths for RACE-Seq sample 
siRNA22(2). .................................................................................................... 154	
Figure 7.4   FASTQC analysis of RACE-Seq samples for site 6 samples for siRNA6 
and shRNA6 samples. ..................................................................................... 155	
Figure 7.5   FASTQC analysis of RACE-Seq samples for site 19 samples for siRNA19 
and shRNA19 samples. ................................................................................... 157	
Figure 7.6   Analysis of failed TTR RACE-Seq sample ......................................... 159	
 
 
 
 
 
 
 
 
 
 
 
 
	 XV	
ABBREVIATIONS	
3'  3 prime 
5'  5 prime 
AAV8  adeno-associated virus serotype  
AGO2  Argonaute2 
ATP  Adenosine Tri-phosphate 
bp  base pair 
cDNA  complementary DNA 
DMEM  Dulbecco's Modified Eagles Medium 
DMSO  Dimethyl Sulfoxide 
DNA  Deoxyribonucleic acid 
DNase I  Deoxyribonuclease I 
dNTP  deoxyribonucleotide triphosphate 
DsiRNA  Dicer substrate small interfering RNA 
dsRNA  double-stranded RNA 
EMCV  encephalomycarditis virus  
Exo I  Exonuclease 1 
FBS  Foetal Bovine Serum 
FDA  The Food and Drug Administration 
fLuc  firefly luciferase gene 
GAPDH  Glyceraldehyde 3-phosphate dehydrogenase 
H+  hydrogen ion 
HCV   Hepatic C virus 
	 XVI	
IRES  internal ribosome entry site  
ISP  Ion Sphere Particle 
M-MuLV  Moloney Murine leukemia Virus  
miRNA  microRNA 
MRE  microRNA recognition elements 
MTT  3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
Na  Sodium  
Neo  Neomycin 
NGS  Next Generation Sequencing 
nM  nanomolar 
NS  Non-structural 
NSO  non-specific oligonucleotide 
nt  nucleotide 
OH-  hydroxide ion 
OT2  OneTouch2 
P-bodies   Processing Bodies 
PARE  Parallel analysis of RNA ends 
PAZ  Piwi/Argonaute/Zwille domain 
PKC  Protein kinase C mRNA 
pM  picomolar 
pre-miRNA  precursor microRNA (60-70 bp hairpin structures) 
pri-miRNA  primary microRNA; clustered hairpin structures transcribed from  
intronic regions 
Q-RT-PCR  Quantitative real time PCR 
	 XVII	
RACE  Rapid Amplification of cDNA Ends 
RACE-Seq  Rapid Amplification of cDNA Ends and Next Generation Sequencing 
RISC  RNA-induced silencing complex 
RACE  RNA ligase mediated Rapid Amplification of cDNA Ends 
RNAi  RNA interference 
RNase  Ribonuclease 
rSAP  Shrimp Alkaline Phosphatase 
rt-qPCR  reverse transcription quantitative polymerase chain reaction  
shRNA  short hairpin RNA 
siRNA  small interfering RNA 
SSIV III  SuperScript III 
TBE buffer  Tris/Borate/EDTA buffer 
TTR  Transthyretin 
UTR  untranslated region  
µl  microlitre 
µM  micromolar 
	
1	
_ 	INTRODUCTION	
1.1 RNA	interference:	Biology	and	mechanism	of	
action	
Almost 20 years has passed since Fire and Mello published their seminal paper 
confirming double-stranded RNA (dsRNA) as a trigger for specific gene silencing. 
By injecting combinations of both sense and anti-sense RNA fragments of the unc-22 
gene into Caenorhabditis elegans, they concluded that dsRNA fragments resulted in 
more potent interference compared to when sense or antisense RNA strands were 
injected separately. By applying the method to numerous genes and observing 
phenotype alteration, they confirmed that interference was directed to a specific 
target. Further, they linked dsRNA-mediated interference to a reduction of target 
mRNA and showed both systemic and germline activity (Fire et al., 1998). This work 
dismissed a previous observation that single-stranded RNA resulted in gene silencing 
in C. elegans (Guo et al., 1995). The work led to significant insights of dsRNAs as 
triggers for post-transcriptional gene silencing in plants (Hamilton and Baulcombe, 
1999; Chuang and Meyerowitz, 2000; Schweizer et al., 2000). RNAi was soon 
identified as an innate gene silencing mechanism of plants, insects, worms, fungi and 
eukaryotes and soon evolved as the tool of choice for studying gene functions. With 
its potential as a novel therapeutic strategy, it led to the burgeoning new field of RNA 
therapeutics.   
 
In mammals, suppression of gene expression via small dsRNAs (19-22 bp), termed 
microRNAs (miRNAs), is well characterised (Figure 1.1). The sequences encoding 
miRNAs are located in diverse regions throughout the genome, with nearly half of all 
identified miRNAs originating within introns of protein coding genes (Lee et al., 
2004; Kim et al., 2012). These miRNA precursor sequences occur singly or in clusters 
of up to 6 miRNA precursors, although some larger clusters have also been identified. 
The clusters may be arranged as homo-seed clusters (miRNAs with identical ‘seed’ 
sequences), hetero-seed clusters (miRNA with distinct ‘seed’ sequences) or a mix of 
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both (Wang et al., 2016). The miRNA precursors are transcribed primarily by RNA 
polymerase II (Lee et al., 2004; Cai et al., 2004; Saini et al., 2007) which is the 
catalytic complex responsible for transcription of DNA to mRNA, but miRNA 
precursors have also been identified within regions of RNA polymerase III 
transcription activity (Borchert et al., 2006; Gu et al., 2009). Thus, biogenesis of  
miRNA begins in the nucleus with the transcription of long, primary miRNA (pri-
miRNA) that fold back in single or clustered hairpin structures with imperfect pairing 
(Lee et al., 2004). The top part of the hairpin structures are then excised from the pri-
miRNA by the enzyme Drosha, together with its co-factor DGCR8 (also known as 
Pasha) to produce the 60-70 nucleotide precursor miRNAs (pre-miRNAs) (Zeng and 
Cullen, 2003; Cai et al., 2004) having distinct 2 nt, 3’ end overhangs (Lund and 
Dahlberg, 2006; Helvik et al., 2007). This processing of intronic miRNAs occurs in 
unison with mRNA exon processing (Melamed et al., 2013; Ramalingam et al., 2014). 
In cases where miRNA location overlaps an exon region, miRNA processing 
competes with mRNA splicing factors (Melamed et al., 2013).  
 
Exportin-5 next transports the pre-miRNAs to the cytoplasm to be further processed 
by Dicer, an RNase III enzyme. Human Dicer recognises the 5’ end and/or the 2-nt 3’ 
overhang of pre-miRNAs or dsRNA and cleaves ~22 nt into the stem generating 
mature miRNAs (Park et al., 2011; Feng et al., 2012).  In humans, miRNAs may then 
then be loaded to any one of the four members of the Argonaute (AGO) protein family 
in association with other proteins, forming the RNA-induced silencing complex 
(RISC). The passenger strand of the duplex miRNA is released and degraded, 
inducing an active RISC that is guided to target mRNA by sequence homology 
between the miRNA guide strand and the target mRNA (Elbashir et al., 2001; Cai et 
al., 2009). In humans, miRNAs associate with AGO1, AGO2, AGO3 and AGO4. 
While AGO2 is able to cleave target RNA, AGO1, AGO3 and AGO4 do not have this 
endonuclease catalytic activity. MiRNAs generally form imperfect pairing between 
the guide strand and target mRNA and result in a RISC that blocks the translational 
machinery, thus driving gene silencing. The minimal requirement for sequence 
recognition between a miRNA and mRNA target is defined as the ‘seed’ and is the 2-
8 nucleotides counted from the 5’ end of the miRNA guide strand (Lewis et al., 2005). 
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‘Seed’ sequences, as well as their targets which contain the microRNA recognition 
elements (MRE) are conserved across species. In animals, extensive complementarity 
between target mRNA and miRNA is rare, thus a single miRNA may target hundreds 
of RNA transcripts. On the other hand, RISC-mediated endonucleolytic target 
cleavage requires extensive complementarity between the guide stand and target and 
is only mediated by AGO2. Endogenous derived small interfering RNA (endo-
siRNA) with perfect pairing to mRNA targets are synthesised from double-stranded 
endogenous RNAs and incorporate into AGO2 RISC and result in target cleavage 
(Stein et al., 2015). Additionally, exogenously introduced dsRNA designed to have 
high complementarity to an mRNA target can enter the RNAi pathway at either the 
Dicer stage (where it is processed to siRNA) or can associate directly with AGO2, 
generating active RISC and results in cleavage of its target (Tuschl et al., 1999).  
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Figure 1.1    MicroRNA processing and RNA interference in mammals. 
Primary miRNAs (pri-miRNA) are transcribed in the nucleus and cleaved to 
short 60-70 nucleotide primary miRNA hairpins (1), transported to the 
cytoplasm where they are recognised by Dicer (2) and processed to 19-22 bp 
RNA duplex with characteristic 2-nucleotide 3’ overhangs. Dicer processed 
miRNA or synthetic siRNA incorporate into the RNA induced silencing 
complex (RISC) where the passenger strand is released and the guide strand 
directs RISC to target RNA resulting in either blocking of the translation 
machinery (4) or Argonaute 2-mediated cleavage of target RNA (5). (Adapted 
from Heidersbach et al., 2006) 
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1.1.1 Dicer:	structure	and	function	implications	for	siRNA	
Dicer is a critical component of the RNAi pathway and is a large (220-kDa), multi-
domain, RNase III enzyme. The domains of human Dicer include; the 
Piwi/Argonaute/Zwille (PAZ) domain, a dsRNA binding domain, the helicase domain 
(so named for homology rather than function) and two RNase III-like domains (Figure 
1.2 A and B). The PAZ domain recognises the characteristic 2-nt overhang on the 3’ 
end of RNAi intermediates (Park et al., 2011; Liu et al., 2015), docking and securing 
the duplex RNA. The stem region of the dsRNA molecule is then metered out by the 
distance between the PAZ domain and the RNase III domain, which measures 65 
angstrom, the length of 25 base pairs of RNA (MacRae, 2006) (Figure 1.2 C). The 
dsRNA binding domain and platform region also contribute to substrate recognition. 
The RNase III-like domains form an intramolecular dimer to create a single active 
catalytic site responsible for cleavage of RNA (Lau et al., 2012; Ma et al., 2012). 
Further evidence suggests that internal bulge/loop structures and the terminal loop of 
hairpin RNAs may be sensed differently by the helicase domain (Soifer et al., 2008; 
Gu et al., 2012). The mechanisms for Dicer recognition and processing of substrates 
has been intensely investigated with cell-based experiments identifying that Dicer 
processes plasmid expressed shRNAs into different biologically active siRNAs, 
(Flores-Jasso et al., 2009; Gu et al., 2012; Snead et al., 2013; Denise et al., 2014) 
which has the potential to affect their functional efficacy and increases the potential 
for off-target effects. For example, using northern blotting, Gu et al. (2012) showed 
that in Pol III transcription of sh-miR30 from a plasmid vector, containing a passenger 
strand at the 5’ arm, a 9-nt loop and a 3’ guide strand arm, multiple siRNA products 
of varying length for both the passenger strand and the guide strand were processed 
from Dicer cleavage. Additional deep sequencing of these small RNAs produced over 
750 000 reads that mapped to the siRNA guide strand, and showed the guide strand 
to have two distinct start positions. One of the start positions aligned to the expected 
Dicer cleavage site for the shRNA, but approximately 18% of the reads showed a start 
position 2-nt upstream of the expected site. The authors went on to show that such 
non-canonical cleavages might be avoided by placing the cleavage site 2-nt from a 
bulge or loop in the stem of the shRNA, for more precise Dicer processing. Thus, 
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defining the precise rules for Dicer cleavage is an ongoing effort, but is critically 
linked to the design of effective shRNA. Generally, both siRNA and shRNA are 
designed such that one strand, the guide strand, has preferential loading to RISC. 
However, since Dicer performs non-canonical cleavages generating siRNA duplexes 
with different ends this can (i) result in a shift in ‘seed’ region and (ii) allow for the 
possibility that the passenger strand may show increased preference for loading to 
RISC. In either case, this would increase the potential for off target effects.  
1.1.2 Human	Argonaute	2:	Structure	and	function		
Argonaute proteins are highly specialised small-RNA-binding modules comprising 
four distinct domains, namely; the N-terminus, PAZ, Mid and the PIWI domains. 
Structural studies have revealed that human AGO2 proteins are bi-lobed, having the 
N-terminus and PAZ domains as one lobe and the MID-PIWI domains as the other 
lobe, connected by a hinge. This hinge allows for structural re-arrangement during 
RISC binding (Song et al., 2004; Schirle and MacRae, 2012). The PAZ domain binds 
the 3’ end of small duplex RNA, while the MID domain recognises the 5’ phosphate 
at position 1 of the siRNA guide strand (the thermodynamically unstable end of the 
siRNA), anchoring the small RNA to the protein. The N-terminus assists in unwinding 
of duplex RNA, while the PIWI domain (which is structurally similar to RNase H) is 
involved in cleavage of the passenger strand (Matranga et al., 2005; Rand et al., 
2005a) which is released generating the active RISC. The ‘seed’ region of the guide 
is arranged into the AGO2 cleft with bases 2-4 exposed to enable scanning of target 
mRNAs (Nakanishi, 2016) (Figure 1.3). Target recognition enables hybridization of 
the ‘seed’ and additional hybridization of the next 5-8 nucleotides beyond the ‘seed’ 
to form a helix of favourable conformation for cleavage  between mRNA nucleotides 
10 and 11when counting from the 5’ end of the siRNA guide strand (Elbashir Martinez 
et al., 2001; Wang et al., 2009; Salomon et al., 2015). 
 
In designing potent RNAi drugs, increasingly, sugar modifications and 
phosphorothioate backbone modification are employed to improve the 
pharmacokinetic properties of therapeutic siRNA. To shed light on how these 
modifications might impact siRNA interactions with AGO2, Schirle et al., (2006) 
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used crystal structure analysis to compare the interactions of modified vs unmodified 
siRNAs with AGO2. In observing the 5’ end of siRNAs, they found closely matched 
conformation of nucleotide positions 2-4 for modified vs unmodified siRNAs, but 
observed a substantial deviation in conformation of modified siRNA at position 5-8. 
This difference in observed conformational arrangement did not impair knockdown 
potency (Schirle et al., 2016). In this study, the central region could not be modelled 
with confidence, so the impact of conformation alteration on alignment of the siRNA 
with the catalytic centre, and therefore the impact on RISC cleavage precision, could 
not be determined. While in vitro biochemical studies may aid in designing potent 
modified siRNAs (Schlegel et al., 2017),  there remains a lack of  tools to specifically 
characterize the impact of such modifications on RISC behaviour in a biological 
context. The impact of chemical modification, conjugates, siRNA design and delivery 
strategies on target cleavage precision remains an avenue to be investigated.  
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Figure 1.2   Elucidation of Dicer architecture. 
Figure (A) illustrates the various domains of human dicer, with (B) illustrating 
the positioning of the various domains and illustrates the regions of siRNA 
interaction. Figure  (C) illustrates how the “ruler domain” meters out a distance 
between the PAZ domain and RNase III cleavage domain. (Adapted from: 
Ipsaro and Joshua-Tor, (2015); Sawh and Duchaine, (2012))  
 
A.	
B.	 C.	
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Figure 1.3   Schematic of siRNA guide strand hybridization and target 
cleavage. 
The 3’ 2 nt overhang of the guide strand is recognised by a hydrophobic 
pocket of the PAZ domain. The’ seed’ region (nucleotides 2-8) are positioned 
for hybridization to the target. Further hybridization at 10-11 correctly 
positions the target mRNA for cleavage by the PIWI domain. (Yellow = 
siRNA guide strand, brown = mRNA target strand). (Song et al., 2004) 
 
1.2 Targeting	disease:	RNAi	therapeutics	in	the	clinic	
The first Phase I clinical trial of siRNA therapeutics began in 2004, only six years 
after the discovery of RNAi. Considerable advances in research, technological 
improvements and novel applications have led to numerous clinical trials and pre-
clinical investigations (Tabernero et al., 2013; Schultheis et al., 2014; Patel et al., 
2016; Ganesh et al., 2016). Since its first discovery and early adoption, the high 
expectations that these RNAi-based drugs were expected to deliver has thus far failed 
to achieve Food and Drug Administration (FDA) approval. To date, only six 
oligonucleotide therapeutics (reviewed in Stein and Castanotto, 2017) have been 
approved for marketing by the FDA, with no RNAi-based therapeutics currently on 
this list. Pre-2008, RNAi therapeutic development had focused on commercialization 
of intellectual property and proof of principal publications.   The field took a hit when 
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it was realised that certain RNAi formulations led to stimulation of the innate immune 
system (Sledz et al., 2003; Sioud, 2007; Robbins et al., 2009). Post 2011, the field of 
RNAi therapeutics entered a recovery phase, buoyed primarily by an increase in 
quality of science; steered by heightened scientific scrutiny, a drive towards delivery 
technologies, considerable technical improvements, a focus at reducing adverse risks 
in pre-clinical and clinical assessments and advances in enabling technologies.   
 
In late September 2017, Alnylam Pharmaceuticals (in collaboration with Sanofi 
Genzyme) announced the first ever positive Phase III results for an RNAi therapeutic. 
Patients receiving their RNAi drug, Patisiran, showed significant improvement in 
health and drug efficacy scores compared to patients receiving a placebo, after 18 
months. This announcement marks a potentially significant milestone in the journey 
of RNAi therapeutics to the clinic (Alnylam Pharmaceuticals press release on 20 
September 2017 http://investors.alnylam.com/press-releases?mobile=1&items_per_ 
page=20&page=2). 
  
1.2.1 Hepatitis	Virus	C:	Disease	and	molecular	biology	
Chronic infection by Hepatitis Virus C (HCV) results in mild disease, or can lead to 
severe symptoms such as scar-tissue formation and cirrhosis. Cirrhosis can lead to 
hepatocellular carcinoma and can ultimately result in death. Humans are the only 
known natural host of HCV with an estimated 3% of the worlds’ population 
chronically infected, placing significant pressure on public health systems.  HCV is 
classified into at least seven major genotypes, whose genomes differ by at least 30%, 
with genotype prevalence showing varied worldwide distribution. Genotypes are 
further classified into subtypes (a, b, c, d, etc.). Genomic characterisation of HCV is 
further complicated as in infected individuals, HCV circulates as a population of 
diverse but closely related variants referred to as “quasispecies” (Smith et al., 2014).   
 
HCV is a single strand, positive sense, RNA virus of the family Flaviviridae, genus 
Hepacivirus. The RNA genome is of approximately 9,600 nucleotides long and 
encodes a single open reading frame (ORF) flanked by a 5’ untranslated region (UTR) 
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and 3’ UTR (Dubuisson and Cosset, 2014). The 5’ UTR has high secondary structure 
and holds an internal ribosome entry site (IRES) that facilitates RNA translation. The 
5’ UTR also holds replication signals including a binding site for the liver specific 
microRNA, miR-122 (Jopling et al., 2005). The 3’ UTR also has secondary structures 
essential for virus replication. The single polyprotein transcribed from the ORF is 
cleaved by host and virus proteases into the structural protein (core, envelope 
glycoproteins 1 and 2), an ion channel protein (p7) and the seven non-structural (NS) 
proteins (NS2, NS3A, NS3B, NS4A, NS4B, NS5A, NS5B). NS5B is a RNA 
dependent RNA polymerase (RDRP) and is responsible for synthesising the 
complementary negative-strand RNA intermediate used as template in virus 
replication (Lohmann et al., 1999). This RDRP lacks proof-reading activity resulting 
in a high rate of error-prone replication generating quasispecies RNA.  
1.2.2 HCV	as	a	target	and	modulator	of	RNAi.	
HCV has evolved to utilize the human RNAi pathway in a unique manner. Instead of 
being downregulated, HCV sequesters a liver microRNA, microRNA-122 (miR-122) 
as a replication factor. MiR-122-induced RISC cleavage enhances virus replication 
and translation. Two critical miR-122 sites are found in the 5’ UTR region, where 
hybridization of both the 5’ ‘seed’ region as well as the 3’ end of miR-122 at the two 
sites is required to elicit a replication advantage (Machlin et al., 2011). MiR-122- 
induced RISC interaction confers a conformational change to parts of the 5’ UTR, 
stabilizing the HCV RNA and enhancing replication (Pang et al., 2012). Further 
evidence for additional miR-122 interaction at various sites on the HCV genome other 
than the 5’ UTR was confirmed using HITS-CLIP (Luna et al., 2015).  
 
HCV infection has been shown to sequester host factors from Processing (P)-bodies 
(cellular granules used for storage of cellular mRNA). Along with mRNA transcripts, 
P-bodies house various RNA degradation enzymes, (e.g. decapping proteins, 5’-3’ 
exonucleases and decapping activators), other non-sense mediated decay proteins and 
RNAi machinery components (AGO2, miRNA and GW182) (Parker and Seth, 2009). 
HCV diverts P-body components, including Dcp2, Xrn1, AGO2 and miR-122 to lipid 
droplets, the sites of HCV replication and assembly (Biegel and Pager, 2016). 
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Interestingly, a number of these components of P-bodies are well known in their roles 
in mRNA decay, but have been shown to be required for efficient HCV replication 
(Shimakami et al., 2012; Li et al., 2015). Although lipid droplet formation has been 
found to play central roles in both viral replication and viral assembly, the exact nature 
of the interaction of mammalian viruses and the host RNAi system remains unclear. 
HCV dependence on miR-122 has even been exploited in an anti-viral therapeutic 
approach that sequesters miR-122 using a locked nucleic acid-modified, DNA 
phosphorthioate antisense oligonucleotide (Janssen et al., 2013). Numerous studies 
have shown that HCV RNA can be targeted via the RNAi pathway by supplying 
designed siRNA or Dicer substrate RNA (Seo et al., 2003; Sagan et al., 2010; Chang 
et al., 2010). 
1.2.3 TT-034,	a	DNA-directed	RNAi	therapeutic	
TT-034 (Benitec Biopharma, Sydney, Australia) is a novel, DNA directed RNAi 
therapeutic against HCV. It consists of a recombinant adeno-associated virus serotype 
8 (AAV8) vector that expresses three shRNAs, that target three distinct regions of the 
HCV genome (Figure 1.4). The expressed shRNA pro-drugs are substrates for Dicer 
processing, resulting in three separate antiviral-active siRNA drugs: siRNA6, 
siRNA19 and siRNA22. The AAV8 vector is replication incompetent, the TT-034 
genome is released and is converted to a non-integrating stabilized episomal 
transcriptionally active double- stranded DNA in cells, allowing long-term expression 
of the RNAi pro-drugs. Strong evidence of pre-clinical safety, (Suhy et al., 2012) in 
vitro characterisation (Lavender et al., 2012) and in-depth evidence of confirmed 
mode of action obtained from 5’RACE studies (Denise et al., 2014) motivated the 
FDA to authorise initiation of clinical trials which began in January 2014. The clinical 
trials reached Phase I/IIa stage with the third patient dosed on 7 January 2015 and a 
further announcement on the 7 April 2015 stating that results from liver biopsies 
confirmed that the trial was proceeding as expected. However, by the end of February 
2016, the company had announced termination of the programme due to reduced 
competitive advantage as more effective HCV therapeutics began to enter the market 
(Benitec Biopharma, Announcement https://blt.irmau.com/irm/PDF/1656_0/ 
UPDATEONHCV CLINICALTRIAL). 
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Figure 1.4   Diagrammatic representation of a DNA-directed RNAi-based 
drug TT-034 that targets three positions of the HCV genome.  
Each shRNA pro-drug is expressed from the DNA template and processed to 
siRNAs by Dicer. The siRNAs associate with RISC, resulting in cleavage of 
HCV RNA. (Adapted from Lavender et al., (2012)) 
 
 
 
 
 
Figure 1.5   Schematic illustration of HCV I389/NS3-3’/LucUbineo-ET 
subgenomic replicon.  
The replicon is composed of the HCV 5’ UTR , 342-389 nucleotides of the core 
region fused to a firefly luciferase gene (fLuc), the ubiquitin gene (Ubi), the 
neomycin phosphotransferase gene (NeoR) which confers resistance to 
geneticin, the internal ribosome entry site (IRES) of encephalomycarditis virus 
(EMCV), then sequences for the non-structural HCV  proteins NS3, NS4A, 
NS4B, NS5A and NS5B, and concludes with the HCV 3’ UTR. The replicon is 
capable of persistent replication in Huh-7 cells. (Adapted from Krönke et al., 
(2004)) 
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1.2.4 HCV	replicon	reporter	cell	lines		
The development of HCV replicon systems as a virology tool has greatly advanced 
HCV research (Berke et al., 2011). HCV replicon systems use a genetically modified 
HCV genome that incorporates a reporter signal and selectable marker (Figure 1.5). 
Replicon systems for many HCV subtypes have already been developed and utilized 
(Blight et al., 2003; Butt et al., 2011; Yu et al., 2014; Shier et al., 2016).  HCV replicon 
systems are non-infectious and only express the non-structural proteins under control 
of a selectable marker. Although the replicon system does not produce all the virus 
life cycle phases (it does not have the entry and exit phases) it offers a system for drug 
activity validation. The non-structural proteins NS3 and NS5B are particular targets 
for drug development as they encode well-defined enzymatic activities crucial for 
virus replication (Blight et al., 2002). In some instances, adaptive mutations have been 
identified that increase viral replication in cell culture (Krieger et al., 2001; Lohmann 
et al., 2001).  
1.3 Assays	confirming	RNAi	activity		
RNAi induced effects can be measured using a number of different indirect 
measurements. The reduction of target mRNA or protein compared to an 
untreated/non-specific control is the most commonly used approach in determining 
RNAi potency in cell culture systems, preclinical studies, as well as clinical trials. 
However, reduction of target levels is an implied proof of the expected RNAi 
mechanism of action, and other off-target processes may also drive the observed 
downregulation (Liang et al., 2013). Reverse-transcription quantitative PCR (RT-
qPCR) is currently the method of choice for direct quantification of mRNA, as it is a 
sensitive, robust and well-established method. However, much care must be taken to 
avoid potential non-specific amplification and other artefacts. Holmes et al. (2010) 
and others (Shepard et al., 2005; Chen et al., 2011; Herbert et al., 2011) have shown 
that location of the primer pairs could have implications for validation of siRNA 
knockdown. For example, two different siRNAs were targeted to two locations on 
PKC-ε mRNA and then five primer pairs were used to amplify regions along the 
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length of the mRNA. Knockdown of mRNA was detected with the primers targeting 
mRNA regions upstream of the target location, while primer sets designed to amplify 
targets downstream of the cleavage position, and particularly towards the poly A 
region of  the mRNA were still able to detect mRNA fragments (Holmes et al., 2010). 
The 3’ RISC cleaved product of targeted RNA is known to persist as it contains 
mechanisms (recognition elements) that bypass immediate degradation, allowing the 
3’ fragment to persistent after RISC cleavage (Orban and Izaurralde, 2005; 
Yoshikawa et al., 2013).  
 
An indirect method of determining mRNA reduction is to measure the reduction of 
endogenous protein levels. However, this requires good, highly specific antibodies 
against endogenous proteins. Such antibodies are not always available and 
additionally, the method is not well suited to high throughput applications. 
Recombinant antigen tagged proteins (eg. HA, FLAG, His) can also be used, but 
remains an option only for validating assays in overexpression systems. Additionally, 
fluorescent or enzymatic reporters can be fused to gene targets to produce 
recombinant proteins for simplified, light-based target level quantification. Reporter 
constructs may also be generated by cloning the cDNA of the target downstream of 
the translational stop codon of the reporter. Transcription of the construct produces a 
chimeric mRNA from which only the reporter protein is translated. Targeting of the 
cDNA by RNAi leads to degradation of the entire mRNA and a proportional reduction 
in reporter is measured (Yeung et al., 2008; Lin et al., 2007). However, measurement 
of mRNA or protein by any of these methods is clearly insufficient evidence to 
conclude that the observed downregulation of a target is directly due to RNAi activity. 
Reduction of mRNA, and therefore protein may arise due to off-target effects, such 
as activation of Toll-like receptor (Robbins et al., 2009) which is induced by presence 
of siRNA (Grimson et al., 2007; Jackson and Linsley, 2010). 
1.3.1 Assays	for	direct	confirmation	of	RNAi	activity					
Detection and confirmation of the 5’ end generated by AGO2-directed cleavage 
remains the only means of directly confirming RNAi activity. Initially, confirmation 
of RISC cleaved RNA used in vivo assays that relied on autoradiograpic detection of 
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cleaved 32P-cap-labelled synthetic RNA targets (Rand et al., 2005b; Koller et al., 
2006). Adaptation of the 5’ Rapid Amplification of cDNA Ends (5’RACE) assay 
originally developed to amplify full length mRNA transcripts (Frohman et al., 1988; 
Frohman, 1994; Schaefer, 1995) is currently the “gold standard” for  confirming an 
RNAi mechanism of action (MOA) in vivo (Soutschek et al., 2004; Koller et al., 2006; 
Davis et al., 2010). In 5’ RACE, an RNA adapter containing a 3’ hydroxyl group is 
ligated to the 5’ newly cleaved end of the target mRNA using T4 RNA ligase. The 
RNA adapter becomes a known sequence for the forward primer during PCR. A 
reverse primer specific to the transcript of interest is used in first strand cDNA 
synthesis. The cDNA product is then purified and PCR amplified using a forward 
primer specific to the 5’ adapter and a reverse primer to the cDNA, resulting in a PCR 
product of defined size (Lasham et al., 2010). The method is commonly referred to as 
RNA ligase-mediated (RLM)-RACE (Figure 1.6). The amplicon is then sequenced 
(by Sanger sequencing) to confirm the position of the cleavage site.  
 
Additionally, a number of authors have proposed modified protocols for confirming 
RISC cleaved products. For example, Lasham et al., (2010) proposed using a 
molecular beacon probe to specifically detect the junction between the RNA adapter 
and RISC-cleaved product of 5’ RACE cDNA template or first round PCR reaction 
(Figure 1.6). However, although qPCR assays are now standard in many laboratories, 
each new target would require an optimised qPCR assay. Additionally, high 
throughput analysis would be hampered by upstream sample preparation activities 
such as RNA extraction, adapter ligation and RNA clean up by chloroform extraction. 
For the standard 5’ RACE assay, fragment sequences are confirmed by cloning the 
PCR fragments into a vector and then sequencing a number of clones to identify the 
expected cleavage position. This is a time-consuming operation restricting its 
application in processing of large numbers of samples at one time.  
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Figure 1.6   Diagram of RNA ligase-mediated Rapid Amplification of cDNA Ends 
(RLM RACE) vs molecular probe detection of 5’ RACE products. 
After targeted knockdown, total RNA is collected, adapter ligated and reverse 
transcribed using a gene specific primer. The cDNA is amplified and can then be 
cloned and sequences. Alternatively, the ligation position can be quantified by probe-
based quantitative PCR.  
 
 
1.3.2 Confirmation	of	RISC	cleavage	using	RACE-Seq	
In plants, miRNAs show extensive complementarity to their target RNA with many 
having perfect pairing (Baumberger and Baulcombe, 2005). These miRNAs are more 
appropriately termed endogenous siRNA and result in cleavage of their target. 
Degradome sequencing (also known as parallel analysis of RNA ends (PARE)) is a 
widely used method that reveals the activity of these endogenous siRNAs by 
identifying their targets. Degradome sequencing is a high throughput method for 
capturing uncapped RNA ends. An RNA adapter is directly ligated to the 5’ end of 
uncapped RNAs prior to poly-A reverse transcription. The fragments are then digested 
by Mmel, a Type II restriction endonuclease. A 3’ DNA adapter is added and the short 
fragments amplified and Next Generation Sequencing libraries prepared and 
sequenced (Addo-Quaye et al., 2008; German et al., 2008). The reads are then aligned 
cleaved		mRNA	ligated	to	RNA	adapter		and	cDNA	synthesis		
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to the transcriptome and compared to the plant miRNA database to reveal miRNA 
activity. Degradome sequencing has also been used to identify miRNA-dependant 
cleavage activity in humans (Bracken et al., 2011).  
 
To date, there are only four publications applying (NGS) (in lieu of Sanger 
sequencing) of targeted 5’ RACE products to confirm a specific interaction of 
introduced siRNA or shRNA via an RNAi MOA in humans or human cell lines 
(Tabernero et al., 2013; Denise et al., 2014; Barve et al., 2015; Ganesh et al., 2016). 
The assay is termed RACE-Seq and is very much in early implementation stage, with 
no standardized approach to performing and validating assays with variations in 
preparing NGS libraries, performing alignments, 5’ end counting and data reporting. 
NGS is a powerful technology, with the capacity to bring new insights to RISC 
behaviour. Of the four publications, only Denise et al., (2014) sought to utilise RACE-
Seq to infer RISC behaviour beyond confirming an expected cleavage product, with 
their result hypothesising that RISC may show preference for additional cleavage 
positions at nucleotides13-15.  
 
A number of barriers currently hinder the fluid uptake of RACE-Seq application; these 
may include; the overall higher cost of NGS, long protocols involving manual 
handling operations, lack of experience in preparing RACE-Seq libraries, lack of 
experience of commercial NGS facilities in handling 5’RACE samples and lack of 
easy to use data analysis options.  
1.4 Next	Generation	Sequencing:	Ion	Torrent	PGM	
NGS is also known as high-throughput sequencing, massive parallel sequencing or 
second-generation sequencing, and are terms used to describe different modern 
sequencing technologies such as Illumina sequencing, SOLiD sequencing and Ion 
Torrent sequencing. These sequencing technologies allow simultaneous sequencing 
of thousands to millions of individual DNA fragments.  Steady improvements in 
technology, chemistry and data analysis improvement has seen the cost of NGS 
technologies decrease and the development of innovative sample preparation has led 
to expanded applications of NGS. The Ion Torrent sequencing platform differs 
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substantially from the Illumina platform, although both systems require an amplified 
template signal, with the Ion Torrent system using clonal amplification on beads in an 
emulsion PCR reaction. The beads are then deposited into wells on the sequencing 
chip and the change in pH due to the release of a H+ ion when a nucleotide is 
incorporated to a growing complementary strand is monitored for each well. This 
signal is interpreted and the number of bases incorporated determined. 
1.4.1 NGS	 sample	 preparation	 and	 emulsion	 PCR	 for	 Ion	 Torrent	
Sequencing	
NGS library preparation kits for Ion Torrent are now available from a number of 
manufacturers including; Thermo Fisher Scientific (who supply the official Ion 
Torrent validated protocols and reagents), New England Biolabs (NEB, Ipswich, 
MA), KAPA Biosystems (Roche), BIOO Scientific (Austin, TX) and LABGENE 
Scientific SA (Freiburg, Switzerland).  Sample and reagent storage as well as good 
laboratory practices are particularly important, with the use of precision pipettes, filter 
pipette tips, and certified nuclease-free consumables highly recommended. There are 
a number of standardized sample requirements when preparing NGS libraries. It is 
recommended to assess DNA samples by gel electrophoresis to confirm samples are 
of the expected size and that DNA is of satisfactory integrity.   The quality of the 
purified DNA should yield anOD260/280 ratio of 1.8 to 2.0 and an OD260/230 ratio of 2.0 
to 2.2, the former being more critical. Samples may be rejected for sequencing based 
on poor OD assessment, or, poor OD assessment may indicate that the sample requires 
a clean-up procedure before input to library preparation (Endrullat et al., 2016). The 
sample amount needs to be accurately assessed, a step that becomes particularly 
important when processing multiple samples. Accurate DNA quantification is carried 
out using fluorescent-based DNA quantification methods such as the Qubit DNA 
assay (Thermo Fisher Scientific) or using electronic fragment analysers such as the 
Agilent Bioanalyzer system (Agilent Technologies, Santa Clara, CA).  
 
For Ion Torrent library preparation, double stranded DNA is blunt ended and 5’ 
phosphorylated using a mixture of enzymes (Head et al., 2014). A clean-up step may 
be required at this point for some protocols. The Ion Torrent Sequencing adapters 
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(termed A-adapter and P1-adapter) are then added to the blunt ended fragments in a 
ligation reaction. The A-adapter has a short barcode allowing samples to be 
individually tagged for later pooling and sequencing in a single reaction (multiplex 
sequencing), and also holds the consensus key, which is a short sequence used to 
validate the sequencing signal at the start of the sequencing reaction. The P1 adapter 
sequence is the end that becomes attached to the Ion sphere particles during emulsion 
PCR. Since the fragment ends and adapter ends are both blunt ended, the adapters 
ligate to the fragment ends in a mix of configurations (Figure 1.7). The adapter ligated 
samples undergo a bead-based clean-up protocol. DNA clean-up using magnetic 
beads can efficiently remove free adapter and short fragments from sample 
preparations (Bronner et al., 2013). A short round of PCR is commonly used to enrich 
for fragments that have P1-adapter on one end and A-adapter on the other. Another 
round of bead clean-up is then performed. An alternative approach is to quantify the 
library using quantitative PCR. Fragments having a P1and A-adapter are amplified 
and a region on the P1 adapter is used for Taqman probe hybridisation, thus only 
fragments that have the potential to be amplified in emulsion PCR are detected and 
quantified. 
 
The Ion Torrent platform requires that the final DNA library is within the validated 
fragment size range, thus additional size selection may be required prior to 
sequencing. A number of manual and automated protocols and instruments are 
available for size selection of DNA fragments. These may include: manual extraction 
by gel excision and purification, E-gel Size Select system (Thermo Fisher Scientific) 
and automatic size selection instruments such as the LabChip XT (PerkinElmer Inc., 
MA, USA) and Pippin Prep (Sage Science Inc., MA, USA). Irrespective of method 
used, validation of fragment size and accurate quantification are critical for input to 
emulsion PCR.  
 
The OneTouchTM2.0 emulsion PCR system is a fully integrated automated system that 
performs the clonal amplification of the DNA library onto the sequencing beads. The 
instrument generates an emulsion consisting of an aqueous phase in oil. The aqueous 
phase has all the components for PCR, ie. template (ideally a single fragment of the 
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DNA library per droplet), amplification primer, bead (the bead holds a primer tag 
complementary to the P1-adapter sequence), DNA polymerase, dNTPs and required 
buffer reagents for PCR (Figure 1.8). This bead emulsion undergoes in situ thermal 
cycling PCR and finishes with breaking of the emulsion using detergent, allowing the 
beads to be recovered by centrifugation (Merriman et al., 2012). The extracted beads 
are now templated with the library, but need to undergo further enrichment to select 
for beads that have been well templated and to exclude ‘empty’ beads. This is 
achieved using the OneTouch Enrichment System which is also a fully integrated 
system.  First, a biotinylated tag is hybridized to the terminal adapter sequence of the 
templated bead pool. Beads that did not template will not be captured. The biotin-
tagged beads are then bound to magnetic streptavidin capture beads and the complex 
is collected magnetically, washed several times and the templated beads eluted. This 
eluate is the final templated beads that will be prepared for sequencing (Kohn et al., 
2013). Validated chemistries, protocols and instrument calibration ensure that the 
emulsion PCR and enrichment processes typically yield over 98% of a bead 
population carrying template. 
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Figure 1.7   Workflow of library preparation for the Ion Torrent Sequencing 
Technology. 
Fragmented DNA or PCR products undergo end repair, which generates blunt ends. 
The ends are 5’ phosphorylated and can be tagged with the sequencing adapters. The 
fragment ends are ligated with either the A adapter or the P1 adapter. A short round 
of PCR selects for the correct orientation of adapters to generate the final NGS library.   
(Adapted from: https://www.neb.com/products/e6270-nebnext-fast-dna-library-prep-
set-for-iontorrent)  
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Figure 1.8   Illustration of Emulsion PCR reaction utilised in Ion Torrent library 
preparation. 
The OneTouch instrument preforms the emulsion PCR reaction. A mix of emulsion 
oil, sequencing beads tagged with a primer complementary to the P1 adapter 
sequence, PCR mix, primer and library DNA are emulsified to create micro-reactors. 
PCR cycling denatures the double stranded DNA and one strand is templated to the 
bead. PCR cycling generates copies of the DNA in each of the reactors.  The free 
strand is also copied, increasing the number of templates attaching to the beads. 
(Adapted from: http://www.atdbio.com/content/58/Next-generation-sequencing# 
figure-emulsion-pcr) 
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1.4.2 Ion	Torrent	semiconductor	sequencing	technology		 		
The Ion Torrent Technology uses a semiconductor sensor array chip for sequencing and 
data collection with a simple, on-chip sequencing chemistry (Figure 1.9). Templated beads 
from emulsion PCR are loaded onto the sequencing chip, where one templated bead 
occupies a single well. The chip is a highly sensitive pH meter. Using native dNTPs, one 
nucleotide at a time is flowed into the wells. Incorporation of dNTPs in a template specific 
manner releases hydrogen ions (H+) from the 3’ OH- incorporation site on the growing 
strand. The change in pH is measured and converted to an electric signal. Unincorporated 
nucleotides are washed away and the next nucleotide added. Importantly, the chemistry is 
such that more than one nucleotide can be added to the template in a single flow, e.g. due 
to homodimer, homotrimer etc. occurrence (i.e. TTT, AAA). The signal is then averaged 
and the number of incorporated nucleotides determined (Rothberg et al., 2011). The base-
calling software then converts the raw data to a nucleotide sequence. 
  
 
Figure 1.9   Illustration of the Ion Torrent Semiconductor chip based sequencing 
technology. 
Detection of incorporated nucleotides is correlated with a change in pH from the 
release of H+ at each flow of nucleotide. (Adapted from: Rothberg et al., 2011) 
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1.4.3 On-system	data	processing	and	analysis		
When the base-call analysis has completed, data quality is assessed by the Ion PGM 
Torrent Server. Proprietary algorithms filter the base-called data for quality assurance and 
removes any ‘obviously low quality’ reads.  Low quality removal includes; the removal of 
reads that have fallen out of phase (i.e. some fragments being sequenced may fall behind 
cycle phase due to improper extension or may advance ahead of phase due to carryover of 
reagents from the previous nucleotide flow), reads with ‘signal droop’ (which is when the 
signal strength of some reads becomes weaker over the course of the sequencing reaction, 
and this ‘signal droop’ can be detected, quantified and used as a criteria for eliminating 
reads from the final dataset), detection and elimination of reads with well-to-well 
crosstalk, and low clonal intensity (the signal from each well can be assessed and the 
relative number of templates that were primed on each bead determined) (Merriman et al., 
2012). After this pre-filtering for quality, reads are de-multiplexed, any reads that are 
adapter-adapter ligations (adapter dimer) or polyclonal (where a mix of templates became 
templated to the same bead) are removed. A report summarising chip loading efficiency, 
filtered read statistics, de-multiplexed sample information (barcode ID, sample name, 
number of reads per sample and average length of fragments per sample) is obtained. Data 
can be made available in a number of formats such as FASTQ and BAM file formats. A 
number of additional data analysis protocols can be performed directly on the system such 
as FASTQC Quality assessment, alignment to a reference genome, variant analysis and de 
novo genome assembly (Seo et al., 2015).  
1.5 A	brief	overview	of	Illumina	Sequencing	Technology		
The two major players in benchtop short read sequencing platforms are Illumina and Ion 
Torrent. The Illumina sequencing platform remains the most widely used sequencing 
technology. Illumina sequencing uses clonal amplification on a solid surface and 
reversible terminator technology (Figure 1.10). After sample preparation, library 
fragments are attached to the sequencing flow cell. The flow cell is covered with two 
different types of oligo tags that are complementary to the ends of the library fragments. 
The fragments hybridize to the tags and become templates for synthesis of a 
complementary fragment that is now attached to the flow cell. The original fragment is 
washed away and clonal amplification of each fragment occurs by bridge amplification by 
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the attached fragment folding over and hybridizing to a neighbouring tag and a 
complementary fragment is synthesised resulting in a copy of the DNA strand. This 
reaction occurs a number of times to create up to 1000 identical clones in close proximity. 
The reverse strands are then removed, leaving a single strand for templating. A sequencing 
primer is added and the forward strand sequenced (Head et al., 2014).  
 
Illumina technology uses fluorescently labelled dNTPs with bound reversible terminators. 
During sequencing, all 4 nucleotides are accessible to the bound clusters, but due to the 
terminator, only one nucleotide can attach to the growing complementary strand. Unbound 
nucleotides are washed away and incorporated nucleotides are stimulated by a laser with 
each fluorescently-tagged nucleotide emitting a characteristic signal. Each strand in the 
cluster emits the same signal, providing an amplified signal that is optically captured. The 
terminator is enzymatically cleaved allowing the next base of the template to be 
incorporated (Figure 1.10). This process of Illumina sequencing is commonly referred to 
as sequencing by synthesis. Since one nucleotide is incorporated at a time, the number of 
flows dictates the read length. Illumina Technology employs paired-end sequencing such 
that each read can be sequenced in both directions. Thus, for short reads (up to 250 bp) for 
current chemistries the reads obtained in both directions helps to eliminate sequencing 
errors, as the read pairs should match. This approach is highly effective in resolving 
structural re-arrangements such as insertions, deletions and inversions. In the case of  long 
templates, a portion of the strand is read in each direction, a strategy which is advantageous 
for the assembly of whole genome reads or for resolving repetitive genomic regions 
compared to single end sequencing (Treangen and Salzberg, 2011). For paired-end 
sequencing, on completion of the first-strand sequencing reaction, the cluster ends anneal 
to the second tag on the flow cell, and the second index sequence is read and the strands 
extended using the first strand as template. This process generates clusters with paired 
strands. The forward strand is then removed with the remaining strand becoming template 
for sequencing  (Ansorge, 2009).   
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Figure 1.10   Outline of Illumina sequencing process. 
Adapter ligated fragments are spread out and captured to a primer-loaded flow cell (1), 
the template strand folds over (2), and is cloned by bridge PCR amplification (3 and 4) 
to produce two strands (5). This continues for a number of cycles to produce clusters of 
fragments (6). After addition of the sequencing primer, a labelled dNTP is added to the 
growing strand (7). The flow cell is excited by a laser (8) and the fluorophore emission 
captured by a camera (9). The sequencing terminator is removed (10) and the sequencing 
cycle continues with the addition of the next nucleotide. The base-calling software 
decodes the raw data generating the sequence (11). (Adapted from https:// 
commons.wikimedia.org/wiki/File:Cluster_Generation.png, and https://en. wikipedia. 
orgwiki/File:Sequencing_by_synthesis_Reversible_terminators.png) 
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1.6 Aims	of	the	project		
The current dogma of RNAi stipulates that active AGO2 RISC cleaves the target RNA 
between bases 10-11 when counting from the 5’ end of the guide strand of the introduced 
RNAi modality (Martinez and Tuschl, 2004; Foster et al., 2012). The 5’ RACE-PCR assay 
remains the only means for directly confirming AGO2-RISC cleavage activity. The assay 
is poorly reported in pre-clinical and clinical trials.  This is likely due to its low throughput 
capacity and the need for extensive manual preparations; as a result, single instances of an 
on-target MOA are extrapolated as continued evidence across drug development pipelines. 
Sanger sequencing is used to confirm the expected cleavage position. Transitioning the 
assay to Next Generation Sequencing is likely to improve throughput and provide 
opportunities for greater insight to RISC activity.  
 
1.7 Work	presented	in	this	thesis	
This work represents a critical evaluation of the application of NGS to 5’RACE analysis 
of RISC cleaved transcripts and opportunities for improving the technique. Briefly, the 
aims of the project were:   
Technical aspects:  
1. To transition the Illumina HiSeq RACE-Seq protocol (Denise et al., 2014) to the Ion 
Torrent PGM.  
2. To improve the 5’ RACE-Seq assay to allow multiplexing of up to 10 samples per Ion 
Torrent 318 sequencing chip.  
3. To evaluate the NGS library preparation criteria required to generate sufficient RACE-
Seq data using the Ion Torrent PGM.  
Data analysis: 
4. To evaluate and implement a simple data analysis workflow for non-expert analysis of 
RACE-Seq data. 
5. To investigate whether RACE-Seq data provides insights into RISC cleavage beyond 
the expected cleavage behaviour.  
Biological insights:  
6. To investigate the RISC cleavage activity of siRNAs, shRNAs and a Dicer substrate 
siRNA (DsiRNA). 
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b 	METHODS	AND	MATERIALS	
2.1 RNAi-based	bioactive	oligonucleotides	
The sequences for all six RNAi oligonucleotides targeting the HCV replicon genome were as 
reported by Lavender et al. (2012) and Denise et al. (2014). The three synthetic shRNA 
analogues (Table 2.1) were designed to mimic the shRNA prodrug sequences expressed from 
TT-034, a DNA-directed RNAi-based drug that expresses three shRNAs targeting three 
different locations on the HCV genome (Figure 1.4). The three siRNA synthetic analogues 
were designed as the most prominent sequences processed by Dicer for the three shRNAs 
expressed from TT-034 (Denise et al., 2014).  
 
Table 2.1   Bioactive oligonucleotides targeting against HCV replicon genome 
 
For shRNA: lowercase = hairpin loop structure  
For siRNA: The siRNAs were selected as the most prominent maturation products from shRNA6, 
shRNA19 and shRNA22 expression from TT-034 (Denise et al., 2014). As a consequence, all of the  
siRNAs hold part of the shRNA loop sequence.  
  
2.2 Rational	design	of	a	siRNA	targeting	Transthyretin	
The widespread use of siRNAs in genomic studies has resulted in a variety of online tools 
that incorporate the many design guidelines for generating highly effective small interfering 
RNA sequences. The online software package Sfold v2.2 (Software for Statistical Folding of 
Nucleotides and Studies of Regulatory RNAs) web service (http://sfold.wadsworth.org/cgi-
bin/sirna.pl) was chosen for its simple application and interpretation of results. The software 
incorporates methodologies for siRNA design, including target accessibility prediction and 
siRNA duplex thermodynamic properties and generates both graphical and text output (Ding 
et al., 2004). An easy to follow filtering and scoring system makes this a very user-friendly 
software package.  
 Guide strand  Passenger strand 
siRNA22 5’-AUUGGAGUGAGUUUAAGCUga-3’ 5’-AGCUCAAACUCACUCCAAUuu-3’ 
siRNA19 5’-CAACUCCUGGCUAGGCAAuuugu-3’ 5’-uagUUGCCUAGCCAGGAGUUGAC-3’ 
siRNA6 5’-GAAAGGCCUUGUGGUACUgaa-3 5’-gAGUACCACAAGGCCUUUCGC-3’ 
shRNA22 5’-AUUGGAGUGAGUUUAAGCUgaagcuugAGCUUAAACUCACUCCAAUuuuuu-3’ 
shRNA19 5’-GUCAACUCCUGGCUAGGCAAuuuguguagUUGCCUAGCCAGGAGUUGACuuuuuu-3’ 
shRNA6 5’-CGCGAAAGGCCUUGUGGUACUgaagcuugAGUACCACAAGGCCUUUCGCuuuuu-3’ 
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To design the siRNA sequence, a 100 bp region within the coding sequence of Transthyretin 
(TTR) mRNA (NM_000371.3) from position 450 bp to 550 bp was chosen as input into the 
Sirna programme within Sfold v2.2 web service and siRNA analysis executed using the 
default design criteria. In order to view the siRNA sequences generated, the “Output for all 
siRNAs” option was selected. This produced an analysed text output showing a list of all 
possible siRNAs, beginning at the start position of the input sequence. An example of the 
analysed sequence is presented in Figure 2.1, which also highlights the filtering and scoring 
criteria that was used to choose siRNA-TTR. A duplex thermodynamic score of 2, was 
identified as an ideal start point for filtering the initial siRNA sequence, as this score is 
derived from two other design criteria namely; 1 point is gained for siRNAs with differential 
stability of siRNA duplex ends with score >0 and 1 point is gained for siRNAs with average 
internal stability values >-8.6 kcal/mol. A requirement of siRNA sequences to meet a duplex 
thermodynamic score of 2 filtered the siRNA list from 106 possible sequences to 3 sequences. 
These three siRNA sequences were evaluated using the pass criteria in Figure 2.1. The 
sequence with the most pass criteria was selected. BlastN analysis confirmed that the siRNA 
sequence selected was specific for TTR mRNA. The chosen siRNA sequence was synthesised 
by IDT, as individual RNA strands, siRNA-TTR-AS 5’-UCGUUGGCUGUGAAUACCAtt-
3’and siRNA-TTR-SS  5’-UGGUAUUCACAGCCAACGAtt-3’ (at 100 nmol with standard 
desalting purification, capital letters=RNA bases, tt=DNA bases, AS = antisense strand, SS 
= sense strand). 
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Figure 2.1  Criteria for selection of siRNA-TTR.  
A 100 bp region of the TTR mRNA sequence (NM_000371.3) from position 450 – 550 bp, 
was used to select an siRNA using Sfold. Initially, the three siRNA sequences (in red) were 
identified with a duplex thermodynamic score of 2, and these were then further assessed 
against the selection criteria under lane 2. The minimum pass criteria are underlined. The 
blue highlighted sequence passed the selection criteria.   
 
 
2.3 Design	and	synthesis	of	a	Dicer	Substrate	siRNA	
targeting	Transthyretin		
A custom Dicer substrate siRNA (DsiRNA) was selected using the IDT RNAi Design Tool 
(https://eu.idtdna.com/site/order/designtool/index/ DSIRNA_PREDESIGN). The same 100 
bp region of the TTR mRNA sequence (position 450 bp to 550bp) used to design the siRNA 
was input into the RNAi design tool to generate a list of DsiRNAs. The tool automatically 
aligns the DsiRNAs to the Human transcriptome. From the list generated, one molecule, ID: 
CD.Ri.25599.13.23, was specific for TTR mRNA only, while the other molecules generated 
from the list showed alignment to various human transcripts.  DsiRNA-TTR was synthesised 
by IDT at 2 nmol with affinity purification and was supplied as a pre-annealed lyophilized 
Line		1:
Line		2:
Line		1:
Line	 2:
Line		1:
Line	 2:
(want	a	score	of	6	or	more)
(score	of	2)
(GC%	closer	to	30%)
(below	 -10	kcal/mol)
(value	>0)
(value	greater	than	-8.6	kcal/mol)
(highest	probability	 score	that	
meets	above	criteria)
Sequences	23-,	24- and	25- are	the	three	top	candidate	siRNA	for	the	TTR	input	 sequence,	predicted	by	Sfold software	.	
The	criteria	below	was	used	to	evaluate	the	three	sequences,	underlined	 descriptions	highlight	 the	desired	criteria	for	
chosing the	siRNA.	Sequence	25	fit	the	filter	criteria	best.	
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sample. The sequence for DsiRNA-TTR was sense strand 5’-AUGCAGAGGUGGUAU 
UCACAGCCaa-3’ and antisense strand 5’-UUGGCUGUGAAUACCACCUCUGCAUGC-
3’ (capital letters=RNA bases, aa = DNA bases).  
2.4 Primer	design	
A truncated GeneRacer adapter was used for RLM RACE assays. The RNA adapter sequence 
was as reported in Denise et al., (2014) (Table 2.2). All primer sequences used in RLM RACE 
assays for HCV and TTR are listed in Table 2.3. Primers were designed using the Integrated 
DNA Technologies (IDT) PrimerQuest Tool  (https://www.idtdna.com/PrimerQuest/ 
Home/Index?Display=AdvancedParams) and analysed using the Oligoanalyzer 3.1 Tool 
(https://eu.idtdna.com/calc/analyzer), both from IDT.  The 5’ RACE primers were designed 
to ideally to be length 22-28 nucleotides, have GC content of 50-70%, and no more than two 
G or C residues at the 3’ end of the primer. Primers were analysed for self-complementarity 
and hairpin formation. The gene-specific reverse primers were designed with the same 
criteria. PCR amplification primers were additionally designed to have similar melt 
temperature to the GeneRacerF1 primer. The annealing temperature for amplification primer 
pairs was checked using the NEB Tm Calculator (https://tmcalculator.neb.com/#!/). Primers 
were synthesised by IDT at 25 nmol with standard desalting. The quantitative PCR (qPCR) 
amplification primers for measuring knockdown of TTR mRNA were as reported in Hayashi 
et al. (2012) (Table 2.3). GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was used as 
the internal reference control (see Table 2.3 for primer sequences).  
 
 
Table 2.2   GeneRacer RNA adapter sequence  
 
 
Purpose Name Sequence 
Adapter ligation  GeneRacer 
adapter 
GGACACUGACAUGGACUGAAGGAGUAGAAA 
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Table 2.3   RACE-Seq primers used in this thesis 
 
*Primer selected from Denise et al., 2014    
 
2.5 Cell	culture	and	Bioassays	
2.5.1 Routine	cell	maintenance	
Experiments were carried out on a human hepatocellular carcinoma cell (Huh-7) line which 
harbours the I389/NS3-3’/LucUbiNeo-ER replicon of HCV genotype 1b (Con1 isolate) 
(Frese et al., 2002) kindly gifted from ReBLikon GmbH, Schriesheim, Germany). The cell 
line is commonly referred to as Huh7/Con1b. The cells expressing this non-packaging, self-
replicating, luciferase-expressing subgenomic replicon of HCV were maintained as an 
adherent monolayer in 75 cm2 flasks and propagated in complete media. At 80-90% 
confluency spent media was poured removed and cells washed for 1 minute with 5 ml of pre-
warmed Dulbecco’s Phosphate-Buffered Saline(DPBS) (Thermo Fisher Scientific, Waltham, 
Ma) to remove residual media serum. Cells were detached in 1-2 ml of TrypLE Express 
reagent (Thermo Fisher Scientific) and incubated at 37oC for 4-5 minutes. Flasks were 
observed under the microscope to ensure sufficient cell detachment and dislodged by gentle 
but firm tapping of the flask. TrypLE Express reagent was deactivated by washing cells with 
5 ml of pre-warmed complete media.  Cells were centrifuged in 15 ml conical tubes at 400 
Purpose Name Sequence
Melt Temp 
(oC)
Expected size of 
RACE-Seq
amplicon 
reverse transcription/PCR 22+2* CGAACCAGCT GGATAAATCCAACTGGGA 62 78 bp
reverse transcription 6+L1 GTATCTCTTCATAGCCTTATGCAGTTG 55.3
PCR 6+L3 GCCGGGCCTTTCTTTATGT 55.7 182 bp
PCR 6+L2 GCGCCC GTT GGT GTT ACG 59.6 144 bp
reverse transcription 19+L4 GGCCATGGAGTCGTTGAA 55.2
PCR 19+L2 GTAGGTCAAGTGGCTCAATGGAGTA 58.1 186 bp
PCR 19+L1 TTGTTCCTGAGCTAGAAGGATGGAGAAG 59.4 121 bp
reverse transcription primer 22+L2 TAGGAGTAGGCACCACATGAA 55.2
PCR 22+L1 GGTCGGGCACGAGACAG 58.6 126 bp
PCR 22+L2 GACAGGCTGTGATATATGTC 50 114 bp
reverse transcription primer TTR+L1 TTGTCTCTGCCTGGACTTCTAACATAGC 59.7
PCR TTR+L2 TCGTCCTTCAGGTCCACTGGAGGAGAAGT 65 ~170 bp
qPCR human TTR forward CATTCTTGGCAGGATGGCTTC 56.5
qPCR human TTR reverse CTCCCAGGTGTCATCAGCAG 57.7
qPCR GAPDH forward CCCACTCCTCCACCTTTGACG 59.9
qPCR GAPDH reverse CCACCACCCTG TTGCTGTAG 58.1
PCR GeneRacerF1 GGACACTGACATGGACTGAAGGAGTA 59.6
PCR GeneRacerF2 GGACACTGACATGGACTGAAGG 57.4
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rpm for 5 minutes at 18oC, and the resulting pellet re-suspended in 3-9 ml of fresh media. 
Cells were split 1:3 or 1:4 as required and incubated at 37oC with 5% CO2. Cell passage was 
normally carried out 2-3 times per week. For HCV knockdown experiments, cells at up to 
passage 38 were used.   
The complete media consisted of:  
Dulbecco’s Modified Eagle’s Medium, (DMEM) (Thermo Fisher Scientific) supplemented 
with 10% (w/v) foetal bovine serum (FBS) (Thermo Fisher Scientific), 1 mM sodium 
pyruvate (Thermo Fisher Scientific), 1x non-essential amino acids (Thermo Fisher Scientific, 
UK), 1x penicillin-streptomycin (Thermo Fisher Scientific) and 0.5 mg/ml Geneticin 
(Thermo Fisher Scientific).  
2.5.2 Cell	revival	and	plating		
Stored cells were removed from liquid nitrogen and thawed in a 37oC water bath for 2 minutes 
with 2-3 inversions during thawing. Cells were added to 10 ml of pre-warmed complete media 
without Geneticin and were gently pipetted up and down to mix. The entire volume was 
transferred to a 25 cm2 flask and incubated overnight at 37oC in a humidified 5% CO2 
incubator. The following day, media was changed to DMEM complete media (as above) 
containing 0.5 mg/ml Geneticin. At 80-90% confluence, cells were transferred to a 75 cm2 
flask for routine cell maintenance.  
2.5.3 Cell	counting		
For experimental purposes, cells were counted and viability determined using Trypan Blue 
dye (Thermo Fisher Scientific) (Riss et al., 2004). Cells were detached and pelleted as 
previously described and re-suspended in 3-5 ml complete media or Opti-MEM reduced 
serum media (Thermo Fisher Scientific). Cells were mixed thoroughly by gentle pipetting at 
least 5 times using a 10 ml serological pipette and immediately, 100 µl of cell suspension was 
diluted with 100 µl Trypan Blue for a 1:2 dilution or a mix of 100µl Trypan Blue and 200 µl 
DPBS for a 1:4 dilution. Then, 10 µl of cell suspension in Trypan Blue was added to each 
side of a haemocytometer chamber and cells counted under an inverted phase-contrast 
microscope.  
 
 
 
	
35	
The number of total cells vs live cells/ml was established using the formula:  
Average count x n x 104 = number of cells/ml 
Where n = dilution factor and the average count is the total number of cells divided 
by the number of counting chamber squares, and where 104 is the multiplication  
factor to convert chamber depth (0.1 mm3) to cm3   
2.5.4 Cell	storage	
Single or multiple 75 cm2 flasks of confluent (80-90%) cells were washed with DPBS and 
detached with TrypLE Express reagent and cells pelleted as described in 2.3.1. Cells were re-
suspended in 5 ml of freezing medium consisting of 5 ml DMEM, 20% FBS and 10% 
DMSO). Cells were aliquoted at 1 ml volumes to cryogenic vials and kept overnight at -80oC 
before being transferred to liquid nitrogen storage.  
2.6 RNAi	knockdown	assays		
2.6.1 Dose	response	assays		
Oligonucleotides were tested at half-logarithmic dilutions for dose response assays. The 
concentration of active RNAi oligonucleotide ranged from either 5 nM to 0.167 fM with a 
final oligonucleotide concentration of 30 nM for siRNA22 and shRNA22 and 50 nM to 0.16 
pM for siRNA6, shRNA6, siRNA19 and shRNA19, with a final oligonucleotide 
concentration of 50 nM. The final concentration of bioactive RNAi analogue was therefore 
as follows: 50 nM, 15.9 nM, 5 nM, 1.6 nM, 0.5 nM, 0.16 nM, 0.05 nM, 0.016 nM, 0.005 nm, 
0.0016 nM, 0.0005 nM and 0.00016 nM.  
 
All stock oligonucleotides were first diluted from 100 µM concentration to 5 µM working 
stock concentrations in nuclease-free water. For dose-response assays working dilutions of 
the RNAi oligonucleotides were first prepared at 2000 nM, 100 nM, 3 nM and 0.1 nM 
dilutions in Opti-MEM reduced serum media. To obtain a final concentration range, each of 
the dilutions were prepared at 2X concentration so that after addition of the cells to the assay 
plate, the final concentration of active RNAi reagent is at the desired concentration. Working 
in a deep-well plate, the assay dilutions were prepared by adding the required volume of 
oligonucleotide (to give 2x the desired concentration) to assay wells. The final concentration 
of oligonucleotide for each dilution was equalised to 30 nM or 100 nM using the non-specific 
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oligonucleotide (NSO) (5’-GACCACTTGCCACCCATC-3’) and the volume made up to 20 
µl volume. For the NSO control, NSO was diluted to 30 nM or 100 nM in 20 µl Opti-MEM. 
The mock control consisted of diluted transfection reagent in Opti-MEM. The non-transfected 
control consisted of Opti-MEM only.  
 
Dharmafect3 (Thermo Fisher Scientific) was diluted in Opti-MEM to 0.0025 µl/µl by adding 
24 µl of Dharmafect3 to 9.6 ml of Opti-MEM. The Dharmafect3 dilution was mixed 
thoroughly and 330 µl added to each deepwell oligo dilution, to give a total reaction volume 
of 350 µl. This reaction was mixed and 50 µl of each dilution transferred to assay plates in 
triplicate. Assay plates consisted of one white 96-well plate (VWR, Leicestershire, UK) for 
the luciferase assay and one clear cell culture plate (Corning) for the MTT assay. The NSO 
control preparation had 480 µl diluted Dharmafect3 added to it and 50 µl volumes transferred 
to the assay plate in triplicate. For the mock control, 50 µl of diluted Dharmafect3 was added 
to assay mock control wells. The non-transfection control wells had 50 µl Opti-MEM added 
to them.  
 
The Dharmafect3-oligo complexes were allowed to form for 30-45 minutes during which 
time the cells were prepared. Cells from two or three 75 cm2 flasks at 80-90% confluency 
were detached and pelleted as per section 2.5.1. Cells were re-suspended in 5 ml of Opti-
MEM, counted in duplicate by Trypan Blue assay, and diluted as necessary with Opti-MEM 
to obtain 7000 cells per 50 µl volume. At the end of the oligo-complex formation incubation 
step, 50 µl of cell suspension was added to each well. Plates were viewed under the 
microscope to ensure even distribution of cell in the wells and then incubated at 37oC with 
5% CO2. After 24 hours, Opti-MEM was removed and replaced with complete media without 
Geneticin. Cells were incubated for a further 24 hours. For luciferase assays, media was 
gently removed from the plates by pipetting and cells washed once with DPBS. All excess 
liquid was removed and 50 µl of a mixture of equal volumes of BriteLite Plus Reagent (Perkin 
Elmer, Waltham, MA) and DPBS (Ca+/Mg+) (Thermo Fisher Scientific) added to each well. 
After 5 minutes room temperature incubation, bioluminescence was read on the Glomax 
Multi Detection system (Promega, Southampton, UK) using the Bright-Glo pre-programmed 
protocol with default setting. Knockdown percent was calculated by subtracting the blank 
reading and calculating each bioluminescence reading as a percent of the mean of the NSO 
control. Values were subtracted from 100% to determine the percentage knockdown. EC50 
and R2 goodness of fit was compared for each siRNA vs shRNA HCV RNAi analogue by 
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calculating the nonlinear regression curve fit as log (agonist) vs response (three parameters) 
with the bottom of the curve constrained to zero using GraphPad Prism 7 for Mac OSX.  
2.6.2 Knockdown	of	HCV	replicon	for	collection	of	RNA	for	RACE-Seq		
For knockdown assays, RNAi oligonucleotides were calculated to give 2X the desired active 
concentration in the final required volume of Opti-MEM. See table Table 4.1 for final 
concentrations of oligonucleotides. For example, for siRNA22, the desired concentration was 
0.5 nM. Therefore a 1 nM concentration of siRNA22 was prepared in 3000 µl of Opti-MEM 
by adding together 6 µl of siRNA22 at 500 nM, 59.4 nM NSO at 5 µM and 2,934 µl Opti-
MEM. Then 7 µl of Dharmafect3 was added to give ~0.0025 µl/µl Dharmafect3 and the oligo 
preparation mixed and 50 µl volumes aliquoted to assay plates. The NSO, mock and non-
transfection controls were prepared as previously (Section 2.4). After 30-45 minutes 
incubation to allow complexes to form, 7000 cells in 50 µl was added to each well. As with 
the dose-response assays, media was changed after 24 hours. Cells were collected after a 
further 24 hours incubation.  Knockdown was determined by a luciferase assay and viability 
determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenytetrazolium bromide (MTT) 
assay.  
2.6.3 Knockdown	of	Transthyretin	for	collection	of	RNA	for	RACE-Seq	
Annealing of siRNA duplex 
To prepare siRNA-TTR, each of the single RNA strands, siRNA-TTR-AS and siRNA-TTR-
SS were resuspended to 100 µM in duplex buffer (IDT). To anneal the siRNA-TTR strands, 
50 µl of each RNA strand (AS and SS) was pooled in a PCR tube, mixed and heated to 92oC 
for 2 minutes, then allowed to slowly cool at room temperature.  
Reverse Transfection 
For knockdown assays, the DsiRNA-TTR, siRNA-TTR and a Scrambled Negative Control 
DsiRNAscr (1 nmol) (catalogue number 51-01-19-08) (IDT) was prepared at 10 nM by 
adding together; 52 µl RNAi Oligo at 500 nM, 20.8 µl NSO at 5 µM and 1,227 µl Opti-MEM. 
1 µl of Dharmafect3 was added to each preparation, mixed well and 250 µl transferred to four 
wells of a 24 well plate. NSO control was prepared by mixing together 26 µl NSO (5 µM), 
1,274 µl Opti-MEM and 1 µl Dharmafect3 and transferring 250 µl to assay wells. The mock 
control was prepared as 1 µl Dharmafect3 in 1300 µl Opti-MEM. The non-transfected control 
was prepared by adding 250 µl Opti-MEM to assay wells. Huh7/con1b cells were prepared 
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by washing two times with warmed DPBS, detached with 2 ml TrypLE Express, washed and 
cells pelleted by centrifugation at 400 rpm for 5 minutes. Cells were resuspended in 5 ml 
Opti-MEM. After duplicate cell count, cells were diluted to 168,000 cells/ml and 250 µl cell 
suspension added to each well to give ~42,000 cells/well. Media was changed after 24 hours 
to standard DMEM media without G418. After a further 24 hours incubation at 37oC, 5% 
CO2, total RNA was either extracted directly from the plate by the TRIzol® method, or cells 
harvested and stored at -80oC. Cell viability was determined by the MTT assay using the 
remaining treatment well as described in Section 2.7.1 with the following amendments: 500 
µl of prepared MTT reagent (0.05 mg/ml) was added to the 24 well plate. Plates were 
incubated at 37oC, 5% CO2 for 4 hours and then the supernatant removed.  The Formazan 
crystals were dissolved by adding 200 µl DMSO to each treatment well. Then 50 µl per 
treatment was transferred to a 96 well plate and absorbance read at 540 nm as described in 
section 2.7.1. Routine Cell Assays  
2.6.4 Cell	viability	assay	
To assess possible cytotoxic effects of experimental procedures, the MTT reduction assay 
(Riss et al., 2004) was performed as a measure of cell viability. These assays were carried out 
in clear 96-well cell culture plates. Media was removed and 100 µl prepared MTT reagent 
(0.05 mg/mL in DMEM) (Thermo Fisher Scientific) added to each well. Plates were 
incubated at 37oC in a humidified 5% CO2 incubator for 4 hours. After incubation, the 
supernatant was carefully removed and plates either stored at -20oC or processed 
immediately. Formazan crystals were dissolved by the addition of 50 µl Dimethyl Sulfoxide 
(DMSO) to each well and plates incubated in the dark for 10 minutes. The blank reagent 
control consisted of DMSO only. Absorbance was read at 540 nm on the SPECTROstar Nano 
(BMG LABTECH, Aylesbury, UK) and analysed using the MARS data analysis software. 
Viability was calculated by subtracting the blank OD value from all reading, then calculating 
each reading as a percent of the mean NSO control value.  
2.6.5 Luciferase	reporter	assay	
Luciferase reporter assays are commonly used to monitor cellular events coupled to gene 
expression. These reporters are very sensitive since no background luminescence exists in 
host cells. The HCV replicon in the Con1B cell line contains a firefly luciferase gene in lieu 
of the viral packaging genes (Krönke et al., 2004), producing bioluminescent luciferase 
	
39	
protein at amounts proportional to the viral content in the cells. Thus, quantification of 
bioluminescence in these cells is an appropriate measure of replicon levels (Krieger et al., 
2001). To determine the lower limit of detection for luciferase-expressing Con1B cells, the 
luciferase activity of serially diluted cells was measured. To do this, cells from a single 75 
cm2 flask at 90% confluency were re-suspended in 2 ml DMEM. Duplicate cells counts were 
determined using the Trypan Blue assay. Cells were diluted at half-logarithmic (3.16 fold) 
dilution in triplicate in white 96 well plates. To do this, 48,000 cells in 146 µl volume were 
added to well A1, A2 and A3. Cells were mixed well and 46 µl transferred to the next well 
that contained 100 µl of DMEM. This was repeated for consecutive wells on the plate. The 
final cell count was therefore approximately 30,000 cells, 10,000 cells, 3,000 cells, 1,000 
cells, 300 cells, 100 cells and 30 cells. Cells were pelleted by centrifuging at 1000 rpm for 5 
minutes and media removed by gentle pipetting. For the luciferase assay, an equal volume of 
DPBS (Ca+/Mg+) (Thermo Fisher Scientific) and BrightLite Plus luciferase reagent 
(PerkinElmer, Coventry, UK) was mixed together and 50 µl added to each well. Blank reagent 
control consisted of luciferase reagent mix without cells. Bioluminescence was determined 
on the Glomax Multi Detection system (Promega, Southampton) using the Bright-Glo pre-
programmed protocol with default setting. Standard curves were generated by subtracting the 
blank from readings and then plotting the mean and error vs number of cells per well.    
2.6.6 Generating	cDNA	templates	for	qPCR	
The following method was used to generate the cDNA templates for both the qPCR 
amplification efficiency experiments as well the qPCR assays for determining TTR 
knockdown. Total RNA was quantified using the Qubit RNA High Sensitivity kit (Thermo 
Fisher Scientific) and then diluted in nuclease-free water to give 500 ng RNA in 10.5 µl 
volume. SuperScript IV (SSIV) Reverse Transcriptase (Thermo Fisher Scientific) was used 
for all reverse transcription assays following the manufactures instructions. Reverse 
transcription was carried out in 20 µl reactions and prepared by placing the following together 
in a PCR tube; 10.5 µl total RNA at 500 ng, 1 µl dNTP mix (10 mM), 0.5µl oligo d(T)22 (100 
µM), 1µl TTR-rt primer at 2 µM. Components were gently mixed by pipetting and then heated 
at 65oC for 5 minutes in the TC-PLUS thermal cycler (Techne). Samples were cooled directly 
on ice, then spun down and the reverse transcription mix added. Reverse transcription reaction 
mix was prepared as a master mix consisting of; 4 µl 5 X SSIV buffer, 1 µl DTT (100 mM), 
0.2 µl RNase Inhibitor (40,000 U/ml) (NEB), 1 µl SSIV Reverse Transcriptase enzyme (200 
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U/ µl) and 1.3 µl water.  Then 7 µl was added to each RNA mix, mixed gently, spun down 
and cDNA synthesis reactions carried out at 55oC for 10 minutes with heat inactivation of 
Reverse Transcriptase enzyme at 75oC for 10 minutes. cDNA was stored at -20oC and kept 
on ice when in use.   
2.6.7 Validation	of	primer	amplification	efficiency		
All qPCR reactions were carried out on the Applied Biosystems 7500 Fast PCR Instrument 
and using Luna Universal qPCR Master Mix (NEB). Primer amplification efficiency for TTR 
and GAPDH qPCR primers was verified prior to evaluating relative TTR mRNA levels after 
treatment. PCR amplification efficiency was established using calibration curves. To generate 
the calibration curves, total RNA was extracted from Huh7/con1b cells, DNase I treated, 
purified and quantified in duplicate using Qubit RNA High Sensitivity kit. Then 500 ng of 
purified RNA was reverse transcribed using SSIV reverse transcriptase and a pooled primer 
mix of TTR reverse primer and Oligo d(T)22 primer. Primer efficiency was measured using 
serially diluted cDNA (50 ng, 10 ng, 5 ng, 1 ng, 0.5 ng 0.1 ng and 0.05 ng) as template in 
qPCR reactions. Reactions were carried out in triplicate and CT values used to calculate PCR 
efficiency by plotting average CT value vs log of cDNA input amount. To test for DNA 
contamination in RNA extractions, a sample of purified RNA was used as template in the 
DNA contamination control reactions. Cycle conditions were; 95oC for 30 seconds, followed 
by 40 cycles of 95oC for 5 seconds, 55oC for 30 seconds, 72oC for 30 seconds (Hayashi et al., 
2012).  The R2 and the equation of each standard curve was calculated and the slope value of 
each standard curve was used to compute primer efficiency percentage and the amplification 
factor for each primer set using the online qPCR Efficiency Calculator tool from Thermo 
Fisher Scientific (https://www.thermofisher.com/uk/en/home/brands/thermo-scientific/ 
molecular-biology/molecular-biology-learning-center/molecular-biology-resource-library 
/thermo -scientific-web-tools/qpcr-efficiency-calculator.html).  
2.6.8 Relative	gene	expression	by	the	2-∆∆CT	Method		
For determining the relative mRNA knockdown, qPCR reactions were performed in triplicate 
and included both a non-template control and DNA contamination control (consisting of RNA 
as template). All qPCR reactions were carried out as 12 µl reactions. Template cDNA for 
each treatment was generated as described in Section 2.6.6, and diluted 1:2 resulting in 
approximately 25 ng/µl cDNA template. Then, 2 µl of the diluted template was used for each 
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qPCR reaction. A master mix of reagents was prepared which consisted of 6 µl Luna 
Universal qPCR Master Mix (NEB), 0.6 µl forward primer, 0.6 µl reverse primer and 2.8 µl 
water per well.  GAPDH was used as internal reference gene.  Cycle conditions were as per 
section 2.6.7. The 2-DDCT method (Schmittgen and Livak, 2008)  was used to calculate the 
relative change in gene expression level by real-time quantitative PCR.  
2.7 RNA	extraction	and	purification	
2.7.1 Collection	of	cells	from	96	well	plates	
For collection of cells from 96-well plates, cells were washed twice with pre-warmed DPBS 
and incubated with TrypLE Express reagent at 50 µl per well for up to 8 minutes at 37oC with 
5% CO2. Then, 100 µl of media was added to row one of the plate and cells were mixed at 
least 7 times to dislodge the cells and then cells transferred to the next column. This was 
repeated for the whole plate and dislodged cells collected in a 15 ml conical tube. Plates were 
observed under the microscope to ensure cells had been dislodged and collected. Cells were 
centrifuged at 1000 rpm for 5 minutes at 4oC. Supernatant was removed and cell pellets stored 
at -80oC for RNA extraction. Cells were collected from 36 wells of a 96-well plate for RACE-
Seq assays.  
2.7.2 RNA	extraction	using	the	PureLinK	RNA	Extraction	Kit		
Total RNA was isolated using the PureLink RNA Mini Kit (Life Technologies, UK). Cell 
pellets were removed from -80oC storage and 600 µl lysis buffer containing 1% v/v 
2-mercaptoethanol added and vortexed for a full 1 minute. After addition of equal volume of 
70% v/v ethanol and a brief vortex, samples were transferred to spin columns. Columns were 
centrifuged at 12 000 x g for 15 seconds, then washed with wash buffer I and wash buffer II. 
Total RNA was eluted in 50 µl RNase free water. RNA was stored in two aliquots at -80oC. 
2.7.3 Extraction	of	RNA	by	TRIzol®	method		
Total RNA was extracted directly from 24 well plates or pelleted cells using TRIzol® reagent 
(Thermo Fisher Scientific). For the extraction of RNA directly from 24 well plates, cells were 
washed twice with approximately 1 ml warmed DPBS and all excess liquid removed. For 
each knockdown treatment, the extract from three wells was pooled by adding 200 µl of 
TRIzol® to each well, mixing vigorously and then transferring the lysate to a 1.5 ml 
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microcentrifuge tube containing 1.5 µl GlycoBlueTM Coprecipitant. Chloroform at 200 µl/1ml 
TRIzol® was added to each tube and contents mixed by inversion for 10 seconds then 
incubated at room temperature for 5 minutes. After centrifugation at 12,000 x g for 15 minutes 
at 4oC, the upper phase was carefully transferred to a new tube and isopropanol at half the 
original volume of TRIzol® added. Samples were gently mixed by inverting three times and 
the samples incubated at room temperature for 10 minutes. After centrifugation at 12,000 x g 
for 10 minutes at 4oC, the supernatant was gently removed leaving behind a blue pellet. Pellets 
were washed with 500 µl 75% ethanol by gentle inversion and flicking, centrifuged at 10,000 
x g for 5 minutes at 4oC and the ethanol removed. Pellets were allowed to air dry and the 
purified RNA resuspended in 44 µl nuclease-free water.  
Deoxyribonuclease I Treatment 
RNA was DNase treated by adding 5 µl of 10x DNase buffer (Thermo Fisher Scientific) to 
each 44 µl volume of total RNA, then 1 µl of Deoxyribonuclease I (DNase I) (1U/ml) 
(Thermo Fisher Scientific) was added, samples mixed and incubated at 37oC for 10 minutes 
on a heat block. To deactivate DNase I, ethylendiaminetetraacetic acid (EDTA) was added to 
a final concentration of 1 mM, mixed and samples heated to 85oC for 10 minutes.  
Final purification 
DNase treated RNA was purified by Phenol-chloroform extraction. Reactions were made up 
to 100 µl with nuclease-free water and an equal volume of phenol/chloroform added, and 
centrifuged at 12,000 x g for 5 minutes. The aqueous phase was removed to a new tube 
containing 1.5 µl of 15 mg/ml GlycoBlueTM Coprecipitant (Thermo Fisher Scientific), 10 µl 
3M Na acetate, pH 5.2 (Thermo Fisher Scientific) and 200 µl (2x volume) of absolute ethanol 
(VWR). Samples were vortexed briefly and incubated for 30 minutes on dry ice. Samples 
were then centrifuged at 16,000 x g for 20 minutes at 4oC and the supernatant carefully 
removed. The RNA pellet was washed once with 500 µl 70% v/v ethanol, with mixed by 
inversion, then vortexed for 10 seconds. After centrifugation at 16,000 x g for 2 minutes the 
supernatant was carefully removed and RNA pellets were air dried for up to 5 minutes, 
resuspended in 30 µl RNase-free water and kept on ice. 
RNA analysis and quantification 
RNA quality was assessed by Nanodrop and RNA quantified using the Qubit RNA High 
Sensitivity kit.  
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2.8 Assessment	of	nucleic	acids	
2.8.1 NanoDrop	quantification	(DNA	and	RNA)		
Concentration and purity of nucleic acid extractions were determined using a NanoDrop 1000 
spectrophotometer (Thermo Fisher Scientific). 1 µl of purified nucleic acid was analyzed 
using default setting for DNA or RNA as required.   
2.8.2 Qubit	quantification		
DNA or RNA quantification was assessed using either the Qubit dsDNA HS assay kit 
(Thermo Fisher Scientific) or the Qubit RNA HS assay kit (Thermo Fisher Scientific) 
following the manufacturer’s protocol. Briefly, Qubit working solution was prepared by 
diluting Qubit reagent 1:200 with the Qubit buffer. 1 µl of sample was then added to 199 µl 
of working solution in Qubit assay tubes. Standards were prepared by diluting 10 µl of each 
standard in 190 µl of working solution in Qubit assay tubes. After 3 minutes incubation, 
standards and samples were read on the Qubit 2.0 Fluorometer. 
2.9 RNA	Ligase-Mediated	Rapid	Amplification	of	cDNA	
Ends	(RLM	RACE)		
An outline of the RLM RACE assay is illustrated in Figure 1.6. Adapter ligation reactions, 
were prepared as either 10 µl volumes, or scaled to 20 µl volumes. For the 20 µl reactions, 2 
µl of truncated GeneRacer RNA adapter (100 µM) and >1 µg of total RNA (total volume 
12.5 µl) was heated at 65oC for 5 minutes in a thermal cycler then snap cooled on ice for 2 
minutes. Then, 5.5 µl of a ligation mix (consisting of 2 µl of 2x ligase buffer (NEB, Hitchin, 
UK), 2 µl 10 mM Adenosine 5’-Triphosphate (ATP) (NEB), 0.5 µl RNase Inhibitor, Murine 
(40,000 units/ml) (NEB) and 1 µl T4 RNA ligase (10,000 units/ml, NEB) was mixed by 
pipetting and briefly centrifuged at 10 000 x g. Adapter ligation was carried out at 37oC for 1 
hour in a Techne TC-PLUS thermal cycler (Bibby Scientific, Staffordshire, UK) with heated 
lid setting turned off. RNA precipitation was carried out by bringing the reaction volume to 
100 µl with nuclease-free water, then 100 µl of acid phenol/chloroform (Thermo Fisher 
Scientific) was added to each adapter ligation reaction and vortexed for 30 seconds.  PCR 
tubes were centrifuged at 12 000 x g for 5 minutes at room temperature and approximately 
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100 µl of the upper phase was carefully removed to a 1.5 ml nuclease-free centrifuge tube. 
1.5 µl of 15 mg/ml GlycoBlue (Thermo Fisher Scientific) and 10 µl 3M sodium (Na) acetate, 
pH 5.2 (NEB) and 200 µl (2x volume) of absolute ethanol (VWR) was added to each volume 
and vortexed briefly. After 30 minutes incubation on dry ice to precipitate the RNA, tubes 
were centrifuged at 16 000 x g for 20 minutes at 4oC. Being careful not to disturb the pellet, 
tubes were carefully removed from the centrifuge and the supernatant removed by pipetting. 
The pellet was washed by adding 500 µl of 70% v/v ethanol and mixed by inversion, then 
vortexed for 10 seconds. After centrifugation at 16 000 x g for 2 minutes, supernatant was 
carefully removed.  Tubes were centrifuged for a further 10 seconds at 16 000 x g and residual 
ethanol removed. RNA pellets were air dried for up to 5 minutes and RNA re-suspended in 
11 µl RNase-free water and kept on ice.  
 
First strand cDNA was synthesised using either SuperScript III reverse transcriptase enzyme 
(Thermo Fisher Scientific) or Moloney Murine Leukemia Virus (M-MuLV) Reverse 
Transcriptase (NEB). First, 11 µl of RNA, 1 µl of the gene-specific reverse primer at 2 µM 
and 1 µl of dNTP (10 mM each, Sigma-Aldrich, Poole, UK) were mixed together and then 
heated for 5 minutes at 65oC to remove secondary structure and samples snap cooled on ice 
for 2 minutes.   
 
For SuperScript III: A master mix was prepared consisting of: 4 µl 5X First strand buffer, 1 
µl of 0.1 mM DTT, 0.2 µl RNase Inhibitor, 1 µl of SuperScript III reverse transcriptase 
enzyme and the mix made up to 7 µl volume using nuclease-free water was added to the 
RNA.  
 
For M-MuLV: A master mix was prepared consisting of: 2 µl 10X reaction buffer, 0.2 µl 
RNase Inhibitor, 1 µl of M-MuLV reverse transcriptase enzyme and the mix made up to 7 µl 
volume using nuclease-free water. This was added to the prepared RNA. Reverse 
transcription was carried out at 55oC for 30 minutes and enzyme inactivated by increasing the 
temperature to 70oC for 15 minutes. cDNA was stored at -20oC or used immediately in PCR 
reactions. 
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2.9.1 		PCR	amplification		
The cDNA was amplified by anchored PCR reaction using forward primer, GreneRacerF1 
and a gene-specific reverse primer.  PCR reactions were set up as 40 µl volume reactions as; 
20 µl Q5 Hot Start High-fidelity 2X Master Mix (NEB), 2 µl GeneRacerF1 primer (10 µM), 
2 µl gene-specific reverse primer (10 µM), 4 µl cDNA template (10 % of PCR volume) and 
made up to 40 µl with nuclease-free water (Thermo Fisher Scientific). PCR amplification was 
carried out on the Techne TC-PLUS thermal cycler (Bibby Scientific) with the following 
cycle conditions; 98oC for 30 seconds, 35 cycles of (98oC for 15 seconds, 60oC for 10 seconds, 
72oC for 15 seconds), then 72oC for 2 minutes and hold at 10oC. 
 
When second-round PCR was required, first round PCR was scaled down to 15 µl reactions 
and PCR amplification carried out as the above conditions. Then, residual primers were 
enzymatically degraded and dNTPs dephosphorylated using the NEB Rapid PCR Clean up 
Enzyme Set (NEB). To a PCR tube, 5 µl of first-round PCR reaction was added to 1 µl of 
Exonuclease I (Exo I) enzyme and 1 µl of Shrimp Alkaline Phosphatase (rSAP) enzyme. The 
contents were mixed gently, briefly centrifuged and placed in the thermal cycler at 37oC for 
5 minutes followed by 80oC for 10 minutes. Then, 4 µl of cleaned PCR was used in a 40 µl 
PCR reaction as above using GeneRacerF2 primer and a gene specific primer located at a 
position internal to the first PCR primer sequence. Up to 10 µl of PCR reaction was analysed 
by electrophoresis on a 2 %TBE agarose gel. The remaining PCR reaction was used for 
library preparation 
2.9.2 		Agarose	gel	electrophoresis	
Gels of 2% w/v agarose was prepared by dissolving agarose (Appleton Woods, Birmingham, 
UK) in 50 ml 1 X Tris/Borate/EDTA (TBE) buffer (Thermo Fisher Scientific) in a microwave 
until all solid particles were completely dissolved. The heated solution was allowed to cool 
for 10 minutes and 2 µl of SYBR Safe DNA staining dye (Thermo Fisher Scientific) was 
added to the gel. The agarose was poured into its gel tank and allowed to solidify. Then, 5 - 
20 µl of PCR sample was diluted 1:4 with 6X Orange DNA loading Dye (Thermo Fisher 
Scientific) before being loaded onto the gel. 5 µl of pre-dyed ladder, GenerRuler 100 bp DNA 
ladder (Thermo Fisher Scientific) was loaded per well. Gels were run at 100 volts for 40 - 60 
minutes prior to UV analysis.  
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2.9.3 		Gel	extraction		
Bands were visualised under blue light on the Safe Imager 2.0 Blue Light Transilluminator 
(Thermo Fisher Scientific) and target bands excised from the gel using a scalpel. DNA was 
extracted from gel slices using the NEB Monarch DNA Gel Extraction Kit (NEB). Briefly, 
each gel slice was dissolved in 4 volumes of gel dissolving buffer at 50oC for 5-10 minutes 
and loaded to the Monarch DNA clean up column. Columns were centrifuged at 13 000 rpm 
for 1 minute followed by two washes with DNA Wash Buffer. Purified DNA was eluted in 
10-20 µl DNA elution buffer (NEB) or nuclease-free water. 
2.10 		Ion	PGM	library	preparation		
2.10.1 		AMPure	bead	clean	(amplicons	>100	bp)	
The Agencourt AMPure XP bead system uses solid-phase paramagnetic beads in an 
optimised polyethylene and salts buffer. DNA binds to the beads in a concentration-
independent manner, but associates with the beads in a size-dependent manner when 
adjusting the volume of bead suspension ratio to DNA solution. Bound DNA is separated 
from the supernatant and excess primers, nucleotides and salts using a magnet. The separated 
DNA is washed and then purified DNA eluted from the beads (Rodrigue et al., 2010). 
Amplified libraries were bead cleaned by adding 1.6X volumes of room temperature 
Agencourt AMPure XP beads (Beckman Coulter, High Wycombe, UK) and mixed 
thoroughly by pipetting. Samples were then incubated on the bench for 5-8 minutes before 
being placed on a magnetic rack for 3 minutes. The supernatant was removed and beads were 
washed twice with 300 µl of 70% v/v ethanol. Residual ethanol was removed and beads were 
air dried for 3-5 minutes. Purified DNA was re-suspended in 25 µl Tris/EDTA (TE) (supplied 
with library preparation kit), vortexed briefly, centrifuged at 0.3 x g for 5 seconds and placed 
on the magnetic rack for 2 minutes. Purified DNA was collected in the supernatant (~23 µl) 
and used for library preparation.  
2.10.2 		AxyPrep	Mag	PCR	clean	(amplicons	<100	bp)	
A mix of 70 µl of isopropanol and 180 µl of AxyPrep beads was prepared. A 25 µl volume 
of this mix was added to each 10 µl volume of PCR product, mixed by pipetting, and 
incubated for 5 minutes at room temperature. Tubes were then transferred to a magnetic rack 
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for 3 minutes, the cleared supernatant removed and magnetic bead pellets washed two times 
with 200 µl 70% v/v ethanol without disturbing the pellet. Residual ethanol was removed by 
centrifugation at 0.3 x g for 5 seconds. Beads were allowed to air dry for up to 5 minutes and 
DNA re-suspended in 40 µl TE buffer.  
2.10.3 		5’	RACE	library	preparation	using	NEBNext	Library	Prep	Set	
Amplicon libraries were generated using the NEBNext Fast DNA Prep set for Ion Torrent 
(NEB) as outlined in Figure 3.8. First, amplicons were bead cleaned using either the AxyPrep 
Mag PCR beads for recovery of fragments less than 100 bp or the Agencourt AMPure XP 
beads for PCR amplicons greater than 100 bp. Purified DNA was quantified by Qubit HS 
DNA assay kit and then 200-500 ng DNA was used in the end repair reaction, which consisted 
of 17 µl purified DNA, 2 µl NEBNext End repair reaction buffer and 1 µl NEBNext End 
repair enzyme mix. DNA was blunt-ended in the end repair reaction with a 20 minute 
incubation in a thermal cycler set to 25oC followed by 10 minutes at 70oC. The adapter 
ligation mix was prepared as a master mix consisting of: 6 µl nuclease free water, 3.3 µl T4 
DNA ligase buffer for Ion Torrent, 0.9 µl P1 adapter, 0.9 µl Ion Xpress Barcode Adapter 
(Thermo Fisher Scientific), 0.3 µl BSt 2.0 WarmStart DNA Polymerase and 2 µl T4 DNA 
ligase. This (13.4 µl) was added to the end repair reaction, mixed and placed in thermal cycler 
at 25oC for 15 minutes followed by 5 minutes at 65oC. Barcoded reactions were bead cleaned 
using Agencourt AMPure XP beads and purified DNA eluted in 30 µL TE buffer. Samples 
were then amplified using NEBNext Q5 Hotstart HiFi PCR Master Mix and the sequencing 
amplification primer set supplied in the kit. Samples were amplified in 7 cycles of PCR with 
initial denaturation 98oC for 30 seconds, then 7 cycles of (98oC for 10 seconds, 58oC for 30 
seconds, 65oC for 30 seconds) followed by 5 minutes at 65oC and hold at 10oC.   
2.10.4 		Library	size	selection	using	the	Labchip	XT	instrument		
Labchip XT 300 bp kit (Perkin Elmer) contained all the reagents for DNA extraction. The 
chip was prepared as per manufacturer instructions and wells to be loaded washed with chip 
buffer. LabChip XT Software version 2.1.1233.0SP1 (Perkin Elmer) was launched and a run 
set up. Size range was specified as the expected size of 5’ RACE libraries ± 10% and the 
extract and pause operation selected. Samples were prepared by mixing together 10 µl of 
DNA and 2 µl of the 6X sample buffer. Samples were vortexed briefly, spun down and kept 
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on ice. The DNA marker was prepared by adding 2 µl of ladder to 2 µl 6X sample buffer and 
bringing the volume up to 12 µl with nuclease-free water or TE buffer.  
 
Then 15 µl of XT DNA dye was added to the waste reservoir well and mixed by gently 
rocking the chip. Then, 20 µl of collection buffer was added to collection wells and 20 µl of 
stacking buffer was carefully added to sample wells and any bubbles removed. The entire 12 
µl volume of sample or DNA marker was loaded to sample wells by inserting the tip of the 
pipette to the bottom of the well and slowly but smoothly pipetting the dye labelled sample 
beneath the stacking buffer. The chip was run till completion and size selected fragments 
collected from the collection well and kept on ice.   
2.10.5 		Library	size	selection	using	the	Size	Select	2%	E-gel	system	
The Size Select™ E-gel® (Thermo Fisher Scientific) is a double-comb, precast agarose gel 
system that allows PCR products to be collected directly from the gel, without the need to cut 
sections from the gel and column purify. The gels contain a proprietary fluorescent nucleic 
acid stain, allowing migrating DNA bands to be visualised in real time on the E-gel iBase™ 
blue light transilluminator (excitation/emission 490/522 nm). Samples were prepared by 
diluting 1:5 with 2X Orange DNA loading Dye and added to each well of the Size Select™ 
2% E-gel® and 10 µl of 25 bp DNA ladder (Thermo Fisher Scientific) loaded to the central 
well. All well volumes were made up to 25 µl using nuclease-free water. The gel was set to 
run the pre-set program (number 8). Migration of DNA bands was monitored until the band 
of interest reached the reference line. The run was paused and collection wells topped up to 
25 µl with nuclease-free water. The run was re-started and bands were monitored as they 
flowed into the collection well where the sample was pipetted out of the well and transferred 
to 1.5 ml low-bind Eppendorf tubes (VWR, UK) where they were kept on ice or stored at -
20oC.  
2.10.6 		Gel	extraction	and	purification	of	NGS	libraries	
RACE-Seq libraries were excised from 2% agarose gels and DNA purified as in section 
2.10.3.  
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2.10.7 		DNA	fragment	analysis		
The Bioanalyzer system (Agilent, Santa Clara, CA) and accompanying High Sensitivity DNA 
Kit were used to assess the NGS libraries. The Agilent Bioanalyzer 2100 system uses micro-
capillary electrophoresis on a chip to rapidly analyse DNA fragments with high sensitivity.  
The gel-dye mix was first prepared by adding 15 µl of the blue dye concentrate to the DNA 
gel matrix, mixing by vortexing, centrifuging to pellet the contents and the entire volume was 
transferred to a spin filter tube. The mix was centrifuged at 2,300 x g for 10 minutes and kept 
at 4oC for up to six weeks. On the day of assay, all reagents were allowed to equilibrate to 
room temperature for at least 30 minutes. Samples were prepared by first pipetting 9 µl of the 
gel-dye mixture into the appropriate well and forcing the mixture into the micro-channels by 
applying pressure to the well via a 1 mL syringe on the chip priming station. Then 9µl of the 
gel-dye mixture was also added to the other two wells for gel. All the ladder and sample wells 
were loaded with 5 µl of the DNA marker before loading of 1 µl of either the molecular size 
ladder or 1 µl of sample to wells on the chip. After mixing by vortexing at 2400 rpm on the 
IKA Vortex Mixer, (Agilent) the chip was immediately inserted into the Bioanalyzer 2100 
instrument (Agilent Technologies), the appropriate DNA assay selected and the programme 
started. On completion of the run, the Agilent 2100 Bioanalyzer software identifies DNA 
peaks between the lower and upper marker peaks, reporting size range and fragment length 
as well as picomolar quantification of fragment range. After quantification on the 
Bioanalyzer, samples were each diluted to 1000 pM and pooled in equimolar concentration 
by adding the same volume of each sample to a low-bind Eppendorf. Pooled libraries were 
again quantified in duplicate on a Bioanalyzer High Sensitivity DNA chip prior to dilution to 
13 to 20 pM for input to emulsion PCR. 
2.11 Preparation	and	sequencing	of	NGS	samples		
2.11.1 		Emulsion	PCR	and	enrichment		
DNA fragments are templated to proprietary sequencing beads, the Ion Sphere Particles 
(ISPs) using the Ion Torrent OneTouch2 (OT2) instrument (Thermo Fisher Scientific) and 
accompanying kit Ion PGM Hi-Q OT2 kit (Thermo Fisher Scientific).  The Ion OT2 
instrument was first cleaned by running the cleaning protocol utilising a used amplification 
plate and tubes on the instrument. The used consumables are removed and new collection 
tubes containing 150 µl breaking fluid inserted to the centrifuge. A new plate was inserted 
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and the tubing and needle put in position. The level of the Oil Ion OneTouch Reagent tube 
was filled to half and the Recovery Solution Ion OneTouch Reagent tube was filled to one-
quarter level. The emulsion PCR reactions were prepared by adding in order, to a 2-ml Ion 
PGM Reagent Mix tube containing 800 µl of reagent mix, 25 µl nuclease-free water, 50 µl 
Ion PGM Enzyme Mix, 25 µl diluted library and 100 µl Ion PGM Hi-Q ISPs. After vortexing 
for 5 seconds, the mix was transferred to an Ion OneTouch Reaction Filter as a single 1000 
µl volume by slowly pipetting through the sample port. The reaction tube was placed on the 
OT2 instrument and the 200 bp programme executed. After the run, the ISP pellet was 
collected by removing all but 50 µl of supernatant from the collection tubes. Then 500 µl of 
Ion Wash Solution (Thermo Fisher Scientific) was added to each tube, mixed well and 
transferred to a 1.5 ml low-bind Eppendorf tube. The ISPs are pelleted by centrifugation at 
15,500 x g for 3 minutes and all but 100 µl supernatant removed. A 2 µl volume was 
transferred to a PCR tube for Quality assessment, and the remainder was placed into well 1 
of an eight-well strip. The supernatant from 13 µl of Dynabeads™ MyOne™ Streptavidin C1 
Beads was removed by placing the beads in a 1.5 ml Eppendorf tube on a magnetic rack. 
Then 130 µl of MyOne™ Beads Wash Solution was added and the beads re-suspended. The 
beads were added to well 2 of the 8-well strip. Melt-Off Solution was prepared by mixing 
together 280 µl Tween™ Solution and 40 µl 1 M NaOH, and transferring 100 µl to well 7 of 
the 8-well strip. 300 µl of Ion OneTouch™ Wash Solution was added to wells 3, 4 and 5. A 
new tip was installed in the Tip Arm and 10 µl of Neutralization Solution added to a 0.2 µl 
PCR tube in the collection well. The programme was initialized. Immediately at the end of 
the run, the collection tube was mixed by inversing five times. The enriched ISPs were kept 
at 4oC for up to 3 days.   
2.11.2 		Quality	assessment	of	templated	ISP		
The 2 µl sample of ISPs was quality assessed for enriched ISPs using the Ion Torrent Quality 
Control (QC) kit. Briefly, 19 µl of annealing buffer was mixed with 1 µl of Probe in a PCR 
tube containing 2 µl of ISP sample. The probe mix was incubated in a thermal cycler at 95oC 
for 2 minutes then 37oC for 2 minutes and immediately placed on ice for 2 minutes. Excess 
probe was washed by addition of 200 µl of Quality Control Wash buffer, vortexing and 
centrifugation at 15 500 x g for 2 minutes. All but 10 µl was removed, without disturbing the 
pellet and a second wash performed. Then the ISPs were resuspended to a total volume of 
200µl in Quality Control Wash buffer which was transferred to a Qubit tube. Negative control 
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consisted of 200 µl Quality Control Wash Buffer. Samples were read on a Qubit 2.0 
Fluorometer (Thermo Fisher Scientific) and QC percent calculated with a QC pass accepted 
at 10 to 30% as recommended by the manufacturer. Samples passing these criteria were 
progressed to sequencing on the Ion Torrent PGM.  
2.11.3 		Preparation	of	sequencing	reaction	and	chip	loading		
On the day of sequencing, a chlorite wash and water wash was performed. The reagent bottles 
were washed and prepared as per manufacturer protocols and placed on the instrument and 
the instrument initialized. At this stage, baseline pH is set by mixing the solutions. Once the 
initialization had passed the required criteria, the dNTPs were added to the instrument and 
the new sequencing chip checked. The samples were prepared for sequencing by first adding 
5 µl of Control ISPs (Thermo Fisher Scientific) to the enriched ISPs and then centrifuging at 
15,000 x g for 2 minutes. All but 15 µl of the supernatant was removed and 12 µl of 
sequencing primer added to give a total volume of 27 µl. After mixing and centrifuging to 
collect the contents, the sequencing primer was annealed to the ISPs by heating for 2 minutes 
at 95oC followed by 2 minutes at 37oC and then kept at 25oC.  The checked chip was removed 
from the instrument and all liquid removed from the from the chip using a pipette. The sample 
was removed from the thermal cycler and 3.3 µl of Ion PGM Sequencing Hi-Q polymerase 
added, mixed thoroughly and then 30 µl taken up into the pipette. The chip was slowly filled 
by winding down the pipette at 0.5 µl per second. After first round centrifugation in the 
MiniFuge (Thermo Fisher Scientific), the sample was mixed on the chip by tilting the chip to 
a 45o angle and slowly mixing 25 µl out and back into the chip three times without creating 
bubbles. The chip was centrifuged again on the MiniFuge for 30 seconds. All liquid was 
removed from the chip, and the chip transferred to the Ion PGM. The prepared sequencing 
templates was selected on the PGM and run option selected. The sequencing run was 
monitored on the Ion Server. At the end of the run, the reagent bottles were removed and the 
Instrument washed.  The sequencing data becomes available on the Ion Torrent Server on 
completion of the run.   
2.12 RACE-Seq	data	analysis	
All bioinformatics analysis for this project was carried out on an Apple MacBook Pro, 8 GB 
memory, macOS Sierra version 10.12.5. The following command line packages were used:  
cutadapt (version 1.8.3) (http://cutadapt.readthedocs.io/en/stable/index.html) and FASTX 
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ToolKit (version 0.0.13) (http://hannonlab.cshl.edu/fastx_toolkit/). The alignment and 5’ end 
counting was performed using adapted versions of the RACE-SEQ-lite pipeline (Theotokis 
et al., 2017). The pipeline performs the alignment of RACE-Seq data to the reference using 
Bowtie and the 5’ ends counted using SAMtools. The programme is presented as a custom R 
programme and executed in RStudio. To run the file, the processed RACE-Seq data file as a 
.FASTQ format file, the RACE-SEQ-lite pipeline file and the reference file as a .fasta format 
file was placed into the same folder. The RACE-SEQ-lite file was opened in RStudio, the 
region of the RISC hybridization site adjusted and the mismatch criteria set. The pipeline was 
then executed to generate a comma-separated value (CSV) file containing each position on 
the reference sequence, the corresponding nucleotide, the depth of coverage reported as 5’ 
end counts, the percent of aligned reads at each position and the log10 transformation of read 
counts.  
2.12.1 		Filtering	of	RACE-Seq	datasets	
At the end of the sequencing run, files for each RACE-Seq sample was obtained from the Ion 
Torrent Server as de-multiplexed FASTQ files. Each file was assigned with its barcode and 
sample name as assigned prior to sequencing. The Ion Torrent adapter sequences had been 
auto removed from reads. To prepare samples for alignment to the reference, samples were 
first pre-filtered to specifically select for high quality target specific reads. Each set of data 
was filtered by applying the sequence of queries below, which were executed line-by-line in 
the command line environment (Table 2.4). 
 
The following sequence of actions was used for filtering of reads to generate a ‘filtered 
dataset’ with reads >30-nt length (see Table 2.4 for the accompanying code). 
I. Reads	were	filtered	by	identifying	the	truncated	GeneRacer	adapter	sequence	on	the	
5’	end	of			reads	and	the	reverse	complement	of	the	GeneRacer	adapter	sequence	on	
the	3’	end	of	reads.		
II. Reads	containing	the	reverse	complement	sequence	of	the	GeneRacer	adapter	at	the	
3’	end	were	reverse	complemented	using	the	FASTX	toolkit.		
III. The	reverse	complemented	file	was	concatenated	to	the	RACE.fastq	file.		
IV. The	GeneRacer	adapter	sequence	was	trimmed	from	all	reads	with	--no-indels,	that	sets	
the	insertion	and	deletion	tolerance	to	0.		
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V. The	sequence	of	the	reverse	primer	was	 identified	on	the	3’	end	of	reads	and	reads	
partitioned	 to	 a	 new	 file	 with	 either	 trimming	 of	 the	 sequence	 for	 RACE-Seq	 long	
amplicon	assay	or	no-trimming	for	the	legacy	RACE-Seq	assays.		
VI. The	3’	ends	of	reads	were	quality	trimmed.		
VII. Short	reads	were	removed	(with	minimum	length	set	at	30-nt	for	the	legacy	RACE-Seq	
assays.)		
The datasets were then analysed using an adapted RACE-SEQ-lite pipeline where the adapter 
trimming code has been removed since adapter trimming had been done during the filtering 
process.  
 
For aligning the reads to the reference sequence, the Bowtie aligner can allow up to three 
mismatches. Mismatch criteria was generally set to zero for aligning RACE-Seq data. 
However, the quasispecies nature of the HCV RNA genome means that there is naturally a 
high amount of sequence variability from the amplified target. Therefore, there would always 
be a subset of data that failed to align and therefore failed to be included in the RACE-Seq 
analysis. For the RACE-Seq data analysis, the region immediately after the RNA adapter is 
really what is of primary importance. Therefore, in order to capture more of the RACE-Seq 
relevant dataset, an alternative filtering protocol was implemented to shorten the reads prior 
to alignment (Tabernero et al., 2013; Ganesh et al., 2016) and thus eliminate the part of the 
read that may hold mismatches to the target that exclude the read from alignment. The read 
quality of the shortened datasets was analysed using the FASTQC tool version 0.11.4.  
 
The following sequence of actions was used for filtering of reads to generate the’ filtered 
dataset’ with reads of adapter+20-nt, see Table 2.5. 
Steps (i), (ii) and (iii) were carried out as before using the code as per Table 2.4.  
iv. The reverse primer sequence was identified on the 3’ end of reads and trimmed. 
v. For the reads the held the reverse primer trimmed, reads were filtered for those reads 
that   additionally held the sequence of the next 10 bases immediately internal the 
reverse primer position. This action specifically enriched for the amplified target and 
eliminated non-specific amplified reads.  
vi. Reads were shortened to contain the RNA adapter sequence and the next 20-nt after 
the adapter using ‘fastx_clipper’. The last 4 bases of the RNA adapter sequence were 
excluded from the sequence at this stage to account for variability at the 5’ end of the 
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sequence adapter that may have occurred during the Ion Torrent Server trimming of 
the sequencing adapter sequences from reads.     
This adapter+20-nt dataset constituted the filtered dataset. The RACE-SEQ-lite pipeline 
trimmed the RNA adapter sequence and performed the read alignment and 5’ end counts.  
 
Table 2.4   Command line code used for filtering RACE-Seq datasets 
	 Command	line	code	
i	 cutadapt	-a	revRACE=TTTCTACTCCTTCAGTCCATGTCAGTGTCC	-g	
RACE=GGACACTGACATGGACTGAAGGAGTAGAAA	--no-trim	-o	{name}.fastq	input_name.fastq	
	 	
ii	 fastx_reverse_complement	-Q33	-i	revRACE.fastq	-o	name1.fastq	
	 	
iii	 cat	RACE.fastq	name1.fastq	>name2.fastq	
	 	
iv	 cutadapt	 -g	 name3=^GGACACTGACATGGACTGAAGGAGTAGAAA	 --no-indels	 -o	 {name}.fastq	
name2.fastq	
	 	
v	 cutadapt	-a	name4=reverse_primer_sequence	-o	{name}.fastq	name3.fastq	
v*	 cutadapt	-a	name4=reverse_primer_sequence	--no-trim	-o	{name}.fastq	name3.fastq	
	
vii	 cutadapt	-q	30	-o	name5.fastq	name4.fastq	
	 	
viii	 cutadapt	--minimum-length	30	name5.fastq	>	final_output_name.fastq	
 
v* = code for selecting reads without trimming the reverse primer sequence 
 
 
 
Table 2.5   Command line code for adapter+20-nt filtering of RACE-Seq data 
	 Command	line	code	
i	 cutadapt	-a	revRACE=TTTCTACTCCTTCAGTCCATGTCAGTGTCC	-g	
RACE=GGACACTGACATGGACTGAAGGAGTAGAAA	--no-trim	-o	{name}.fastq	input_name.fastq	
	 	
ii	 fastx_reverse_complement	-Q33	-i	revRACE.fastq	-o	name1.fastq	
	 	
iii	 cat	RACE.fastq	name1.fastq	>name2.fastq	
	 	
v	 cutadapt	-a	name3=reverse_primer_sequence	-o	{name}.fastq	name2.fastq	
	 	
v	 cutadapt	-a	name4=internal-10-nt	-o	{name}.fastq	name3.fastq	
	
vi	 fastx_clipper	 -Q33	 -a	 ACTGACATGGACTGAAGGAGTAGAAA	 -d	 20	 -i	 name4.fastq	 -o	
final_output_name.fastq	
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2.12.2 	Data	presentation	
Bar chart plots of 5’ end counts vs nucleotide within the RISC hybridization site or count as 
a percent of total aligned reads were generated.  
2.12.3 	Generating	hybridization	images	for	RNAi	bioactives	
Hybridization images for the RNAi molecules were generated using Unafold online server 
(http://unafold.rna.albany.edu/) using the ‘Two-state melting (hybridization)’ programme for 
siRNA and Dicer substrate RNAi and the ‘Two-state Folding’ programme for shRNA using 
default settings  (Zuker, 2003). 
2.12.4 	Analysis	of	unaligned	data		
Reads that did not align to the HCV replicon reference sequence when mismatch criteria was 
set to 3, were retained for reanalysis. To facilitate manual review, the reads were collapsed 
and then the top 100 sequences were aligned to the reference sequence using T-Coffee, 
(https://www.ebi.ac.uk/Tools/msa/tcoffee/) an online multiple sequence aligner. This aligner 
uses a combination of local and global alignment and generates a position-specific scoring 
scheme in a progressive alignment method.  Additionally, since values obtained for a given 
pair of sequences is evaluated against information from the other sequences in the set, a 
significant increase in alignment accuracy is obtained (Notredame et al., 2000) To better 
visualise the output, MView (http://www.ebi.ac.uk/Tools/msa/ mview/) was used. This is a 
tool that converts the results of a multiple sequence alignment to a coloured format where hits 
are stacked against the query. Pyrimidines (CT) appear as light blue while purines (AG) are 
dark blue (Brown et al., 1998). Default settings were used.   
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l 		TRANSITIONING	RACE-SEQ	TO	
THE	ION	TORRENT	PGM	
3.1 Introduction		
The 5’ RLM-RACE assay is a semi-specific targeted assay, that is used to capture and enrich 
for the downstream cleaved product generated by the catalytic activity of AGO2-RISC when 
directed to a particular site on the target RNA by the guide strand of an siRNA. The 
downstream cleaved RNA fragment of the targeted mRNA is left with a monophosphate on 
the newly formed 5’ end (Martinez and Tuschl, 2004; Schwarz et al., 2004). After total RNA 
extraction, T4 RNA ligase is used to attach the RNA adapter to the 5’ end of the cleaved 
fragments (Soutschek et al., 2004; Frank-Kamenetsky et al., 2008; Judge et al., 2009). T4 
RNA ligase catalyses the formation of a phosphodiester bond between the terminal 5’ 
phosphate of mRNA and the 3’-hydroxyl-terminated RNA adapter, in a template independent 
manner. Any RNA or single stranded DNA with a 5’ phosphate will be adapter ligated. The 
target sequence of interest is enriched by cDNA synthesis with a gene-specific reverse 
transcription primer and amplification using a primer to the RNA adapter and the mRNA of 
interest. The PCR products are cloned into a vector and individual clones sequenced by 
Sanger Sequencing to confirm the expected cleavage site (Davis et al., 2010; Chang et al., 
2010; Clark et al., 2013).  
 
At the start of this project in early 2014, only two publications had used NGS of 5’ RLM-
RACE products to interpret RISC activity of introduced siRNAs in humans or human cell 
lines.  In both cases Illumina sequencing was used (Tabernero et al., 2013; Denise et al., 
2014). In a first-in-humans trial of an RNAi therapeutic targeting vascular endothelial growth 
factor (VEGF)-A mRNA and kinesin spindle protein (KSP) mRNA in cancer patients, 
Tabernero et al., (2013) sequenced the 5’ RACE-PCR products from 15 patients both pre- 
and post-treatment. The pre-treatment 5’ RACE data was used to set a base level for specific 
cleavage product. Although the authors did not present all their data, they confirmed that for 
two patients, for an average of three measurements from the same biopsied tumour sample, 
the 5’specific cleavage product for VEGF mRNA reached >20% above base level and for a 
further third patient was 4.3% above base level. For KSP mRNA, no specific cleavage product 
was detected by 5’ RACE, and this was attributed to the much lower levels of KSP mRNA 
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compared to VEGF mRNA. The authors also commented that the mix of tumour tissue types 
in the biopsied material (normal liver, necrotic/fibrotic tissue and viable tumour tissue) may 
have impacted mRNA measurement assays.  
 
Denise et al. (2014) sought to use NGS to gain new insights to the processing and activity of 
the shRNAs expressed from TT-034, a DNA-directed RNAi therapeutic targeting HCV. In 
an attempt to comprehensively characterise various aspects of drug activity the hairpin 
sequences expressed from TT-034 after transfection to Huh7/con1b cells were isolated and 
sequenced by NGS. In analysing these sequences they observed that hairpin expression from 
TT-034 was uneven due to variation in the expected transcription start site (Lavender et al., 
2012). They reported that up to 95 siRNA strands could be processed by Dicer cleavage, with 
individual siRNA strands having variable sequences at either of their ends and some of the 
siRNA strands with TT-034 backbone sequences or sequences from the shRNA loop 
structure. Thus, unexpected siRNAs were generated from TT-034.  The most common siRNA 
sequences were selected and synthetic siRNAs purchased and transfected to Huh7/con1b 
cells. RACE-Seq analysis was conducted and sequences analysed. They found cleavage 
products with 5’ ends upstream of the expected cleavage site for siRNA19 and siRNA22 
which led to the proposal that AGO2-RISC might favour a secondary cleavage position 
beyond the expected cleavage site (between bases 10-11).  
 
In this part of the project, the legacy RACE-Seq assay reported by Denise et al. (2014) was 
carried out using a synthetic siRNA22 and synthetic shRNA22. A schematic of the assay is 
presented in Figure 3.1 and indicates the position of the reverse primer, the PCR amplification 
primers and the expected size of the 5’ RACE-PCR product. In 2014, the Ion Torrent PGM 
Platform was still new to the market, having been launched in 2010. It offered a cheaper 
alternative to the Illumina sequencing platform offering broader access to NGS technology, 
and was already showing promise in clinical diagnostics (Singh et al., 2014; Malapelle et al., 
2015).  
 
The main objective of this chapter was therefore to perform the RACE-Seq assay on the Ion 
Torrent PGM. To do this, total RNA after knockdown of HCV genomic RNA was collected 
and 5’ RML-RACE performed. The amplicons were progressed to NGS library preparation 
and libraries passing validation progressed to emulsion PCR and sequencing on the Ion 
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Torrent PGM.  The aligned and unaligned RACE-Seq datasets were comprehensively 
analysed.  
The following approaches were taken towards achieving the objectives:  
• HCV replicon transcripts were targeted using the synthetic siRNA22 and shRNA22 
analogues of TT-034.   
• Cells were harvested, total RNA extracted and the 5’ RLM RACE assays conducted.  
• 5’ RACE amplicons were verified by agarose gel and Bioanalyzer analysis.  
• Two different PCR amplification Master Mixes were evaluated and two different 
NGS library preparation kits for Ion Torrent library preparation were evaluated.  
• NGS libraries were sequenced on the Ion Torrent PGM.  
• Data filtering options for selecting the specific target sequences from the dataset were 
explored. 
• Finally, the RACE-Seq datasets were analysed using online bioinformatics tools, 
command line tools and a custom-built Bowtie aligner pipeline.		
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Figure 3.1   Schematic representation of the Legacy RACE-Seq assay. 
AGO2-RISC cleavage leaves a phosphate at the new 5’ end of the downstream 
fragment of the cleaved RNA. This end is ligated to a short RNA molecule (the RNA 
adapter). After reverse transcription with a gene specific primer, anchored PCR is 
performed with an RNA adapter primer and the reverse transcription primer, 
generating a short (~75 bp) amplicon.  
 
 
 
 
Preparation	of	NGS	library	
Legacy	assay	– amplicon	~75	bp
Preparation	of	NGS	library	
Legacy	assay	– amplicon	~75	bp
Preparation	of	NGS	library	
Legacy	assay	– amplicon	~75	bp
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3.2 Results	
3.2.1 Growth	and	cell	morphology	of	Huh7/con1b	cells	in	culture	
Huh7 cells remain the most permissive cell line for maintaining the replication of HCV 
viral RNA (Blight, et al., 2002; Wakita, et al., 2005; Sainz, et al., 2009; Che, et al., 2012; 
Wose Kinge, et al., 2014;Yu, et al., 2014). The huh7/con1b cell line used in this study 
contains the self-amplifying I389/NS3-3’/LucUbiNeo-ET subgenomic replicon, kindly 
gifted from the lab of Dr Ralf Bartenschlager (Lohmann et al., 1999). The replicon holds 
a number of adaptive mutations that allow increased accumulation of HCV replicon RNA 
under G418 selection. The Huh7/con1b cell line has been used extensively for screening 
of small molecule drugs with the potential to inhibit HCV RNA replication (Devogelaere 
et al., 2012), to optimise drug antiviral potency (Lu et al., 2004), and to elucidate drug 
mechanism of action (Te et al., 2007) . The replicon system allows for the stable expression 
of HCV non-structural proteins.  
 
Huh7 cells were first isolated from a Japanese man with well differentiated hepatocellular 
carcinoma. Morphologically, the cells are large and flattened, grow as monolayer islands 
and exhibit a cuboidal epithelial like cell morphology. They retain a low nucleus-to-
cytoplasm ratio, are mono- and bi-nucleate and contain multiple nucleoli and cytoplasmic 
granules (Figure 3.2 A). A study of eight Huh7 cell lines from different laboratories 
identified morphological differences between cell lines (Sainz et al., 2009). Most cell lines 
had typical Huh7 morphology while some showed slight differences such as the formation 
of tightly packed multi-layered islands and differences in cell size. Infecting the cell lines 
with cell-culture derived HCV (HCVcc) induced HCV-mediated cytopathic effect (CPE) 
including altered cell morphology, where some cells showed high nucleus-to-cytoplasm 
ratio resulting in an amoeboid-like shape (Sainz et al., 2009). In the replicon cell line used 
in this study, this type of CPE was readily observed during cell passage (Figure 3.2 B). 
Over time, these amoeboid-like shaped cells and other CPE such as the formation of 
syncytia (polykaryotes) became more announced with successive cell passage. The 
observation of increased accumulation of such CPE was used to identify the cell passage 
range for knockdown assays. For this work, cells were used up to passage 38 for assays. 
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Figure 3.2   Morphology of Huh7/con1b cells maintaining an HCV replicon under 
G418 selection. 
The cuboidal epithelial-like cells grew as attached monolayer islands (A). HCV 
induced cytopathic effects were typically observed as indicated showing amoeboid-
like shaped cells with a high nucleus to cytoplasm ratio (B). (magnification, 100X) 
 
A.																																																																														
B.																																																																																																																												
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3.2.2 Validation	of	lower	detection	limit	for	luciferase	reporter	cell	line	
The high sensitivity of the Luciferase Reporter Gene Assay is a simple, robust and scalable 
means of assessing specific targeting and suppression of a gene when small double-
stranded RNAs are introduced. The linear range of light detection for the Glowmax Multi 
Detection System (Promega, Madison, USA) was determined by producing a standard 
curve of luminescence verses relative enzyme concentration.  Huh7/con1b cell numbers 
ranging from 30 cells to 30,000 cells was assessed on a plate-based assay using BRITELite 
Plus reagent. (See methods Section 2). Two independent attempts indicate a lower limit of 
quantification of ~300 cells per well with a lower limit of detection of ~30 cells per well 
(Figure 3.3), identifying that experiments with >10,000 cells per well was a suitable 
baseline to reliably discriminate up to 99% knockdown.  
   
   
 
Figure 3.3   Luminescent signal (RLUs) vs fold dilution across a dynamic range 
spanning 5-folds of magnitude. 
A linear relationship is maintained between luciferase signal and cell number even 
down to less than 100 cells. (Error bars represent n=3) 
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3.2.3 Potent	RNAi	by	siRNA22	and	shRNA22		
Knockdown activity for molecules triggering RNAi in a dose dependent analysis of 
siRNA22 and shRNA22, the highest three concentrations trialled for both siRNA22 and 
shRNA22 produced over 90% knockdown (Figure 3.4 A). siRNA22 and shRNA22 are 
designed to target the same region on the HCV replicon genome. As previously noted for 
shRNA (McAnuff et al., 2007; Vlassov et al., 2007), shRNA22 showed higher potency 
compared to siRNA22, with EC50 for shRNA22 at 5.38 pM and EC50 for siRNA22 at 18.9 
pM, for this set of dose response assays. Additionally, for all concentrations of siRNA22 
and shRNA22, cell viability remained above 80 % when measured by MTT assay (Figure 
3.4 B).  
 
From these results, 0.5 nM effective concentration was used for both siRNA22 and 
shRNA22 for the 5’ RACE assays. When measured by the luciferase assay, siRNA22 
achieved 96.3% knockdown (Figure 3.5 A) and shRNA22 achieved 94.8% knockdown 
(Figure 3.5 C) compared to the non-specific oligonucleotide (NSO) control. Cell viability 
was not affected by transfection of RNAi modalities or other transfection reagents (Figure 
3.5 B and D).  
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Figure 3.4   Potency of siRNA22 and shRNA22 in the Huh7/Con1b cell line. 
Huh7/con1b cells were treated with either siRNA or shRNA ranging from 5nM to 
167fM. (A) Dose response curves for siRNA22 and shRNA22. Calculation of the 
half maximal effective concentrations (EC50) found that shRNA22 was more potent 
than siRNA22. (B) Cell viability was determined by the MTT assay with results 
indicating <25% toxicity for any of the oligonucleotide concentrations. The mean 
and standard deviation of n=6 measurements are shown of two independent 
experiments siRNA22 EC50= 18.95 pM, shRNA22 EC50= 5.38 pM (p=<0.0001), 
Non-linear regression. 
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Figure 3.5   Suppressive activity of RNAi analogues.  
Cells were transfected with 0.5 nM shRNA22 or siRNA22 and luciferase activity and 
viability determined after 48 hours. Luciferase knockdown was measured as 
96.3%±0.5 for siRNA22 (A) and 94.8%±6.5 for shRNA22 (B) compared to the NSO 
(non-specific oligonucleotide) control (*P<0.05 by 2-tailes Paired t test). The mean 
and standard deviation of n=3 measurements is shown. Cell viability was determined 
by the MTT assay and did not exceed >25% toxicity for siRNA22 (B) or shRNA22 
(D). control = no oligonucleotide and no transfection reagent. Mock = no 
oligonucleotide but transfection reagent included. NSO = non-specofic 
oligonucleotide and transfection reagent. 
si
R
N
A
22
C
on
tro
l
N
S
O
m
oc
0
50
100
150
Vi
ab
ilit
y 
(%
 o
f C
on
tro
l)
sh
R
N
A
22
C
on
tro
l
N
S
O
m
oc
0
50
100
150
Vi
ab
ilit
y 
(%
 o
f C
on
tro
l)
sh
R
N
A
22
 
N
S
O
m
oc
C
on
tro
l0
50
100
150
200
R
el
at
iv
e 
Kn
oc
kd
ow
n 
(%
 o
f C
on
tro
l)
*
A.																																																																																																																											B.																																																																																																																												
C.																																																																																																																											D.																																																																																																																											
si
R
N
A
22
 
N
S
O
m
oc
C
on
tro
l0
50
100
150
200
R
el
at
iv
e 
Kn
oc
kd
ow
n 
(%
 o
f C
on
tro
l)
*
sh
R
N
A
22
 
N
S
O
m
oc
k
C
on
tro
lR
el
at
iv
e 
K
no
ck
do
w
n 
(%
 o
f C
on
tro
l)
sh
R
N
A2
2 
N
SO
m
oc
k
C
on
tro
l0
50
100
150
200
R
el
at
iv
e 
Kn
oc
kd
ow
n 
(%
 o
f C
on
tro
l)
sh
R
N
A2
2 
N
SO
m
oc
k
C
on
tro
l0
50
100
150
200
R
el
at
iv
e 
Kn
oc
kd
ow
n 
(%
 o
f C
on
tro
l)
sh
R
N
A2
2 
N
SO
m
oc
k
C
on
tro
l0
50
100
150
200
R
el
at
iv
e 
Kn
oc
kd
ow
n 
(%
 o
f C
on
tro
l)
	
66	
3.2.4 RNA	extraction,	5’	RLM	RACE	assays	and	NGS	library	preparation	
 Extraction	of	RNA	from	knockdown	assays	
For RNA extraction from 96 well plates, cells from 24 wells on treated plates were pooled 
by detaching the cells with TrypLE Express and then removing cells from the plate and 
collecting the cell pellet in a 15 ml centrifuge tube. Total RNA was isolated using the 
PureLink RNA Mini kit, yielding 71.4 ng/µl RNA for siRNA22 and 74.4 ng/µl RNA for 
shRNA22 (Table 3.1). Purity of the RNA extractions was measured as A260/A280 2.04 and 
2.07 for the respective RNA extractions. RNA was quantified using the Qubit High 
Sensitivity RNA Reagent kit prior to preparation of 5’ RLM RACE assays. 
 5’	RLM	RACE	assays	and	NGS	library	preparation:	Impact	of	choice	
of	polymerase	and	library	preparation	kit	
5’ RACE assays were prepared by ligating ~450 ng of RNA to the GeneRacer RNA 
adapter. After purification of the adapter ligated RNA, the gene specific primer for HCV 
replicon sequence, primer 22+2 was used to generate the template cDNA. Subsequent 
amplification used the Platinum Hot Start PCR Master Mix and primers GeneRacerF1 and 
primer 22+2 (Table 2.3). The 5’ RACE-PCR amplicons were verified on a 3% agarose gel 
(Figure 3.6). The expected amplicon size was detected, but substantial smear was observed 
around the expected position when visualised on agarose gel, indicating possible non-
specific amplification. Since agarose gel analysis could not indicate a defined peak profile, 
amplicons were also assessed by Bioanalyzer High Sensitivity DNA chip, which identified 
that indeed, the expected amplicon fragment size range, which was approximately 70-85 
bp compared to the full range of fragments observed which ranged from 50-200 bp 
occupied only 16% and 17% of fragments in the PCR sample for siRNA22 and shRNA22 
respectively (Figure 3.7 A and B). Preparation of NGS libraries using the Ion Plus 
Fragment Library Preparation kit (Thermo Fisher Scientific) resulted in the desired 
fragments being 18% and 14% of all fragments in the NGS samples for siRNA22 and 
shRNA22 respectively (Figure 3.7 C and D). Subsequently, after size selection using the 
LabChip XT instrument, the amount of desired fragment size was reduced to only 10% 
and 6% for respective samples (Figure 3.7 E and F). Analysis of the fragment profiles 
produced by Bioanalyzer analysis and past experience sequencing amplicon libraries on 
	
67	
the Ion Torrent PGM strongly indicated that the libraries were of poor quality and were 
likely to yield insufficient data.  
 
The Ion Plus Fragment Library Preparation kit requires a total of four bead clean rounds 
when preparing the RACE-Seq samples, which probably contributed to the loss of desired 
fragment range. The NEBNext Fast DNA Library Prep SetTM protocol on the other hand 
does not have a bead clean step between the end repair step and the adapter ligation step 
(Figure 3.8), which would help to retain the desired fragment range. Additionally, the 
NEBNext kit is much cheaper, reducing the cost per sample for library from ~£50 per 
sample using the Ion Torrent kit to ~£13 using the NEBNext kit. The NEBNext kit uses 
Q5 High Fidelity DNA polymerase as part of the protocol, so this polymerase was trialled 
for amplification of the 5’ RACE cDNA.  Amplification with the Q5 Hot Start High-
Fidelity 2X Master Mix generated a peak profile where the desired fragment range for 
siRNA22 was 51% and shRNA22 was 57% (Figure 3.9A and B). After library preparation, 
the desired fragment range (145-165 bp) was assessed to be around 33% for each of the 
samples (Figure 3.9 C and D) but after LabChip size selection the desired fragment range 
for sample siRNA22 was 44% of the completed library and sample shRNA22 had at least 
50% of the completed library within the desired fragment range (Figure 3.9 E and F).  
 
For library preparation, the PCR reactions were bead cleaned and quantified using the 
Qubit High Sensitivity DNA kit, with samples generating 4.68 ng/µl DNA for siRNA22 
and 5.92 ng/µl for sample shRNA22 (Table 3.1). Subsequently, library preparation used 
25.5 µl volume of each cleaned PCR reaction for library preparation resulting in 119 ng 
and 150 ng as DNA input (Table 3.1). After end repair and adapter ligation reactions, the 
desired fragment size increased from ~74 bp by a further 84 bp due to addition of the 
sequencing adapters. The adapter ligated samples were bead cleaned and then amplified 
in 7 cycles of PCR to enrich for correctly orientated sequencing adapters. The final library 
was quantified as 56.8 ng/µl for siRNA22 and 38.0 ng/µl for shRNA22 (Table 3.1). 
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Table 3.1   Nucleic acid quantification at different stages of RACE-Seq sample 
preparation. 
Sample  RNA 
Input to 
5’RLM 
RACE 
[PCR 
reaction] 
(ng/µl) 
DNA input for 
NGS library 
preparation  
[NGS library] 
(ng/µl) 
siRNA22 428.4 ng  4.68 119.3 ng 56.8 
shRNA22 446.4 ng 5.92 151 ng 38.0 
 
 
 
 
 
Figure 3.6   5’ RACE-PCR analysis on 3% agarose gel. 
Expected amplicon size is ~74 bp. No specific amplification was detected for an 
untreated control sample. (M=molecular ladder, 25 bp ladder) 
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Figure 3.7   Failed library preparation using Platinum Taq Polymerase and Ion 
Plus Fragment Library Preparation kit.  
5’ RACE cDNA was amplified using Platinum Taq Hot Start Master Mix 
generating a desired fragment range (70-85 bp) of 16% and 17% for siRNA22 (A) 
and shRNA22 (B) respectively for total PCR fragments. After library preparation, 
the desired fragment range (145-165 bp) was only 18% and 14% for siRNA22 (C) 
and shRNA22 (D) respectively. Size selection using the LabChip XT instrument 
reduced the desired library size range to 10% and 6% for siRNA22 (E) and 
shRNA22 (F). Bioanalyzer graphs are plots of Fluorescence intensity 
[FU=fluorescent units] which is influenced by the amount of sample in each chip 
well vs migration time in seconds (s) for each sample.  The desired fragment size 
is circled in each case. 
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Figure 3.8  Full outline of RACE-Seq library preparation, sequencing and data 
analysis workflow.  
The workflow for the Ion Torrent Fragment Library kit (grey) and the NEBNext 
Fragment Library Kit (orange) is depicted on the left. After size selection, libraries are 
diluted and pooled for emulsion PCR. The templated library is then sequenced on the 
Ion Torrent PGM. The FASTQ data file output is pre-processed and aligned to the 
reference sequence and the 5’ end counts generated.  
 
 
Amplification – enrich for 
correct adapter orientation
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Figure 3.9   Successful RACE-Seq library preparation using Q5 DNA polymerase 
PCR mix and the NEBNext Library Prep Set for Ion Torrent.  
5’ RACE cDNA was amplified with Q5 Hot Start 2X Master Mix to generate amplicons 
where the desired fragment range (70-85 bp) consisted of at least 51% and 57% for 
siRNA22(A) and shRNA22(B) respectively. After library preparation, the desired 
fragment range (145-165 bp) was about 33% for siRNA22(C) and shRNA22(D). Size 
selection using the LabChip XT instrument increased the desired library size range to 44% 
for siRNA22(E) and 50% for shRNA22 (F). (Bioanalyzer graphs are plots of Fluorescence 
intensity [FU=fluorescent units] which is influenced by the amount of sample in each chip 
well vs fragment size (bp=base pairs).  The desired fragment size is circled in each case.  
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3.2.5 Size	selection	as	a	critical	component	of	library	preparation	
The Ion Torrent System uses an automated emulsion PCR instrument (Ion One Touch2 
instrument) to clonally amplify single templates to special sequencing beads. The reagents 
and protocol are proprietary with all validated protocols from Ion Torrent based on discrete 
fragment insert size of either 100 bp, 200 bp or 400 bp. The standard library preparation 
is for 200 bp inserts with templates larger than this range prone to poor templating. Thus, 
size selection of 5’ RACE amplicons was critical to enable a discrete fragment size range 
for input into emulsion PCR. Size selection also enhanced the fraction of desired fragment 
size. The LabChip XT instrument is an automated fragment analyser capable to 
partitioning a discrete fragment range for collection. The LabChip XT was set at 158 ± 
10% to collect the fraction of fragments around the expected library size (Figure 3.10 A). 
Size selection enriched for the desired fragment size and eliminated larger unwanted 
fragment sizes from the library preparations (Figure 3.10 B). The size selected libraries 
were quantified on Bioanalyzer DNA chip and diluted for input to emulsion PCR. After 
emulsion PCR, samples were cleaned using the Enrichment system and each sample 
sequenced on an individual 318 V2 chip on the Ion Torrent PGM.  
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Figure 3.10   Impact of LabChip size selection on isolation of desired fragment 
size for RACE-Seq library preparation.  
The LabChip automated size selection system partitions a discrete size fraction (in 
red outline) for collection (A). After 5’ RACE PCR (B lanes 2, 3 and 4), NGS 
library preparation captures and amplifies some non-specific products (B lanes 5 
and 6), which were eliminated by size selection using the LabChip XT instrument 
(B lanes 7 and 8). (M= molecular ladder) 
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3.2.6 RACE-Seq	data	analysis	
 The	GeneRacer	adapter	sequence	is	identified	in	both	orientations		
During library preparation, the A and P1 sequencing adapters ligate to amplicons in four 
different configurations (Figure 1.7). The subsequent amplification step post adapter 
ligation enriches for A-amplicon-P1 or P1-amplicon-A ligations which can occur equally 
in either orientation. The P1 end of the library fragments become templated to the 
sequencing beads. Later, the sequencing reaction occurs in the 5’ to 3’ direction, resulting 
in the GeneRacer adapter sequence occurring either at the beginning of the sequenced read 
or at the end of the read (Figure 3.11). Understanding the orientation of the GeneRacer 
adapter sequence in the sequenced dataset was important in designing the first step in 
analysing the data. By searching for the GeneRacer adapter sequence at both ends of the 
reads ensures comprehensive filtering of the dataset and prevents unnecessary loss of 
usable data.  
 
 
Figure 3.11   Illustration to indicate how the RNA adapter sequence is output in both 
the forward and reverse complement directions.  
The A and P1 adapters ligate to 5’ RACE amplicons as Adapter-PCR product-Adapter, 
resulting in a mix of configurations where the A or P-adapter can ligate upstream or 
downstream of the GeneRacer sequence (CGA…AAA) within the PCR amplicon. In 
emulsion PCR, the P1-adapter end becomes templated to the sequencing beads (A). This 
strand acts as the template in the sequencing reaction. Sequencing occurs in the 5’ to 3’ 
direction, resulting in the adapter sequence occurring either in the forward direction (B) or 
the adapter sequence occurs at the end of the sequenced read as the reverse complement of 
the RNA adapter sequence (C).  
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 RACE-Seq	data	output	from	the	Ion	Torrent	PGM		
On the completion of the sequencing run, a run report is generated. The run report provides 
information regarding all aspects of the data analysis.  Besides the statistics on the number of   
templated beads detected on the chip (loading) and loss of data due to standard filtering 
operations (Figure 3.12), samples are de-multiplexed and total number of reads per sample 
reported.  
 Filtering	of	RACE-Seq	datasets	and	alignment	to	the	reference	
Read output from the Ion Torrent Sequencer was approximately 3 million reads for each 
sample. For siRNA22, 47.1% of reads had the GeneRacer adapter sequence in the reverse 
orientation while this was 43.4% for the shRNA22 sample (Table 3.2). Reverse 
complementing these datasets and concatenating the reads with the set of data with the 
expected GeneRacer adapter sequence in the forward direction, captured 90.2% and 92.0% 
of all usable reads for siRNA22 and shRNA22 respectively (Table 3.2).  Further data 
processing steps included removal of the GeneRacer adapter sequence, filtering for reads that 
held the amplification primer sequence on the 3’ end, trimming of low quality bases from the 
3’ end of reads and removal of short reads (<30 bp). This final data set constituted 65.5% 
(1,932,233 reads) and 76.0% (2,377,583 reads) of all usable reads for siRNA22 and shRNA22 
respectively. This filtered dataset was aligned to the HCV replicon genome using an adapted 
version of the RACE-SEQ-LITE pipeline (Theotokis et al., 2017).  The 5’ end counts that 
were generated were then (1) plotted at linear scale as number of 5’ends at positions within 
the expected RISC hybridization site (Figure 3.13 A and C) and (2) the 5’ end counts were 
calculated as a percent of total aligned reads and plotted as the percent of aligned reads within 
the expected RISC hybridization site (Figure 3.13 B and D).  
 
For siRNA22, 22.1% of filtered reads aligned to the HCV replicon reference when zero 
mismatch tolerance was implemented. Further analysis showed that 86.9% of all aligned 
reads for siRNA22 were within the expected RISC hybridization site (Table 3.2), with the 
remaining reads spread out at regions outside of this area. For shRNA22, 25.1% of all filtered 
reads aligned to the HCV replicon reference sequence, with 94.3% of aligned reads at the 
expected RISC hybridization site (Table 3.2). An unexpectedly large number of filtered reads 
for each data set failed to align to the HCV replicon reference, with 77.9% and 74.9% of reads 
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partitioned to the ‘unaligned data’ output file for the siRNA22 and shRNA22 samples 
respectively.   
 
 
Figure 3.12   Ion Torrent PGM summary of data for legacy RACE-Seq assays. 
Each RACE-Seq sample generated approximately 3 million reads. (A) siRNA22 
sample has 55% chip loading which equated to 6,191,146 templated beads and (B) 
shRNA22 has 54% chip loading which equated to 6,046,040 templated beads. The 
Ion Torrent server filtered each of the datasets for polyclonal reads, low quality reads, 
and adapter dimer to give the final output of usable reads.   
 
 
  
Table 3.2 RACE-Seq data analysis for siRNA22 and shRNA22 (legacy assays) 
 
 
A.	 B.																																																																																																																												
siRNA22 shRNA22
Legacy	RACE-Seq data Legacy	RACE-Seq data
Filter	Criteria Read	count	 Percentage Read	count %	of	Total	reads	
Total	number	of	reads	 2948412 3129245
Total	reads	with	GeneRacer adapter 1270582 43.1* 1519754 48.6*
Total	reads	with	inverted	GeneRacer	
sequence 1388602 47.1* 1358774 43.4*
Total	reads	with	GeneRacer	adapter 2658892 90.2* 2878141 92.0*
Reads	remaining	after	filtering	 1932233 2377583
Total	reads	that	align	to	HCV	reference 427070 22.1** 596359 25.1**
Total	reads	that	align	to	target	site 371240 562369
Total	unaligned	reads	 1505163 77.9** 1781224 74.9**
*		Percent	of	total reads
**	Percent	of	filtered reads
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3.2.7 Interpretation	of	RACE-Seq	peak	profiles	
RACE-Seq analysis identified the expected cleavage site for both the siRNA22 and the 
shRNA22 sample by reporting the highest number of reads at the expected cleavage site 
(Figure 3.13 A and C, lightly shaded bar, T=9489). Additionally, for both samples, a 
substantial number of reads (35.7% and 45.3%) were found downstream of the expected 
cleavage site (Figure 3.13 B and D) and are presumed to be degradation products arising from 
5’ to 3’ RNA degradation of the RISC cleaved targets and cannot be validated as possible 
RISC derived cleavages.  Upstream of the expected cleavage site, RACE-Seq reported 
additional 5’ ends for both siRNA22 and shRNA22. The siRNA22 sample had 4 peaks above 
1% at positions upstream of the expected cleavage site. Of these, position A=9486 (at +3 
from expected cleavage site) reported the second highest secondary peak count at 17.0% of 
aligned reads and position C=9488 (at +1 from cleavage site) reported the third highest 
secondary peak count at 7.4% (Figure 3.13 B). For the shRNA22 RACE-Seq sample, one 
additional 5’ end peak stood out at C=9482 with 3.6% of aligned reads (Figure 3.13 D). 
However, this peak position was not corroborated by the siRNA22 RACE-Seq sample.  
 
Sample siRNA22 had 86.9% of all aligned reads with a 5’ end within the RISC hybridization 
site (Figure 3.13 B), while shRNA22 had 96.5% of aligned reads within the RISC 
hybridization site (Figure 3.13 D). In each case, the expected AGO2-RISC-induced cleavage 
position was reported as the primary peak. For the additional peaks at positions upstream of 
the expected cleavage site, whether they are induced by RISC activity remains unclear.  
3.2.8 Analysis	of	unaligned	data	
 Unexpectedly, a large portion of the filtered datasets for siRNA22 and shRNA22 failed to 
align to the HCV replicon reference sequence (Table 3.3). Even when allowing up to 3 
mismatches for the Bowtie aligner, 70.3% of reads for siRNA22 and 68.1% of reads for 
shRNA22 still failed to align, leading to the conclusion that these reads were either not HCV 
sequences or, were HCV reads with >3 mismatches to the reference. When the collapsed 
datasets were mapped to the HCV replicon reference (without reverse primer sequence) a mix 
of HCV and non-HCV sequences were identified (Figure 3.14). The RML-RACE assay is 
not specific for AGO2-RISC cleaved products thus the RNA adapter may attach to other 
transcripts and even the reverse primer may generate spurious cDNA templates.  
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Figure 3.13   Novel 5’ ends identified by RACE-Seq legacy assay on Ion Torrent   PGM. 
For both siRNA22 and shRNA22, RACE-Seq reports captured reads with 5’ ends around the 
expected AGO2-RISC cleavage position. The expected RISC cleavage position is indicated at 
the lightly shaded bar. Graph (A) represents the absolute read count of aligned reads and their 5’ 
end position for sample siRNA22. Graph (B) is the percentage of total aligned reads for each 
peak within the RISC hybridization site for siRNA22. Graph (C) represents the total number of 
aligned reads with 5’ ends within the cleavage site for shRNA22 with graph (D) indicating the 
percentage of aligned reads that can be attributed to each peak within the RISC cleavage site for 
the shRNA22 sample.  
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Figure 3.14  Analysis of unaligned reads for siRNA22 RACE-Seq and shRNA22. 
Data that did not align to the HCV replicon reference at mm=0 had the reverse primer sequence removed, the reads collapsed and then multiple sequence 
alignment performed against the HCV replicon reference sequence at target site 22. The top 40 read counts are analysed for sequence similarity to the 
reference.     
  
 
Expected	cleavage	position	
(sample	siRNA22)%	sequence	identity	 %	sequence	identity	
Expected	cleavage	position	
(sample	shRNA22)
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3.3 Discussion		
This chapter describes the process of transferring a legacy RACE-Seq assay described in 
Denise et al., (2014) from sequencing on a high throughput platform, the Illumina 
HiSeq2000 instrument, to sequencing on the low throughput platform, the Ion Torrent 
PGM. The process revealed a number of critical factors that are generally applicable to 
RACE-Seq but also some that are particular to sequencing on the Ion Torrent platform. 
Typically, greater than 2 µg of RNA is reported as input to the RNA adapter ligation 
reaction for standard 5’ RML RACE assays (Zimmermann et al., 2006; Neff et al., 2011; 
Hagopian et al., 2017). This is largely a carryover from a protocol from one of the most 
popular 5’ RACE Assay Kits, the FirstChoice RML-RACE Kit (Thermo Fisher Scientific).  
The RACE-Seq assay performed here, was able to reduce the RNA input to ~428 ng for 
siRNA22 and ~446 ng for shRNA22. This could prove valuable if the assay were to 
progress to clinical stage use, where a single patient sample i.e., liver biopsy needs to be 
analysed in multiple assays (Tabernero et al., 2013).  
 
Being able to critically evaluate the fragment size range of the 5’ RACE PCR reactions as 
well as the post library and post size selection samples using the Bioanalyzer chip assay 
proved to be a critical tool, ensuring the eventual success of the RACE-Seq assays. It 
allowed performance of the Q5 Hot Start High-Fidelity 2X Master Mix to be evaluated 
against the poorer performing Platinum Hot Start PCR Master Mix. Additionally, after 
size selection of the NGS libraries on the LabChip instrument, Bioanalyzer analysis 
confirmed that there was sufficient amount of the desired fragment size range (44% for 
siRNA22 and 50% for shRNA22) in the final library preparation to advance the sample to 
sequencing on the Ion Torrent PGM. The Illumina sequencing platform may not have the 
same requirement for stringent size selection of libraries that the Ion Torrent PGM does 
(Section 1.5). When sequencing on the Illumina platform, the length of the sequenced 
fragment is determined by the number of flows, so that a 400 bp fragment for example can 
have 150 bp read from one end of the fragment and another 150 bp read from the other 
end of the 400 bp fragment. Since only the region after the GeneRacer RNA adapter is of 
interest, not having the central part of the fragment has little consequence.   
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The LabChip XT instrument allowed a discrete DNA fragment size range to be isolated 
and very efficiently eliminated larger fragments from the final library preparations. 
Electronic fragment analysers (such as the Bioanalyzer) and automated DNA size selection 
instruments (such as the LabChip instrument) are non-standard pieces of laboratory 
equipment. While their implementation may not be an absolute requirement for RACE-
Seq for high throughput NGS systems, certainly they both proved valuable for designing 
and characterising RACE-Seq assays for the Ion Torrent PGM.    
 
Sequencing the siRNA22 and shRNA22 RACE-Seq samples on the Ion Torrent PGM 
generated ~3 million usable reads per sample on 318 V2 sequencing chips. In filtering the 
RACE-Seq datasets for the target sequence, loss of some reads occurred, but the filtering 
criteria still retained 65.5% of usable reads for siRNA22 and 76% of usable reads for the 
shRNA22 RACE-Seq sample. Part of this success hinged on an acute understanding of 
NGS library preparation which highlighted the fact that the RNA adapter sequence could 
appear at either end of the raw sequence reads. As the first step in filtering the data searches 
for the adapter sequence, a failure to capture the reverse complement sequence would have 
resulted in a loss of just under 50% usable reads. For the legacy RACE-seq assay however, 
after mapping the filtered datasets to the HCV replicon reference sequence and counting 
the 5’ ends, a substantial (77.9% and 74.9% for respective samples) number of reads failed 
to align to the HCV replicon reference when mismatch of zero was applied. Since the HCV 
replicon genome actually exists as quasispecies RNA genomes(McWilliam Leitch and 
McLauchlan, 2013; Park et al., 2014; Chen et al., 2016), the mismatch tolerance was 
increased to a maximum of 3, but only marginally increased the number of reads that 
aligned to the reference, with an increase of 7.5% for siRNA22 and 6.8% for shRNA22.  
 
The expected cleavage position for the synthetic siRNA22 analogue and the synthetic 
shRNA22 analogue was reported for each of the RACE-Seq samples and was as reported 
by classic 5’ RACE and Sanger sequencing by Denise et al., (2014). When the Ion Torrent 
PGM RACE-Seq profile for siRNA22 was compared to the Illumina deep sequencing 
RACE-Seq profile reported by Denise et al., (2014), no corroboration of peak incidence 
was detected beyond reporting the expected cleavage position as the major peak. Further, 
the read depth achieved in the Denise et al., (2014) RACE-Seq dataset, (>12 million reads 
reported at the expected cleavage site) resulted in all other 5’ peaks that appeared upstream 
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of the expected cleavage site reporting at less than 0.2% of all reads that aligned within 
the siRNA target site. As with other reports of RACE-Seq datasets (Tabernero et al., 2013; 
Barve et al., 2015), additional 5’ end counts were reported upstream as well as downstream 
of the expected cleavage site. While the downstream products are designated as putative 
degradation products, classifying the upstream 5’ ends remained more challenging.  Since 
adapter ligation by T4 RNA ligase is not specific for RISC cleaved substrates, all 
additional peaks captured by the RACE-Seq assay cannot be exclusively attributed to 
being due to RNAi induced activity. Additionally, since the siRNA22 5’RACE profile 
from Ion Torrent did not correlate to the Denise et al., (2014) profile, this begins to 
highlight the influences that assay design can place on obtaining robust, reliable, unbiased 
data in RACE-Seq assays.  
 
RACE-Seq remains an under-utilized assay, without an established protocol. Primarily, it 
is being used as a substitute for Sanger sequencing to confirm an expected RNAi behaviour 
of a designed RNAi-based bioactive (Tabernero et al., 2013; Barve et al., 2015; Ganesh et 
al., 2016).  The Denise et al., (2014) publication attempted to derive new insights into 
RISC cleavage behaviour using RACE-Seq, concluding with the suggestion that AGO2-
RISC may show preference for a second cleavage site at positions 13-15 rather than just 
position 10-11. However, the RACE-Seq assays for siRNA22 and shRNA22 using the 
same protocol for generating the 5’ RACE amplicons and sequencing on the Ion Torrent 
failed to support such a hypothesis.  
 
The legacy RACE-Seq assay design generated very short PCR products, mainly due to the 
limitations of the Illumina sequencing platform at the time.  However, short amplification 
reactions are likely to be highly efficient (Suzuki and Giovannoni, 1996; Arezi, et al., 
2003) and result in the reaction reaching saturation conditions, including DNA polymerase 
inhibition due to saturated templates. The short length PCR amplification as well as the 
differences in Illumina vs Ion Torrent sequencing platforms is likely to have impacted on 
the failure to derive any new insights regarding RISC behaviour for these Ion Torrent 
RACE-Seq datasets.  
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+ 		AN	IMPROVED	METHOD	FOR	
PREPARING	RACE-SEQ	LIBRARIES		
4.1 Introduction		
The 5’ RACE assay relies on amplifying an adapter-ligated target using PCR. The 
expectation is that the final amplified reaction represents the diversity and relative 
frequency of the original sample. For sequencing on the Ion Torrent PGM, fragment size 
is a critical component of library preparation. A number of Ion Torrent protocols utilise 
size selection, either using magnetic beads or electronic size selection instruments such as 
the LabChip XT instrument. By the end of 2016, the LabChip XT instrument, reagents and 
support was discontinued. The E-gel 2% size select system was chosen as the replacement 
as it offered much cheaper per sample cost and allows up to eight samples to be run on a 
single gel compared to the 3 samples for each LabChip XT chip. However, the E-gel 
system is not an automated system and as such, size selection is prone to manual handling 
error.  
 
The chemistries, protocols and design of NGS technologies have greatly improved over 
the last 5 years, and both Illumina and Ion Torrent technologies accommodate libraries 
with inserts of at least 200 bp. Primer sets for the long amplicon RACE-Seq assay were 
designed to have final amplicon size greater than 100 bp. In addition, since the samples 
were to be pooled, particular care was taken to design 5’ RACE PCR assays with similar 
sized amplicons. To enrich for the expected template, the reverse primer in PCR 
amplification was placed at a position internal to reverse transcription primer position 
(Figure 4.1).  
 
This chapter focuses on two main objectives, first, to design a RACE-Seq assay to be 
compatible with longer amplicon sequencing and second, to explore multiplexing 
practicalities for sequencing on the Ion Torrent PGM.  
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The following approaches were taken in order to achieve the objectives of this chapter: 
 
• Two sets of RACE-Seq assays were conducted at two separate time points.  
• The time point (1) sequencing run consisted of samples; siRNA22, shRNA22, 
siRNA6, shRNA6, siRNA19 and shRNA19. The PCR samples were size selected 
prior to library preparation.  
• The time point (2) run consisted of RACE-Seq assays siRNA22, shRNA22, 
siRNA6 shRNA6, siRNA19*, shRNA19*, siRNA19 and shRNA19 (Figure 4.2). 
The siRNA19* and shRNA19* samples were size selected prior to library 
preparation similar to the time point (1) samples.  
• New sets of 5’ RACE primers were designed and tested. Combinations of reverse 
primer for cDNA synthesis and gene-specific amplification primers were evaluated 
by assessing 5’ RACE PCR products on 2% agarose gels.  
• To allow single round PCR reactions, the amount of RNA input to the RNA adapter 
ligation reaction was increased for time point (2) samples.   
• Two different approaches to obtaining the size selected NGS libraries were carried 
out. Size selection was done either before library preparation or after library 
preparation.  
• The impact of agarose gel extraction on the final NGS library fragment profile was 
evaluated by Bioanalyzer analysis.  
• Multiple 5’ RACE samples were pooled for NGS sequencing runs and the impact 
on chip loading and final data output was evaluated. 
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Figure 4.1   Illustration of long amplicon RLM RACE assay. 
After adapter ligation and reverse transcription, both target and non-target templates may be 
generated.  Amplification using a gene specific primer internal to the reverse transcription 
primer specifically enriches for the target of interest. 
 
cleaved		mRNA	ligated	to	RNA	adapter
P AAAA
cDNA
rt primer	
OH
cDNA		
(target	enrichment	PCR)GSP1
cDNA	 (non-target)X
(target	and	non-target)
Adapter
RNA	adapter
		
86	
 
Figure 4.2   Work flow of RACE-Seq assay for time point 1 and time point 2. 
This diagram details the sample workflow for two different sets of RACE-Seq assays prepared 
at separate time points.  
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4.2 Results		
4.2.1 RNAi	activity	assays			
To determine the optimal concentration of siRNA and shRNA to use for the RACE-Seq 
assays, dose response studies were carried out for siRNA6, shRNA6, siRNA19 and 
shRNA19. Statistical analysis of dose response curves for siRNA6 and shRNA6 revealed 
that they had the same EC50 value (p > 0.05) ( Figure 4.3 A). In contrast, shRNA19 was 
found to be more potent (EC50 = 7.4 pM) than siRNA19 (EC50 = 93.4 pM) (Figure 4.3 C). 
Time point (1) RACE-Seq knockdown assays used the same oligo concentrations as 
reported by Denise et al., (2014). All concentrations, except for shRNA6, gave a luciferase 
response of greater than 70% knockdown (Table 4.1). For time point (1) RACE-Seq 
assays, shRNA6 gave only 59.5% knockdown when 0.5 nmol/l oligo concentration was 
used. This concentration was doubled for the time point (2) RACE-Seq assays resulting in 
an increase in knockdown to 80.5% (Table 4.1).  
 
The siRNA6 assay was initially conducted at 40 nmol/l for the time point (1) RACE-Seq 
assay. However, dose response analysis indicated that concentrations from 50 to 5 nmol/l 
generated a similar response, (Figure 4.3 A) therefore, the concentration of siRNA19 
analogue was halved for the RACE-Seq assay at time point (2). Reducing the 
concentration did not have an effect on luciferase knockdown response with 99.2% 
knockdown being achieved for the lower concentration (Table 4.1).  MTT results for dose 
response assays indicated no cytotoxicity effects for siRNA6, shRNA6, siRNA19 and 
shRNA19 for the concentrations used (Figure 4.3 B and D). MTT analysis also confirmed 
no cytotoxic effects for the individual knockdown assays used for RACE-Seq (Figure 4.3). 
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Figure 4.3   Dose response analysis for siRNA6 vs shRNA6 and siRNA19 vs shRNA19. 
Concentrations for siRNA and shRNA ranged for 50 nM to 0.1 pM for dose response 
assays for the dose response assays and the MTT viability assays. (A) Dose response 
curves comparing half maximal effective concentration (EC50) indicate siRNA6 and 
shRNA6 had similar potency (A), while shRNA19 was found to be more potent than 
siRNA19 (C).  Cell viability as determined by the MTT assay did not indicate >25% 
toxicity for any of the oligonucleotide concentrations used for siRNA6/shRNA6 (B) or 
siRNA19/shRNA19 (D). The mean and standard deviation of n=6 measurements are 
shown of two independent experiments with siRNA6/shRNA6 EC50= 30.7 pM 
(p=<=0.2048, siRNA19 EC50= 93.4 pM and shRNA19 EC = 7.4 pM (p=<0.0001), Non-
linear regression fit.  
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Figure 4.4   Viability assay for RACE-Seq knockdown experiments. 
Cell viability as determined by the MTT assay did not indicate >25% toxicity for any of 
the oligonucleotide. The mean and standard deviation of n=3 measurements are shown 
for each assay. (NSO = non-specific oligonucleotide, mock = only transfection reagent 
(Dharmafect3in Opti-MEM added to cells. Control = only Opti-MEM added to cells). 
The siRNA19* and shRNA19* RACE-Seq samples were processed in a similar manner 
to the time point (1) samples. 
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Table 4.1   Concentration of RNAi analogue vs luciferase knockdown achieved. 
 
The percent luciferase inhibition was determined relative to the non-specific 
oligonucleotide (NSO) control treatment using the 2-tailes Paired t test. Mean luciferase 
inhibition and standard deviation from n=3 measurements shown. 2* indicates that the 
sample processed in a similar manner to the time point (1) samples.  
 
4.2.2 Long	amplicon	RACE-Seq	
 Impact	of	RNA	input	amount	on	5’	RACE	amplicon	generation	
The first step in the RLM RACE protocol is to tag the 5’ end of RISC cleaved RNA with 
the known RNA adapter sequence using T4 RNA ligase. Total RNA was extracted from 
treated cells using either the PureLink RNA extraction kit or by the TRIzol method, as 
indicated in Table 4.2. Both methods produced good quality RNA with A260/A280 values 
1.7-2.1. However, the extractions using the PureLink kit gave variable A260/A230 readings 
while the TRIzol method was more consistent, giving values of A260/A230 = 1.9-2.1. Time 
point (1) assays used an RNA input amount of 500-600 ng RNA. Various primers were 
RNAi  
Treatment 
Time point  Active  
concentration 
Luciferase 
inhibition 
 (%) 
Significance vs 
NSO control 
     
siRNA22 1 0.5 nmol/l 94.8 ± 0.5 P<0.05 
siRNA22 2 0.5 nmol/l 97.0 ± 0.3 P<0.01 
     
shRNA22 1 0.5 nmol/l 99.3 ± 0.5 P<0.05 
shRNA22 2 0.5 nmol/l 95.6 ± 0.8 P<0.01 
     
siRNA6 1 40 nmol/l 96.5 ± 0.8 P<0.05 
siRNA6 2 20 nmol/l 99.2 ± 0.3 P<0.05 
     
shRNA6 1 0.5 nmol/l 59.5 ± 10 P<0.05 
shRNA6 2 1.0 nmol/l 80.5 ± 4.6 P<0.05 
     
siRNA19 1 10 nmol/l 93.2 ± 2.8 P<0.05 
siRNA19 2* 10 nmol/l 87.0 ± 4.1 P<0.05 
siRNA19 2 10 nmol/l 75.9 ± 15 ns 
     
shRNA19 1 0.8nmol/l 78.1 ± 4.8 P<0.05 
shRNA19 2* 0.8 nmol/l 75.3 ± 8.4 P<0.05 
shRNA19 2 0.8 nmol/l 77.6 ± 14 ns 
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tested before the most suitable reverse transcription and amplification primer combination 
for the long amplicon RACE-Seq assays was obtained.  
 
The first round PCR for samples siRNA22(1) and shRNA22(1) at time point (1) produced 
sufficient 5’ RACE product for a single band at 126 bp to be visualised on a 2% agarose 
gel (Figure 4.5 A). However, siRNA6(1), shRNA6(1), siRNA19(1) and shRNA19(1) 
samples did not produce visible bands after a single round amplification. For example, 
Figure 4.5 (C) shows the first round PCR amplification product for siRNA6 and shRNA6 
(indicated by * on the gel image). The band at ~500 bp corresponds to the 5’ start of the 
HCV replicon genome as the site 6 RISC target region lies within the 5’ UTR. This 
confirmed that at least for site 6, the expected fragment was likely to have been amplified, 
but at an insufficient amount to be visualised on the gel. To further enrich for the expected 
fragment, a second round of PCR was carried out. The first round PCR reactions were 
carried out in a small volume of 15 µl. Then, up to 5 µl was used in the second round PCR 
reaction. This criterion was specifically designed to minimise selectivity of fragments that 
might occur when the first round PCR product is diluted or only a small amount is added 
to the second round PCR.  Gel analysis revealed a distinct band at 144 bp for siRNA6(1) 
but a less distinct band for shRNA6(1) with second round amplification. A second 
amplified band was also visible just above the expected 5’ RACE band for siRNA6(1) 
(Figure 4.5 C).  
 
Samples siRNA19(1) and shRNA19(1) had less distinct 5’ RACE bands after second 
round PCR (Figure 4.5 E). Bands were gel extracted and sent for Sanger sequencing. 
Although the expected cleavage site could not be determined from this sequencing result, 
Sanger sequencing confirmed that the expected fragment had indeed been amplified. The 
correct band/smear could then be identified on the gel and extracted for NGS library 
preparation.   
 
The time point (2) RACE-Seq assays had a higher amount of RNA (> 1µg) input to the 
RNA adapter ligation reaction (Table 4.2). The amounts varied depending on the RNA 
concentration of each individual sample. In order to allow more RNA to be input to the 
RNA adapter ligation reaction, the volume of the reaction was increased from a 10 µl 
reaction to a 20µl reaction. This allowed for up to 12.5 µl of RNA to be used in each 
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adapter ligation reaction. Qubit quantification was always used to quantify the RNA for 
input to the adapter ligation reaction to ensure as accurate a determination for input to the 
RNA ligation reaction. As previously, siRNA22(2) and shRNA22(2) cleaved RNA 
samples consistently produced a prominent band at the expected size on 2% agarose gels 
with the non-transfected control failing to produce a band at the expected 5’ RACE 
position (Figure 4.5 B). Increasing the amount of RNA to the RNA adapter reaction for 
siRNA6(2), shRNA6(2), siRNA19(2) and shRNA19(2) enabled a single round of PCR 
amplification to generate a visible band on 2% agarose gels. The siRNA6(2) band was 
consistently more distinct compared to shRNA6(2) (Figure 4.5 D). This did not impact 
visualising the bands for excision from agarose gels as the gel extraction application used 
4X the amount of and under the blue light transilluminator, bands were suitably visible.  
 
Increasing the amount of RNA input to the adapter ligation reaction enabled the 
siRNA19(2), siRNA19(2*), shRNA19(2) and shRNA19(2*) 5’ RACE amplicons to be 
visualised after a single round of PCR. The siRNA bands were generally observed at an 
equal intensity to the shRNA bands for each sample (Figure 4.5 F and G) but a second 
prominent band was observed just above the expected 5’ RACE band for some samples 
(Figure 4.5 F). The non-transfected control failed to generate a 5’ RACE band of the 
expected size (Figure 4.5 E, F, G).  
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Table 4.2   Assessment of RNA for 5' RML-RACE 
 
RNA was extracted from Huh7/con1b cells after treatment with siRNA or shRNA using either the 
PureLink RNA Extraction Kit (Thermo Fisher Scientific) or the TRIzol method. Both extraction 
methods generated good quality RNA, but samples extracted using the TRIzol method showed a 
better A260/A280 value. 2* indicates that the sample processed in a similar manner to the time point 
(1) samples. 
 
RNAi 
analogue 
 
Time point 
RNA 
input 
amount 
 
A260/A280 
 
A260/A230 
RNA 
Extraction 
method 
siRNA22  1 ~600 ng 2.06 1.7 Kit 
siRNA22  2   1496 ng 2.14 0.65 Kit 
      
shRNA22  1 ~600 ng 2.05 1.89 Kit 
shRNA22 2 1360 ng 2.15 0.49 Kit 
      
siRNA6  1 ~500 ng 2.07 1.66 Kit 
siRNA6  2 1355 ng 1.78 1.93 Trizol 
      
shRNA6  1 ~500 ng 2.08 1.36 Kit 
shRNA6  2 1306 ng 1.78 2.13 Trizol 
      
siRNA19 1 ~600 ng - - Kit 
siRNA19  2* 1520 ng 2.09 -1.70 Kit 
siRNA19  2 1633 ng 1.78 2.12 Trizol 
      
shRNA19 1 ~500 ng - - Kit 
shRNA19  2*  737 ng 2.07 -1.26 Kit 
shRNA19 2 1790 ng 1.81 2.06 Trizol 
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Table 4.3   Quantification of DNA input to RACE-Seq library preparation 
 
The above is the total amount of DNA used at the start of the NGS library preparation for 
the time point (1) and the time point (2) RACE-Seq assays. The * indicates that the sample 
processed in a similar manner to the time point (1) samples. 
 
Time	point	1 Time	point	2
Sample	 DNA	amount	(ng) Sample DNA	amount	(ng)
siRNA22 366 siRNA22 196
shRNA22 245 shRNA22 374
siRNA6 301 siRNA6 408
shRNA6 100 shRNA6 248
siRNA19 88 siRNA19* 109
shRNA19 46 shRNA19* 41
siRNA19 480
shRNA19 540
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Figure 4.5   Agarose gel analysis of all RLM RACE samples.  
Following knockdown of HCV replicon genome, 5’ RACE assays were carried out. HCV 
positive strand RNA was reverse transcribed with a primer designed to be specific for each of 
the three RNAi target sites on the HCV genome (site 6, site 19 and site 22). Amplification of 
the cDNA template of each sample used a gene specific reverse primer internal to the reverse 
transcription primer and a forward primer to the adapter sequence. All the 5’ RACE PCR 
reactions were visualised on 2% agarose gels. Assays (A), (C) and (E) were conducted at time 
point 1, and used up to 600 ng input RNA to the adapter ligation reaction. Samples (C) and 
(E) required a second round of PCR using the first round PCR product as template in order to 
visualise the bands on the gel. The (*) in (C) is the first round PCR product. Samples (B), (D), 
(F) and (G) were the time point 2 samples that used >1 µg input of RNA into the adapter 
ligation reaction. Samples (F) were gel extracted prior to library preparation while the other 
time point 2 samples were size selected post library preparation. The size of the expected 
RACE-PCR band is indicated. M=100 bp GeneRuler molecular ladder, bp = base pairs.  
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 Size	selection	strategies	for	RACE-Seq	assays	
Two different strategies were employed for size-selecting the RACE-Seq libraries (Figure 
4.2). All time point (1) samples as well as sample siRNA19(2*) and sample shRNA19(2*) 
were size selected by cutting the DNA bands from a 2% agarose gel prior to library 
preparation. The purified DNA was quantified by the Qubit DNA assay (Table 4.3) and 
samples then progressed directly to library preparation. As a consequence, some samples 
had low (40-110 ng) amounts of DNA available for library preparation after gel extraction 
(Table 4.3). In order to overcome this limitation, for time point (2) samples, the 5’ RACE 
PCR samples were progressed directly to NGS library preparation without size selection. 
This allowed for a greater amount of purified DNA to be input to the library preparation 
(Table 4.3).  
 
Since all NGS libraries were prepared in-house, this allowed the library preparation 
protocol to be adapted to accommodate the variable DNA input to library preparation. The 
time point 1 samples used 9 cycles of PCR when enriching for the correct adapter ligated 
libraries.  In contrast, performing the size selection after library preparation allowed 
greater than 200 ng of purified DNA to be input to NGS library preparation (Table 4.3) 
and only 6 cycles of PCR was used to enrich for the adapter ligated library. Both strategies 
generated sufficient amount of NGS library to progress samples to the emulsion PCR 
stage.  
 
On completion of NGS library preparation, the fragment size range and concentration of 
samples was assessed on the Bioanalyzer DNA chip. Interestingly, two distinct patterns 
regarding fragment size range emerged, depending on the method used for preparing the 
RACE-Seq libraries. Libraries prepared by cutting out the selected band from agarose gels 
before library preparation generally had a fragment profile that included smaller size 
fragments (<150 bp) (Figure 4.6 A, Figure 4.7 A and Figure 4.8 A, B and C). On the other 
hand, RACE PCR samples that were progressed directly to NGS library preparation 
without prior size selection, lacked these shorter size fragments (Figure 4.6 B and C, 
Figure 4.7 B and C and Figure 4.8 D and E). The removal of smaller fragments is likely to 
have been achieved by a combination of bead clean cleanup, which would have eliminated 
residual primers and short amplicons, and the separation and elimination of smaller 
fragments by gel electrophoresis. An interesting observation was that, irrespective of size 
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selection strategy, larger fragments (>300 bp) was observed for the 2% agarose gel 
extractions. This is likely to have occurred due to varied fragment size migration together 
with the lower precision of slicing agarose gel fractions. In contrast, the siRNA22(2) and 
shRNA22(2) samples that were size selected by E-gel did not have fragments greater than 
300 bp (Figure 4.6 B and C).   
 
In summary, all the samples produced a peak at the expected size for NGS libraries, 
regardless of the strategy for size selection. Although variability in the fragment size range 
was observed, the samples were suitable for progressing to emulsion PCR and sequencing.  
 
 
 
Figure 4.6   Fragment analysis for siRNA22 and shRNA22 RACE-Seq samples. 
Samples that were size extracted from 2% agarose gels showed a fragment profile that 
included fragments <150 bp and fragments >300 bp (A).  E-gel size selection of 
siRNA22(2) library sample (B) and shRNA22(2) library sample (C) had fragment profiles 
that were less dispersed. The expected RACE-Seq peak was readily identified (circled) 
when analysed on the Bioanalyzer High Sensitivity DNA chip.  
 
NGS	Library	- shRNA22 (1)A.																																																			
B.																																																																																	C.																																									NGS	Library	- shRNA22 (2)NGS	Library	- siRNA22	(2)
Fragment	size Size	selection	method	
A 90	– 579 bp Gel	excision	prior	to	library	preparation	
B 149	– 356	bp E-gel	extraction	after	library	preparation	
C 218	– 298	bp E-gel	extraction	after	library	preparation	
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Figure 4.7   Fragment analysis for siRNA6 and shRNA6 RACE-Seq samples.  
RACE-Seq library samples that were size extracted from 2% agarose gels showed a fragment 
profile that included fragments <150 bp and fragments >300 bp (A).  For siRNA6(2) library 
sample (A) and shRNA6(2) library sample (B) the fragment profiles from 2% agarose gel 
extraction post library preparation had distinct fragment profiles around the expected size range. 
The expected RACE-Seq peak was readily identified (circled) when analysed on the Bioanalyzer 
High Sensitivity DNA chip.  
 
NGS	Library	– shRNA6 (1)
A.																																																			
B.		 C.																																																							NGS	Library	– shRNA6 (2)NGS	Library	– siRNA6	(2)
Fragment	size Size	selection	method	
A 88	– 1806 bp Gel	excision	prior	to	library	preparation	
B 176	– 339	bp Gel	excision	post	 library	preparation	
C 196	– 249	bp Gel	excision	post	 library	preparation	
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Figure 4.8   Fragment analysis for siRNA19 and shRNA19 RACE-Seq samples. 
Samples that were size extracted from 2% agarose gels showed a fragment profile that 
included fragments <150 bp and/or fragments >300 bp (A, B and C).  Additionally, size 
extraction of libraries from 2% agarose gels post library preparation also produced fragment 
profiles with fragments >300 bp. The expected RACE-Seq peak was readily identified 
(circled) for all samples when analysed on the Bioanalyzer High Sensitivity DNA chip. The 
siRNA19(2)* and shRNA19(2)* samples were processed in a similar manner at time point 
(1) samples. 
 
 
 
 
 
NGS	Library	– shRNA19 (1)
A.																																																																																																														
B.																																																																																									C.																																	
NGS	Library	– shRNA19 (2*)NGS	Library	– siRNA19	(2*)
Fragment	size Size	selection	method	
A 90	– 525 bp Gel	excision	prior	to	library	preparation	
B 90	– 689	bp Gel	excision	prior	to	library	preparation	
C 90	– 293	bp Gel	excision	prior	to	library	preparation	
D 145	487 Gel	excision	post	 library	preparation	
E 166	- 670 Gel	excision	post	 library	preparation	
D.																																																																																										E.																															NGS	Library	– shRNA19 (2)NGS	Library	– siRNA19 (2)
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4.2.3 Multiplex	sequencing	on	the	Ion	Torrent	PGM	
 Impact	of	pooled	samples	on	chip	loading	output	
Applying the templated sequencing beads to the sequencing chip is the final physical 
application stage that can influence the data output. The ISP concentrate is flowed over 
the chip, and beads deposited into wells by centrifugation. The ISP density image for some 
RACE-Seq preparations loaded onto the sequencing chip seemed to exhibit a rarely 
observed phenomenon called bead clumping. This was particularly evident for the 
shRNA22 legacy sample preparation (Figure 4.9 B) but was also observed for the 
siRNA22 legacy preparation (Figure 4.9A) where a single RACE-Seq sample was 
sequenced on each chip.  The time point (2) sequencing run also showed evidence of bead 
climping (Figure 4.9 D). Bead clumping was observed as unevenness of the red heat map 
pattern on ISP density images. The time point 1 preparation was the only preparation to 
show greater than 70% chip loading and exhibited an even ISP density profile (Figure 4.9 
C). Inhibition zones are also easily identified on three of the ISP density maps as dark blue 
zones on the periphery of the chip loading area. These zones constitute further loss of data 
due to failed detection of wells during sequencing and is most often attributed to trapped 
air bubbles that occur during the chip loading procedure. The chip loading process remains 
challenging as it is difficult to assess prior to placing the chip on the instrument for 
sequencing whether any problems at ISP loading has occurred.  
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Figure 4.9   ISP density map for Ion Torrent PGM sequencing chips. 
Chip loading/ISP varied for the different sequencing runs of the PGM. The legacy 
RACE-Seq samples had less even spread of ISP deposit across the chip (A) and bead 
clumping was particularly evident on (B) (arrows) where ISPs had disproportionally 
settled at the outer region of the chip. The long length pooled RACE-Seq samples 
showed more even coverage of ISPs across the chip (C) but also had evidence of 
bead clumping (D).  
 
 
 
 
 
Chip:318																																																												Chip:318																																							
siRNA22	_	ISP	density:	55%																										shRNA22	_	ISP	density:	54%
Legacy	RACE-Seq assay
Chip:318																																								 Chip:318																																												
10	x	samples	_	ISP	density:	72%														 10	x	samples	_	ISP	density:	59%	
Time	point	1																																																		Time	point	2
A.																																															B.		
C.																																																D.																																																
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 Impact	of	multiplexing	on	total	number	of	usable	reads	obtained	
per	318	V2	chip	
The Ion Torrent Server handles all the data for the PGM. The raw data is interpreted and 
the base calls determined by proprietary algorithms and a summary of the data is produced. 
The chip loading percent is related to the number of addressable wells, ie. the number of 
wells where a sequencing bead was detected.  Interestingly, irrespective of chip loading 
density, all the RACE-Seq preparations had a final usable read count of 2.95 million ± 8% 
(Table 4.4).  Thus, for this set of RACE-Seq samples and the assay conditions used in this 
study, a threshold level seems to have been reached. The manufacturer threshold level is 
around 50% of addressed wells, so this falls within the expected minimal output for 
sequencing on the Ion PGM. In all cases, polyclonal and low quality read filtering reduced 
the total number of usable reads. For the time point 1 preparation that achieved >8 million 
deposited ISPs, a higher amount of low quality filtered reads compared to the other 
sequencing runs contributed to reducing the final read count to below 3 million reads. 
Since low quality filtering is more likely to relate to the individual samples, and the time 
point (1) samples were the samples that were extracted from 2% agarose gels prior to 
library preparation this higher low-quality filter may indicate a negative impact associated 
with extraction of RACE amplicons from agarose gels prior to library preparation. 
However, this remains speculation as it is only a single observation.  Although all the runs 
produced sufficient data for downstream RACE-Seq analysis, these preliminary results 
suggest that for sequencing on the Ion Torrent PGM, loss of read output due to polyclonal 
and low quality read filtering are key areas for optimisation.   
 
Table 4.4  Ion Torrent PGM data output for RACE-Seq samples  
 
 
 
 
Assay	&
Chip	size
Addressable	
wells
Chip	
Loading
(%)
Enrichment
(%)
Polyclonal
(%)
Low	
quality	
(%)
Adapter	
dimer	
(%)
Usable
reads
Legacy	_siRNA22 6,191,146 55 99 33 22 4 2,982,359
Legacy_shRNA22 6,046,040 54 99 34 15 4 3,178,404
Time	point	1 8,093,181 72 100 35 36 9 2,853,761
Time	point	2 6,714,882 59 100 46 17 5 2,766,699
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4.3 Discussion		
One of the main limitations to the uptake of RACE-Seq for confirming RISC-mediated 
cleavage events is the lack of reproducible and reliable methods for sample preparation, 
validation and analysis. Within all the current publications of RACE-Seq, issues relating 
to sample preparation and data analysis can be identified.  
 
In the Tabernero et al. (2013) publication, they seem to have prepared more than 60 
5’RACE samples (the exact number is undisclosed) using the GeneRacer kit protocol. It 
is unclear which RNA purification strategy was employed after adapter ligation. After 
reverse transcription and first-round PCR, a second-round PCR was employed to attach 
the Illumina sequencing adapters to samples and the samples sequenced on an Illumina 
platform (the platform was not disclosed in the publication). Since no selection for the 
expected cleavage product size prior to sequencing was performed, together with the fact 
that for Illumina sequencing, the number of flows determines the length, a large fraction 
of reads was picked up outside of the expected siRNA target site This would have impacted 
the data analysis. The datasets were filtered by identifying the exact RNA adapter 
sequence and removing it and then selecting the next 24 bases for each read. These were 
collapsed and counted to produce a set of short unique enumerated sequences. These were 
then aligned to the reference sequence using Bowtie, allowing up to 3 mismatches. The 
data is presented as percentage of aligned reads. They reported that RACE-Seq samples of 
only two patients had peaks at the expected cleavage site at significantly different levels 
to the baseline (from pre-treatment biopsies, banked tumour and normal liver tissue). 
These two patients had 5’ peak levels of ~30% at the expected cleavage site) with the third 
highest report at ~4%. Inspection of the result image of the distribution of 5’ ends for each 
target indicate that at least 70% of reads were outside the RISC hybridization region of 
interest, thus biasing the calculation of RISC-induced peak observation.  
 
The Denise et al. (2014) RACE-Seq assay employed a very short reverse transcription 
length and used the same primer from reverse transcription for the PCR reactions. The 
short length of PCR fragments and lack of size selection prior to NGS library preparation 
for sequencing on the Illumina HiSeq 2000 instrument would have resulted in loss of data 
output due to capture and sequencing of adapter dimer fragments. Of the six data sets 
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presented, one sample is over sequenced with >12 million reads (7 logs) at the expected 
cleavage site while the other three samples are under sequenced with ~1000 reads (3 logs) 
at the expected cleavage site indicating problems with sample preparation.  
 
The Barve et al. (2015) data sets clearly indicate a number of issues with sample 
preparation, as the reported 5’ RISC cleaved end counts are reported at counts of under 25 
reads at the expected cleavage position for the seven patient samples reported. After 
adapter ligation, RNA samples were purified using spin columns rather than the standard 
RNA precipitation cleanup protocol. This is likely to have had the main impact on loss of 
sample. Then, after two cycles of PCR, the samples were pooled and the sequencing run 
spiked with 50% Phi X control (a ready to use library with sequencing adapters for 
Illumina) in an attempt to increase diversity and data quality. The samples were sequenced 
on the Illumina MiSeq. Certainly, the spike-in control would have significantly reduced 
the final amount of usable data per sample.  
 
The latest published RACE-Seq dataset by Ganesh et al. (2016) was also sequenced on the 
Illumina MiSeq instrument. As with Tabernero et al. (2013), the reads were filtered for the 
RNA adapter sequence, which was removed and then the next 15 nucleotides of each read 
selected to make the new dataset that was aligned to the reference sequence. They 
presented their data as percentage of aligned reads but as points rather than the traditional 
bar plots, which allowed all the datasets to be presented in a single plot. Very distinct peaks 
were observed at the expected cleavage site for each of the samples, with less than 2% of 
reads at other positions within the RISC hybridization site. For the expected cleavage 
position, peak incidence is at approximately 14%, 19% and 22% for the various samples, 
indicating that some of the reads aligned outside of the RISC hybridization site, similar to 
Tabernero et al. (2014). Further, the fragment analysis image suggests that RLM RACE 
enriched for at least one other non-target fragment of 300 bp which was also present for 
two of the three placebo controls.  
 
The insights gained from critically evaluating these published RACE-Seq results was used 
improve the development of RACE-Seq libraries for sequencing on the Ion Torrent PGM. 
Size selection of either the RACE-PCR product or the final library reduced the number of 
reads that would align outside of the target region and increased the opportunity to obtain 
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a higher proportion of relevant reads. Additionally, by increasing the read length of RACE-
PCR amplicons to be at least 100 bp, primer dimer could be effectively removed by bead 
clean up or size selection on agarose gels or the E-gel system and again enhanced the 
opportunity to sequence only usable reads. While up to 10 samples could be pooled 
together on a single 318 V2 chip, developing a high throughput protocol for preparing 
large numbers of samples remains challenging. An alternative protocol to using RNA 
precipitation for cleaning up the adapter-ligated RNA is required as this remains the 
bottleneck to processing multiple samples at one time.  
 
This project represents the first instance of developing the RACE-Seq assay for 
sequencing on the Ion Torrent PGM. The difference in the Ion Torrent Sequencing 
platform compared to Illumina has directly impacted on the strategies that evolved for 
RACE-Seq sample preparation. Some of these strategies are likely to prove valuable for 
RACE-Seq sample preparation for Illumina sequencing. As with the experience in 
preparing the legacy RACE-Seq samples, being able to sensitively validate the NGS 
library size range was valuable for assessing whether NGS samples were suitable for 
progressing to the next step. 
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V 		RACE-SEQ	PREDICTS	THE	
MATURE	SIRNA	SEQUENCE	
PROCESSED	FROM	DICER.		
5.1 Introduction		
Transthyretin (TTR) is a plasma protein predominantly synthesised by the liver. A very 
small amount is produced in the area of the brain called the choroid plexus and in the retina 
(Swiecicki et al., 2015). It serves as a transport protein for thyroid hormone and vitamin 
A (retinol).  More than 100 different point mutations have been identified in the TTR gene. 
These mutations result in misfolded proteins and form extracellular protein deposits in 
various tissues, including the heart and peripheral nervous system and results in a range of 
disease conditions leading to mortality. The two hereditary types of disease include 
Familial amyloid polyneuropathy (FAP) and Familial amyloid cardiomyopathy (FAC). 
FAP is very rare with approximately 10,000 people affected worldwide, but the disease is 
well characterised with mutation Val30Met being the most common mutation worldwide 
(Swiecicki et al., 2015). FAC is most common in African American men over the age of 
60. Val122lle has been identified as the most common mutation and is found in almost 4 
in 100 African Americans. This has huge implications for the current health care system 
as liver transplantation is currently the primary treatment for transthyretin amyloidosis 
(ATTR). The third form of ATTR is termed senile systemic amyloidosis and is caused by 
non-mutated, ‘wild-type’ TTR amyloid deposits which result in stiffening of the heart due 
to deposits (Ruberg and Berk, 2012). The disease is slow progressing and is likely to be 
largely underdiagnosed at present.  
 
Currently, organ transplant and treatment of symptoms is the only course of action 
available to affected patients. Of the two drug options currently being evaluated, Tafamidis 
has been approved for use in Europe after showing some slight improvement to patients 
treated very early in disease diagnosis, but has not been approved by the FDA. Diflunsal, 
a common pain killer prescribed for conditions such as arthritis, has the risk of severe side 
effects (Sekijima, 2015). A number of antibody therapy options are also currently under 
		
107	
investigation (Palha et al., 2002; Hosoi et al., 2016). Two RNA therapeutics, one an 
antisense oligonucleotide (ASO) (Benson et al., 2006) and the other a RNAi moiety 
(Coelho et al., 2013) are currently being investigated in clinical trials. IONIS 
Pharmaceuticals (previously Isis), leads the way in RNA-targeted drug discovery, and 
recently announced favourable results for a Phase III clinical trial of its FAP targeting 
ASO candidate, Ionis-TTRRx. Currently, Alnylam  also have Phase II and Phase III clinical 
trials for their formulated siRNA candidates against FAP (Suhr et al., 2015) and at the end 
of 2017 announced favourable results for their Phase III clinical trial.  
 
Coelho et al. (2013) reported cleavage confirmation of ALN-TTR02 targeting TTR mRNA 
in a clinical trial using a 5’ RACE assay, but the position of the siRNA target site pushed 
the placement of the 5’ RACE reverse and amplification primer positions towards the 
lower 3’ end where optimal primer design was less favourable due to low GC% and 
numerous short poly(A) and poly(T) stretches. Additionally, the RACE-PCR product 
would be less and 100 bp, which is less ideal for RACE-Seq. A total of 96 clones from 5’ 
RACE assays for 3 patients was evaluated for the expected cleavage product, before and 
after therapy and for the three patients, 100%, 98% and 40% of post-treatment RACE 
clones aligned to the predicted cleavage site (Coelho et al., 2013). Direct confirmation of 
RNAi activity is greatly underreported in clinical and pre-clinical trials. For example, only 
3 of the 32 participants in this trial were evaluated. Further development of the RACE-Seq 
assay, combined with an intuitive data analysis programme remains a challenge to be 
overcome.  
 
The aim of this chapter was to perform RACE-Seq on an endogenous human transcript 
and to evaluate the pattern of 5’ end peaks obtained. The TTR gene was chosen as a RNAi 
target as it is highly expressed in the liver. A Dicer -substrate siRNA (DsiRNA) and a 
siRNA were designed to target TTR mRNA in Huh7/con1b cells. The IDT RNAi Design 
Tool (https://eu.idtdna.com/site/order/designtool/index/DSIRNA_PREDESIGN) was 
used to design the DsiRNA, while the siRNA sequence was chosen using the Sfold 
software package (http://sfold.wadsworth.org/cgi-bin/sirna.pl). The respective compounds 
were selected based on the design criteria and algorithms for each of the different software, 
resulting in different but overlapping RNAi target sites being selected for each of the 
compounds.  
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5.2 Results	
5.2.1 Primer	efficiency	validation		
In order to ensure appropriate use of the DDCT method, the primer amplification efficiency 
of TTR and an internal control gene, GAPDH was evaluated. PCR efficiency was 
established by calibration curves plotting average CT value vs the log of cDNA template 
amount (Figure 5.1). R2 values for calibration curves were r2=0.95 and r2=0.94 for TTR 
and GAPDH samples respectively, indicating poor accuracy between replicates. Poor r2 
values are usually attributed to pipetting errors (Svec et al., 2015). The slope values of 
each graph was calculated and used to compute the primer efficiency (Table 5.1). Using 
the slope values, efficiency for TTR amplification was determined as 106.7% while 
GAPDH amplification efficiency was determined to be 95.2% for this set of experiments. 
Although the two values fell within the acceptable range of 100% ± 10% as recommended 
by the MIQE (Minimum Information for Publication of Quantitative Real-time PCR 
Experiments) guideline, the values have a greater than 10% difference at 11. 5% 
difference, which is less ideal. The amplification cycles for this efficiency experiment was 
calculated to be 2.06 for TTR and 1.95 for GAPDH when the slope values were input into 
the qPCR Efficiency Calculator (https://www.thermofisher.com/uk/en/home/brands/ 
thermo-scientific/molecular-biology/molecular-biology-learning-center/molecular-
biology-resource-library/thermo-scientific-web-tools/qpcr-efficiency-calculator.html) 
(Table 5.1). 
 
Oligo d(T) reverse transcription was chosen as the best method to generate the templates 
for knockdown determination. The qPCR primers are located upstream of the RNAi target 
site on the TTR transcript, thus reverse transcription with a poly(T) primer or a gene 
specific primer would generate full length templates only for those RNA transcripts that 
had not been cleaved, while reverse transcription of cleaved transcripts would terminate 
prematurely at the RNAi target site, resulting in these truncated templates lacking the 
qPCR amplification region. Use of random hexamer primers risks amplification of 
stabilized 5’ cleaved targets and could lead to compromised knockdown estimation 
(Holmes et al., 2010). When designing the siRNA-TTR and DsiRNA-TTR analogues 
against Human TTR transcript NM_00371.3, the poly(A) tail of TTR was noted to be only 
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12 nucleotides in length. Since the aim was to use poly(T) primer for reverse transcription 
rather than random hexamers, there was a concern that the target would be poorly 
amplified.  
 
Melt curve analysis showed single unique peaks for samples above 5 ng amount for both 
TTR and GAPDH amplification (Figure 5.2 B), and no distinct peak in the no-template-
control or DNA contamination control.  The samples were analysed by electrophoresis on 
2% agarose gel with SYBR Safe stain, confirming single PCR bands and no amplification 
for the no template control and DNA contamination analysis (Figure 5.2 C).  
 
The primer efficiency analysis indicated that there may be some small discrepancy 
between GAPDH and TTR amplification efficiency using the proposed protocol. 
However, since the main aim of the work was not to evaluate knockdown efficacy of 
siRNA-TTR or DsiRNA-TTR, GAPDH was evaluated to be a suitable internal control for 
this set of experiments.  
 
Table 5.1   Reporting of amplification efficiency for TTR and GAPDH 
 Slope value PCR efficiency* Amplification cycle* 
TTR -3.1846 106.7% 2.06 
GAPDH -3.4425 95.2% 1.95 
* Amplification efficiency and amplification cycle were calculated from slope values of 
calibration curves in Figure 5.1, using Thermo Fisher Scientific QPCR Efficiency Tool 
(https://www.thermofisher.com/uk/en/home/brands/thermo-scientific/molecular-biology/molecular-biology-
learning-center/molecular-biology-resource-library/thermo -scientific-web-tools/qpcr-efficiency-calculator.html). 
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Figure 5.1   Determining amplification efficiency by calibration curve analysis.   
cDNA was prepared at 7-point dilution (50 nM, 10 nM, 5 nM, 1 nM, 0.5 nM, 0.1nM, 
0.05 nM). Points are representative of average CT value from triplicate wells.  
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Figure 5.2   Melt curve analysis of PCR efficiency reaction. 
Melt curve analysis for GAPDH (A) confirmed a single peak generated for all 
dilutions of cDNA template. Melt curve analysis of TTR products (B) indicates some 
spurious amplification for concentrations below 5 nM. Agarose gel analysis of TTR 
amplified reactions confirm a single band for all dilutions (C). No template control 
was positive for no amplification of GAPDH. No DNA contamination in RNA was 
positive for no amplification of GAPDH when RNA was used as template (C). 
NTC=no template control; RNA= template for amplification; M=100 bp GeneRuler 
DNA ladder.  
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5.2.2 Targeted	knockdown	of	TTR	mRNA	expression	in	Huh7/con1b	cells		
DsiRNA-TTR and siRNA-TTR targeting two different, but overlapping regions on TTR 
transcripts in Huh7/con1b cells were successful in reducing levels of mRNA target (Figure 
5.3) with siRNA-TTR achieving 79.5% knockdown and DsiRNA-TTR achieving 75.5% 
knockdown when each treatment was applied at 10 nM effective concentration.  
 
 
 
 
 
 
Figure 5.3   Relative TTR mRNA levels after siRNA-TTR treatment and DsiRNA-
TTR treatment in a hepatocellular cell line, stably expressing HCV replicon 
RNA.  
 
 
5.2.3 Validation	of	RACE-Seq	libraries	by	fragment	analysis		
In preparing the 5’RACE-PCR samples, 1 µg or greater had already been established to 
generate 5’ RACE bands in a single round of PCR (Chapter 4). RNA adapter ligation was 
done in a 20 µl volume with the maximum allowed volume of RNA input of 12.5 µl. Care 
was taken to elute RNA that would be used for 5’ RML-RACE into a small volume (~30 
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µl or less). This helped to ensure that > 1.0 µg RNA was input to adapter ligation reactions 
(Table 5.2). After adapter ligation and RNA clean up, 5’ RLM-RACE cDNA templates 
were prepared as previously described (Section 2.9) using primer TTR+L1 for reverse 
transcription. Amplification was carried out using primers GeneRacerF1 and TTR+L2 
primers. PCR reactions were as previously described (Section 2.9.1) and 8 µl of PCR 
sample analysed on a 2% agarose gel with SYBR Safe nucleic acid stain (Figure 5.4 A). 
Gel analysis identified prominent bands of the expected size, ~170 bp, for both the siRNA-
TTR and DsiRNA-TTR samples but not the scrambled control. Additional background 
amplification was easily visible for all three samples. Of note is that a smear of background 
amplification was clearly present for the scrambled control sample, but no prominent size 
band was seen at the expected position for RISC cleavage.   
 
In order to prepare amplicon samples for library preparation, PCR reactions were first 
cleaned using 1.6X Ampure beads. Samples were quantified and siRNA-TTR and 
DsiRNA-TTR NGS libraries prepared as previously described (Section 2.10). Since the 
gel analysis showed very prominent bands for both the samples, E-gel size selection was 
used to extract the expected NGS band size. NGS fragment size after E-gel extraction was 
analysed on the Bioanalyzer High Sensitivity chip. For both siRNA-TTR and DsiRNA-
TTR sample, E-gel extraction of 5’RACE NGS fragments was generally in the range of 
172 bp to 292bp (Figure 5.4 B and C). However, two distinct fragment profiles were seen 
for each sample. A quite distinct single peak at ~250 bp was isolated for siRNA-TTR 
(Figure 5.4 B), but the DsiRNA-TTR sample had a cluster of very prominent peaks at 172 
bp to 221 bp, as well as the prominent ~ 250 bp peak (Figure 5.4 C). Only a few >300 bp 
peaks were picked up in Bioanalyzer analysis, but these were at a very low concentration. 
For both samples, the E-gel isolated NGS libraries met the criteria for sequencing on the 
Ion Torrent for 200 bp sequencing. For these samples, an observation of discrete 5’ RACE-
PCR bands correlated well with using the E-gel system for isolating the desired fragments. 
Isolating the fragments after library preparation very efficiently eliminated <150 bp 
fragments for both samples. The E-gel system elutes the DNA fragments into wells that 
are topped up with ~25 µl nuclease-free water and the fragments aspirated at the 
appropriate point. Since the libraries were prepared in-house, the purity of the final library 
was not assessed. However, if the samples were to be sent for external sequencing, it is 
likely that a minimum OD260/280 = ~2.0 would be required. Since the DNA passes through 
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a gel matrix, it is feasible that some buffer components transfer into the collection well 
and interfere with purity determination. The DsiRNA-TTR and siRNA-TTR samples were 
pooled with the HCV 5’RACE samples, samples quantified, diluted and transferred to 
emulsion PCR and then progressed to sequencing.  
 
Table 5.2   Nucleic acid quantification for 5’RML-RACE and RACE-Seq 
 
  
Qubit	Quantification	 Nanodrop analysis		 Amount	RNA	
input	to	5'	RLM-
RACE
Amount bead
cleanedDNA	
input to	NGS	Sample	 Average	[ng/ul] Average	[ng/ul]  A260/280  A260230
DsiRNA-TTR 340 405 2.04 1.57 2,105	ng 270	ng
siRNA-TTR 302 350 2.03 1.39 2,395	ng 282	ng	
Dscr 302 363 2.04 1.63 1,428	ng	 119	ng	
(Total	RNA	is	calculated	as	Qubit	quantified	 amount	RNA	x	12.5	µl)	
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Figure 5.4   Visualisation of 5’RML-RACE amplicons and RACE-Seq libraries 
post E-gel size selection. 
Distinct bands at the expected size (~170 bp) were obtained for 5’RML-RACE 
siRNA-TTR and DsiRNA-TTR samples (A). NGS libraries were prepared from 
5’RML-RACE samples and the expected size band extracted using the E-gel Size 
Selection System. A discrete fragment range was observed for siRNA-TTR size 
selected RACE-Seq sample (B), while the DsiRNA-TTR sample had a peak fragment 
range 172 bp to 257 bp (C).   
 
Fragment	size Size	selection	method	
A 174	– 292	bp E-gel	extraction	after	library	preparation	
B 172	– 474	bp E-gel	extraction	after	library	preparation	
A.				 B.																																																																																																											NGS	Library	– DisiRNA TTRNGS	Library	– siRNA	TTR
Fragment	size Size	selection	method	
A 174	– 292	bp E-gel	extraction	after	library	preparation	
B 172	– 474	bp E-gel	extraction	after	library	preparation	
A.				 B.																																																																																																											NGS	Library	– DisiRNA TTRNGS	Library	– siRNA	TTR
A.																																																																												
C.			 	 	 	 	 	 	 	 	 	 	 	
B.																																																																												
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5.2.4 RACE-Seq	data	analysis		
RACE-Seq sample siRNA-TTR, generated 373,056 reads, while RACE-Seq sample 
DsiRNA-TTR generated 313,200 reads (Table 5.3). After filtering the data and aligning 
reads to the reference, 64,167 reads and 20,035 reads aligned to the reference for siRNA-
TTR and DsiRNA-TTR respectively (Table 5.3).   
 
To identify why the rest of the filtered reads failed to align to the reference, the reads were 
collapsed and mapped to the TTR reference. This identified that for siRNA-TTR, the 
unaligned data was in fact primarily TTR sequence that had failed to align due to mutations, 
insertions or deletions. A poly-C5 region 17 bases from the expected siRNA-TTR RISC 
cleavage site seemed to be particularly problematic. For the DsiRNA-TTR sample, 
mapping collapsed reads to the TTR reference revealed non-TTR sequence that was 
identified as contaminating HCV sequence that aligned to site 19 on the HCV replicon 
reference sequence. This contamination is likely to have occurred at a stage prior to 
ligation of sequencing adapters as the contaminating reads had been de-multiplexed to the 
respective TTR barcoded samples. Interestingly, these contaminating HCV reads seem to 
have either held the TTR amplification primer sequence or escaped the read filtering 
process, as one of the pre-filtering steps selects for reads containing the TTR+L2 sequence. 
Therefore, a likely conclusion is that the contamination occurred during amplification of 
TTR 5’ RACE cDNA. 
 
The loss of aligned data due to sequence variation beyond of the RISC cleavage site and 
presence of contaminating/non-target sequence led to a new strategy for filtering the 
RACE-Seq data (Figure 5.5). Since the sequence just after the RNA adapter is the region 
of interest, a strategy that shortens all the reads to a fixed distance beyond the RNA adapter 
was a sensible approach and had previously been implemented for RACE-Seq data 
filtering (Tabernero et al., 2013; Ganesh et al., 2016). A strategy that selects 20 bases after 
the RNA adapter was chosen due to the homopolymer C region in close proximity to the 
siRNA-TTR RISC cleavage site. Additionally, the short 20 bases length would also be 
more suitable to analysing the HCV RACE-Seq data as the HCV replicon sequence was 
expected to be highly variable. To eliminate contaminating reads and non-specific 
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amplicons from the dataset, a strategy to specifically filter for the target sequence was 
implemented (Figure 5.5).  
 
The FASTQ datasets were filtered by searching for the RNA adapter sequence in both 
directions, reverse complementing the reads that were in reverse order and then adding 
these to the reads with the correctly orientated adapter sequence. The gene specific reads 
were selected by first removing the RNA adapter and then searching for reads that had the 
expected 10 bp sequence at the 3’ end. This gave a filtered data set of 112,939 reads for 
siRNA-TTR and 64,257 reads for DsiRNA-TTR. The GeneRacer adapter sequence was 
then removed and reads aligned to TTR. This found that 90,252 reads aligned to TTR for 
the siRNA-TTR sample and 51,105 reads for DsiRNA-TTR (Table 5.4). Thus, the new 
data filtering strategy increased the total number of aligned reads from 64,167 to 90,252 
reads for siRNA-TTR and from 20,035 to 51,105 reads for DsiRNA-TTR (Table 5.3 vs 
Table 5.4). For DsiRNA-TTR, the number of filtered reads decreased from 159,535 reads 
to 64,257 reads, but represented reads that were truly the expected target sequence. 
 
 
  
Table 5.3   RACE-Seq read analysis using filtering to retain long length reads  
 
  
siRNA DsiRNA
Filter	Criteria Read	count Percentage Read	count Percentage
Total	number	of	reads 373,056 313,200
Reads	remaining	after	filtering	 135,806 159,535
Total	filtered	reads	that	align	to	TTR	 64,167 47.2* 20,035 12.6*
Unaligned	reads	 71,637 52.8 139,500 87.4
*	percent	of	filtered	reads
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Table 5.4   Read analysis for RACE-Seq siRNA-TTR and DsiRNA-TTR 
 
 
 
 
 
 
 
 
Figure 5.5   Data analysis strategy for filtering RACE-Seq datasets to generate the 
adapter+20-nucleotide short filtered datasets.  
 
 
siRNA DsiRNA
Filter Criteria Read count Percentage Read count Percentage
Total number of reads 373,056 313,200
Total reads with GeneRacer adapter 171,000 45.8 148,357 47.4
Total reads with inverted GeneRacer sequence 148,448 39.8 116,315 37.1
Total reads with GeneRacer adapter 319,448 85.6 264,672 84.5
Reads with reverse primer sequence(trimmed) 193,259 221,422
Reads specific to target (10 bp internal) 144,578 77,770
Total filtered reads (adapter trimmed) 112,939 30.3 64,257 20.5
Total reads that align to TTR 90,252 79.9* 51,105 79.5*
Unaligned reads 22,687 20.1* 12,228 20.5*
*	percent	of	filtered	reads
Search	for	adapter	
sequence	(RACE)	
and	reverse	
complement	
adapter	
sequence(revRACE)	
Reverse	
complement	
the	revRACE file	
and	
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by	trimming	
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3’	end	of	reads
Further	enrich	for	
target	by	trimming	
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the	next	10nt	from	
3’	end
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counts
		
119	
5.2.5 RACE-Seq	confirms	the	expected	cleavage	product	for	siRNA-TTR	
The siRNA-TTR RNAi bioactive had been designed to be a standard 21 bp duplex siRNA 
with 3’ 2-nt DNA overhangs (Figure 5.6 A). Aligning the filtered RACE-Seq siRNA-TTR 
dataset to the TTR reference gene resulted in 79.9% of aligned reads with a 5’ end at the 
expected RISC cleavage position, C=483 (Table 5.5). This corresponded exactly to 
canonical siRNA-mediated cleavage of the target between bases 10-11 from the 5’ end of 
the expected guide strand. Interestingly, RACE-Seq reported an additional 5’ end peak at 
+1 of the expected cleavage site (Figure 5.6 B). Whether this second peak of 5’ ends was 
generated by guide strand-mediated RISC activity remains unclear. For this peak to have 
been generated by canonical RISC cleavage, the siRNA would need to have been cleaved 
such that the guide strand now had nucleotide two as the first nucleotide, but retained 3’ 
and 5’ structural elements necessary for AGO2 recognition. Confirmation of such a 
sequence can only be obtained by capturing the siRNA fraction of active RISC by 
immunoprecipitation of AGO2 and isolating and sequencing the small RNA fraction. The 
observation of a second 5’ peak at +1 position suggests that RACE-Seq has the potential 
to provide novel information regarding on-target RISC activity for siRNA duplexes 
generating multiple guide strand species.  
5.2.6 RACE-Seq	 identifies	 the	 sequence	 of	 the	 active	 guide	 strand	
processed	out	of	Dicer	for	DsiRNA-TTR	
Figure 5.7 (A) illustrates the predicted Dicer processing of DsiRNA-TTR to produce a 21-
mer or 22-mer siRNA. DsiRNA-TTR was designed to be a 25-27 duplex with a 2-nt 3’ 
overhang to promote directional processing by Dicer and preferential strand selection. The 
other end is blunt ended to preclude Dicer binding at that end. Two DNA nucleotides are 
included at the blunt end of the sense strand. Thus, Dicer recognition of the 3’ overhang 
enforces asymmetric loading. Dicer processing  is expected to result in a major 21-mer 
and may produce a minor 22-mer active siRNA (Amarzguioui and Rossi, 2008).  
 
When the RACE-Seq data for DsiRNA was aligned to the TTR reference, a peak at G=475 
emerged, rather than the expected T=474 (Table 5.5). This led to the conclusion that Dicer 
processing had occurred at 5-nt internal to the guide strand, rather than the expected 6-nt 
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internal to the guide strand (Figure 5.7 A). In conclusion, RACE-Seq analysis could 
identify the sequence of the guide strand that must have been processed out of Dicer.  
5.2.7 RACE-Seq	 predicts	 that	 the	 unprocessed	 DsiRNA-TTR	 is	 itself	 a	
substrate	for	AGO2-RISC	
For the DsiRNA-TTR RACE-Seq sample, a further unexpected observation was noted. A 
distinct peak at position T=480 of 25.8% aligned reads was generated (Table 5.5). Initially, 
this peak had been classed as putative degradation product. Surprisingly the second peak 
exactly corresponded with canonical RISC cleavage of target if the 27-mer RNA of 
DsiRNA-TTR is used as a guide strand. (Figure 5.7 B). Whether the entire 27-mer guide 
strand sits within the active RISC or a shortened version of DsiRNA-TTR was derived is 
unclear. Dicer processing of 25/27 duplex siRNA is expected to yield primarily a 21-mer 
siRNA (Kim et al., 2005). Canonical Dicer processing is expected to cleave 6-from the 
27-mer guide strand, so that, if the opposite end of the duplex were to be cleaved, this 
would yield a shorter duplex with compatible ends for AGO2 recognition. Such a theory 
remains to be validated.   
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Figure 5.6   RACE-Seq result for siRNA-TTR. 
(A) Diagram illustrating the expected cleavage position for siRNA-TTR, a 21-mer 
oligo with 19 bp duplex stem and 2-nt overhang. (B) RACE-Seq confirms the 
expected RISC cleavage site at the highest peak. (TT) at the 3’ and 5’ overhangs = 
DNA; siRNA-TTR duplex is labelled in 5’ to 3’ direction of guide strand (target 
hybridization orientation); grey bar = RISC cleaved site.   
 
 
Figure 5.7  RACE-Seq identifies the siRNA guide strand of DsiRNA-TTR 
(A) Illustration of the DsiRNA-TTR duplex indicating the expected Dicer cleavage site 
(dotted line) which would generate a 21-mer duplex and expected cleavage position at open 
triangle. The RACE-Seq predicted Dicer processed position is indicted by the solid black 
line, to generate an expected 22-mer product (A). A distinct 5’ peak confirms RISC activity 
of a 22-mer siRNA processed out of Dicer (B). (aa) at 3’ end of passenger strand = DNA; 
DsiRNA duplex is labelled in 5’ to 3’ direction of guide strand from the expected 22-mer 
5’ end. grey bar = RISC cleaved site.   
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Table 5.5   Table indicating the percent aligned reads for siRNA-TTR and 
DsiRNA-TTR from RACE-Seq assays 
 
RACE-Seq datasets were pre-filtered to specifically select for the target sequence and 
then trimmed to adapter+20-nt length. These short reads were input to the RACE-SEQ-
lite analysis pipeline which performed the alignment reported the 5’ end counts as a 
percent of total aligned reads. For siRNA-TTR, position 483 = C = 79.89% corresponds 
to a count of 10 from the 5’ end of the hybridized siRNA. For DsiRNA-TTR, two major 
peaks are observed (red); position 480 = T = 25.8% corresponds to a count of 10 from 
5’ end of the unprocessed DsiRNA-TTR guide strand and position 475 = g = 47.0 % 
corresponds to a count of 10 for a proposed Dicer processed guide strand with start 
position 458 (grey).  
 
 
siRNA-TTR DsiRNA-TTR
siRNA	at			
hybridization	
site	
TTR
nucleotide
position
Nucleotide
Aligned	
reads
(%)
DsiRNA at
hybridization	
site	
TTR
nucleotide
position
Nucleotide
Aligned	
reads
(%)
3' 474 T 0.0 3' 463 G 0.0
475 G 0.8 464 C 0.0
476 G 0.0 465 A 0.0
477 T 0.0 466 T 0.0
478 A 0.0 467 G 0.0
479 T 0.0 468 C 0.0
480 T 0.5 469 A 0.0
481 C 0.0 470 G 0.0
482 A 11.4 471 A 0.0
483 C 79.9 472 G 0.0
484 A 1.2 473 G 4.2
485 G 0.1 474 T 0.3
486 C 0.0 475 G 47.0
487 C 0.0 476 G 0.7
488 A 0.0 477 T 0.1
489 A 0.0 478 A 0.1
490 C 0.0 479 T 0.2
491 G 0.0 480 T 25.8
5' 492 A 0.0 481 C 0.9
482 A 0.3
483 C 1.8
484 A 0.1
485 G 0.1
486 C 0.1
487 C 0.1
488 A 0.0
5' 489 A 0.1
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5.3 Discussion		
The present study was designed to assess the RACE-Seq protocol (implemented in Chapter 
4) and accompanying analysis pipeline when applied to a genomic transcript. The TTR 
gene was chosen as the test transcript as it is known to be highly expressed in hepatic cells 
(Costa et al., 1990). A standard siRNA of 19 bp duplex and 2-nt DNA overhang was 
designed using a web-based tool. The algorithms utilised in such design software 
incorporate extensive experimental and computation analysis of validated potent siRNAs 
(Reynolds et al., 2004). Dicer processing of longer RNAi triggers has been implicated to 
have higher potency compared to 21-mer triggers as Dicer processing is believed to 
promote more efficient incorporation into RISC (Ketting et al., 2001; Boudreau et al., 
2008; Snead et al., 2013). The design of DsiRNA often begins by choosing an optimal 21-
mer and then extending the 5’ end by 6 nucleotides and designing a blunt end that 
terminates in two DNA bases. The free 3’ 2-nt overhang on the guide strand is the signal 
for Dicer capture while the blunt-end is thought to be recognised in a similar manner to 
shRNA loop structures (Amarzguioui et al., 2006).  
 
In this Project, we present a computationally simple workflow for analysing RACE-Seq 
data. Being able to implement the adapter removal, sequence enrichment and any quality 
filtering analysis as a stand-alone operation allowed in-depth analysis of the datasets. 
While each command-line code was executed manually as a single line, it is possible to 
write simple code that would execute the desired commands and produce a summary 
output of text and graphics.  
 
For the siRNA-TTR sample, RACE-Seq reported the expected cleavage site as the major 
peak, however a second peak at +1, and third peak at +2 were also reported. Whether these 
additional peaks were generated by siRNA-mediated RISC activity remains unknown, but 
would require that a fraction of the siRNA-TTR underwent processing in vivo, such that 
the 5’ end of the guide strand was cleaved by 1 and 2 bases, but retained the 2’nt overhang 
and 5’ phosphate for AGO2 recognition.  
 
On the question of Dicer processing of the DsiRNA, the expectation was for a 
predominantly 21-mer active product and minor 22-mer product (Amarzguioui and Rossi, 
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2008). However, for DsiRNA-TTR, RACE-Seq identified a cleaved target that points to a 
preference for a 22-mer Dicer processed RNAi trigger from DsiRNA-TTR. A major 22-
mer has previously been identified from Dicer processed 25/27-mer by Snead et al., (2013) 
who also identified a major 22-mer processed out of Dicer for a 25/27-mer and by deep 
sequencing the small RNAs from DsiRNA transfected cells, identified that the 22-mer 
corresponded to 5-nt being trimmed from the 5’ end of the guide strand rather than 6-nt as 
expected. They surmised that there may be link between Dicer processing and generation 
of a guide strand more favourable for strand selection and gene silencing.  
 
For standard 5’ RACE, which uses Sanger sequencing to confirm the sequence of 5’ RACE 
clones, data is typically reported as expected cleavages per total clones with 5’ end at the 
expected cleavage site (Davis et al., 2010; Clark et al., 2013; Sakurai et al., 2013). 
Typically, 5’ end counts outside of the expected observed cleavage site is not reported, so 
that, depending on the number of clones sequenced, a true shift in RISC cleavage site may 
not be detected.  
 
Interestingly, a group at Dicerna Pharmaceuticals, Inc., presenting their work evaluating a 
lipid-nanoparticle (LNP)-formulated 2’-O-Me modified DsiRNA in vivo confirmed a 
RNAi mechanism of action using RACE-Seq. Despite showing the expected canonical 
processing of their DsiRNA by Dicer to generate a 21-mer in the introduction of the poster, 
the RACE-Seq data (a peak reporting >90% cleavage) prompted the acceptance that a 22-
mer was processed by Dicer with a shift in the expected cleavage position and added the 
statement; “The location of Ago2 cleavage predicts the sequence of the mature siRNA 
(post-Dicer processing)”. This statement, although obscurely buried on a poster, 
encompasses the greatest opportunity for RACE-Seq to enter the RNAi field as a standard 
assay for confirming a RNAi mechanism of action. The poster was accessed on 30 May 
2017 (but has since been removed from the internet). Some of the information is available 
in a presentation from the 12th Annual meeting of the Oligonucleotide Therapeutics 
Society, 28 September 2017 (http://files.shareholder.com/downloads/AMDA-
2IH3D0/5213734735x0x909887/15FC393C-6764-4983-87C0-64DED88FD75D/DCR-
MYC _Presentation_for_OTS _2016 _FINAL.pdf).  
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This chapter represents the first observation of RISC-induced canonical cleavage of target 
by an non-cleaved 27-mer Dicer substrate guide strand. The current assumption is that the 
entire 27-mer was loaded to RISC which is supported by the work of Snead et al., (2013) 
who undertook to investigate the basis for improved gene silencing by Dicer substrate 
siRNA. They identified that the 27-mer bottom strand of a Dicer substrate was purified 
from immuno-precipitated AGO2. Much of the early work investigating 27-mer siRNA 
focused on determining the optimal structural elements for enhanced potency and used 
electrospray ionization mass spectrometry (ESI-MS) to examine the oligonucleotides as 
well as in vitro cleaved Dicer products (Kim et al., 2005; Rose et al., 2005; Amarzguioui 
et al., 2006). Further support for the theory of unprocessed 27-mer guide strand comes 
from the work by Salomon et al., (2010) who showed that an unmodified 25-mer blunt end 
duplex cleaved its target at the expected position between bases 10-11 from the end of the 
25-mer guide strand. They employed an in vitro mRNA cleavage assay incubating 32P-
labelled target RNA and immune-precipitated AGO2 together and then analysing the 
cleaved products for the expected size fraction (Salomon et al., 2010). In conclusion, for 
this experiment, RACE-Seq predicts a RISC-induced on-target mechanism of action for 
two different guide strand species of DsiRNA-TTR.  
 
Currently, validation of RNAi drug activity is driven by reporting of clinically relevant 
information such as efficacy, reduction in dosage, increased bioavailability, improved 
targeting, reduced immune activation, no off-target effects and safety. The standard 5’ 
RACE assays dictated reporting an expected RISC cleaved product based on the design of 
the RNAi bioactive. In contrast, RACE-Seq provides the opportunity to characterise RISC 
activity in an unbiased manner. For Dicer substrate RNAi triggers, RACE-Seq allows a 
means of reverse predicting Dicer behaviour, as RACE-Seq defines the mature siRNA and 
thus predicts Dicer cleavage action. 
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] 		RACE-SEQ	REPORTS	THE	ACTIVE	
SIRNA	SEQUENCE		
6.1 Introduction		
Our understanding of AGO2-mediated RNAi activity is that RISC cleaves target RNA  
opposite bases 10-1l of the siRNA guide strand, when counting from the 5’ end of the 
hybridized strand (Gu et al., 2012; Liu et al., 2015). This implies that the sequence of the 
cleavage product can predict the sequence (or at least the 5’ end) of the active siRNA guide 
strand. Currently, RML-RACE with Sanger sequencing remains the gold standard for 
confirming a direct mechanism of action of AGO2-mediate RISC cleavage. However, the 
much lower read throughput of Sanger sequencing may result in a misleading or narrowed 
interpretation of RISC activity,  as currently the method is used to confirm a pre-conceived 
expectation for the behaviour of a designed RNAi-based trigger (Frank-Kamenetsky et al., 
2008; Judge et al., 2009; Davis et al., 2010). While AGO2-RISC cleavage remains precise, 
‘imprecise’ Dicer cleavage is well documented (Saayman et al., 2010; Starega-Roslan et 
al., 2011; Harwig et al., 2015) and a number of attempts have been made to define the 
precise sequence and/or structural characteristics of Dicer substrate including shRNAs 
(Rose et al., 2005; Dallas et al., 2012). Results from Chapter 5, regarding the expected vs 
RACE-Seq predicted cleavage site for DsiRNA-TTR, prompted the notion that RACE-
Seq could identify the sequence of the RNAi trigger.  
 
In the following chapter, RACE-Seq was applied in an unbiased manner to investigate the 
potential RISC-induced cleavage products of six RNAi bioactive oligonucleotides 
targeting the HCV replicon genome. This information was then used to predict the 
sequence of the active siRNA trigger and to hypothesize Dicer processing activity.  
 
6.2 Results		
6.2.1 Data	output	per	sample	and	read	depth		
In Chapter 4, two independently prepared RACE-Seq sequencing runs which were 
conducted at separate time points is described. The total number of reads for each sample 
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in the runs varied greatly across the 14 samples (Table 6.1 and 6.2). All RACE-Seq 
analysis was carried out by filtering reads to have adapter+20 nt as indicated in Figure 5.5. 
The data filtering protocol included searching for the adapter in both directions, reverse 
complementing the reads with the adapter sequence in the reverse orientation, pooling the 
reads from the two files, filtering reads for the target sequence by trimming expected 
sequences from the 3’ end of reads before trimming reads to length adapter+20-nt and then 
this final short read file was used as input to the RACE-SEQ-lite pipeline (Theotokis et 
al., 2017) which removes the RNA adapter sequence and maps the reads to the reference 
to determine the 5’ end counts. 
 
The peak information is most easily interpreted as a bar graph of 5’ end counts that align 
at the various positions within the expected RISC hybridization site. However, variation 
in read amount can make it difficult to assess each sample on its individual merit. 
Presenting the data as a percent of aligned 5’ ends solves this by allowing each sample to 
be assessed individually, but uses a common factor, percentage aligned reads. For 
example, siRNA22(2) had 71,152 reads at the expected cleavage site, while sample 
siRNA22(1) had almost twice as many reads (135,571) at the expected cleavage site 
(Figure 6.1 A and B). Comparing them side by side may misinterpret that the sample with 
fewer reads is a ‘poorer’ sample. However, when each of the datasets is presented as a 
percentage of aligned reads, siRNA22(1) had 43.8% of 5’ ends at the expected cleavage 
site and siRNA22(2) had 50.8% of all aligned 5’ ends at the expected cleavage site.  
 
When presented as the proportion of aligned reads, read amount becomes less of an 
obstacle to data interpretation. By the same token, only presenting the data as a percentage 
of aligned reads, without disclosure of total filtered reads (ie. the number of reads that 
were input for alignment), can mask data which is truly less robust. For example, RACE-
Seq analysis for samples shRNA6(1) and shRNA6(2) reported 36.2% and 40.1% of 5’ 
ends aligned at the expected cleavage position for the respective samples. If presented only 
as percentage of 5’ ends aligned to the target, without disclosure of the total reads (5,812 
and 29,934 reads respectively) and total number of reads after cleaning the data (1,988 and 
19,409 reads), the fact that both samples had lower than expected number of reads for each 
of the respective sequencing runs (Table 6.2) would not be disclosed. Ultimately, the total 
number of reads obtained for each sample in the HCV knockdown RACE-Seq assays had 
no impact on confirming the expected RISC cleavage position. However, this hinges off 
good quality control checkpoints during sample preparation (ie. primer validation for 5’ 
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RML-RACE, verification of 5’ RACE-PCR product by agarose gel analysis, size selection 
to eliminate unwanted fragments from NGS library preparation and sensitive validation of 
NGS sample fragment size by electronic fragment analysis.  
 
Thus, regardless of the variability in the number of reads obtained for each sample, RACE-
Seq robustly reported the RISC-induced cleavage site (Figure 6.1 and Figure 6.3). 
Additionally, the independent experiments reported very similar peak patterns for the same 
RNAi-based trigger. This indicates that the various downstream protocols for this RACE-
Seq assay, from adapter ligation through to size selection of NGS samples, was robust.  
For shRNA6, despite sub-optimal knockdown conditions, ~60% knockdown when using 
0.5 nmol/l effective concentration (Table 4.1), RACE-Seq still reported the expected 
cleavage site (Table 6.4, Figure 6.3 C). Interestingly, when the concentration of shRNA6 
analogue was increased from 0.5 nmol/l to 1.0nmol/l (Table 4.1), an increase in silencing 
resulted in a greater number of RACE-Seq reads being obtained (Table 6.2, Figure 6.3 C 
and D). This is as expected as the increased dose would have resulted in improved 
knockdown and an increase in RISC cleaved products which could be captured by RML 
RACE and reported by NGS sequencing. Thus, well defined RML RACE assays and 
quality controlled NGS library preparation generated a robust RACE-Seq assay.  
 
 
Table 6.1   Read statistics for siRNA6, siRNA19 and siRNA22.  
 
 
 
Reads	that	align	to	
target
Total	
Reads Adapter+20nt
Reads	with	
adapter <10	bp 
Total	aligned	
reads
Unaligned	
reads
%	of	total	
reads
%	of	reads	
with	
adapter
siRNA22	(1) 613,557 441,731 392,102 1 309,725 82,376 50.5 79.0
siRNA22	(2) 478,979 271,934 206,110 3 143,986 62,121 30.1 69.9
siRNA6	(1) 216,114 179,132 107,903 3,035 95,286 9,582 44.1 88.3
siRNA6	(2) 151,825 120,459 107,668 113 100,028 7,527 65.9 92.9
siRNA19	(1) 624,683 490,279 422,419 3,226 374,938 44,255 60.0 88.8
siRNA19	(2) 153,319 130,606 115,298 408 106,143 8,747 69.2 92.1
siRNA19	(3) 443,420 329,909 300,926 5,227 259,579 36,120 58.5 86.3
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Table 6.2   Read statistics for shRNA6, shRNA19 and shRNA22. 
 
 
 
6.2.2 RACE-Seq	confirms	the	expected	cleavage	site	for	siRNA22				
Previous RACE-Seq analysis for siRNA22 using Illumina high throughput sequencing 
reported the expected RISC cleaved site at position T=9489 on the sense strand of the 
HCV replicon RNA genome (Denise et al., 2014). Using the legacy RACE-Seq assay, the 
expected cleavage site for siRNA22 was confirmed when sequencing on the Ion Torrent 
PGM (Chapter 3). Additionally, a second peak 3-nt upstream of this expected cleavage 
site was reported at 17% of aligned reads at position A=9486 (Chapter 3, Figure 3.13). No 
correlation between the Illumina data from Denise et al. and the Ion Torrent legacy RACE-
Seq siRNA22 data could be determined. In the absence of corroborating evidence that this 
second peak was potentially generated by RISC-induced activity, this second site was 
dismissed as undetermined origin.  
 
For the long amplicon RACE-Seq assays, the FASTQ file for each sample was pre-filtered 
as outlined previously and then aligned to the HCV replicon reference genome using the 
RACE-SEQ-LITE pipeline. For siRNA22, the RISC hybridization site lies at position 
9479 to 9498 on the replicon genome. For each of the samples, despite the difference in  
 
 
 
 
Reads	that	align	to	
target
Total	
Reads Adapter+20nt
Reads	with	
adapter <10 bp 
Total	aligned	
reads
Unaligned	
reads
%	of	total	
reads
%	of	reads	
with	
adapter
shRNA22	(1) 359,022 258,543 240,931 0 171,196 69,735 47.7 71.1
shRNA22	(2) 468,498 223,793 187,621 5 139,912 47,704 29.9 74.6
shRNA6	(1) 5,812 3,750 1,988 142 1,632 214 28.1 82.1
shRNA6	(2) 29,934 21,775 19,409 117 17,280 2,012 57.7 89.0
shRNA19	(1) 615,160 437,169 344,639 1,171 294,357 49,111 47.9 85.4
shRNA19	(2) 162,539 144,082 131,871 247 121,055 10,569 74.5 91.8
shRNA19	(3) 701,310 509,694 450,578 2,722 383,353 64,503 54.7 85.1
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total read count (Table 6.1), each of the independently prepared and sequenced siRNA22 
samples reported the expected peak at T = 9489 (Figure 6.1). When the peak profiles for 
each sample was analysed as a percent of aligned reads, sample siRNA22(1) reported 
43.8% of reads at the expected cleavage site and sample siRNA22(2) reported 50.8% of 
reads at the expected cleavage site (Table 6.3). In each case, the expected peak was reliably 
detected by RACE-Seq and confirmed the sequence of the guide strand and that the 
siRNA22 molecule had performed in the expected manner for the design of the duplex 
(Figure 6.1 A and B, Figure 6.2 A).  
 
However, a second 5’ end peak at 2-nt upstream of the expected cleavage site was also 
reported for both samples (Figure 6.1 A and B), which had 14.5% of reads for siRNA22(1) 
and 6.8% of reads for siRNA22(2) (Table 6.3). The RACE-Seq legacy assay for siRNA22 
had reported a second peak at 3-nt (A=9476) upstream of the expected RISC cleavage site, 
but in the absence of corroborating evidence, was dismissed as being unlikely to have been 
generated by RISC activity. However, since this A=9487 peak was reported by both 
samples as the second highest count, this warranted a closer look at the peak profiles and 
speculation on their possible origin. If the secondary peak is to be taken as real reporting 
of RISC activity, this would infer that an active siRNA22 species of compatible sequence 
and possessing the necessary 2-nt 3’ overhang structure for AGO2 recognition had been 
generated in vivo or a part of the siRNA22 sample. Dicer is not known to process 21-mer 
siRNA such as siRNA22, and only a small set of published work that included a 21-mer 
in a Dicer cleavage assay could be found. For example, an in vitro Dicer assay was 
performed by incubating a 21-mer, 23-mer, 25-mer, and 27-mer siRNA with recombinant 
Dicer for 24 hours. The products were separated on a polyacrylamide gel, stained and 
compared to a set of untreated samples. The 21-mer remained unchanged, but all the other 
duplex sizes showed a shift in size that corresponded to the 21-mer untreated sample 
position in the gel (Kim et al., 2005). Whether this second upstream peak is induced by a 
siRNA22 species remains to be further investigated.  
 
Both the siRNA22 RACE-Seq samples also reported a peak at A=9479, G=9481 and 
T=9483 (Figure 6.1 A and B). The nature by which these peaks were derived can only be 
speculated to be due to some other biological processing/cleavage of RNA. They are 
unlikely to be as a result of a RISC-induced siRNA22 species as the duplex length required 
would be too short for AGO2-RISC recognition.  
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6.2.3 RACE-Seq	confirms	the	expected	cleavage	site	for	shRNA22		
Both the shRNA22(1) and shRNA22(2) RACE-Seq samples reported the expected 
cleavage position, with 53.7% and 51.2% of filtered reads aligning to position T=9489 for 
respective samples (Table 6.3). The shRNA22 synthetic hairpin molecule was designed to 
mimic the shRNA22 pro-drug expressed from TT-034. The hairpin is designed as a reverse 
orientated shRNA, meaning that the guide strand is on the 5’ side of the hairpin structure 
(Lavender et al., 2012). Therefore, any unexpected cleavage events by Dicer processing 
would not alter the start position of the guide strand as the 5’end of the guide strand 
remains unaffected (Figure 6.4 A). The expectation is that the first nucleotide on the 5’ 
end of the shRNA is the first nucleotide of the active guide strand. A count of 10 from the 
end of the guide strand then positions AGO2-RISC cleavage at the expected position for 
cleavage of the target RNA, giving a peak of 5’ ends after RACE-Seq (Figure 6.3 A and 
B).  
 
For shRNA22(2) a second peak, is reported as 6.8% of aligned reads (Table 6.3, A=9487) 
at 2-nt positions upstream of the expected cleavage site. However, some caution must be 
taken in interpreting this second peak as a RISC-driven cleavage observation. One possible 
explanation for the second peak could be cross contamination of PCR samples, as the 
siRNA RACE-Seq samples do show a second peak at this position. The siRNA22(2) and 
shRNA22(2) samples were being processed at the same time and even a very small amount 
of cross contamination would be amplified and detected by NGS.  Since this second peak 
was only observed in one of the samples, and was not seen in shRNA22(1), this gives less 
credence to this peak deriving from RISC-associate activity. Further, it is unlikely that a 
suitable guide strand could be generated from shRNA22 due to the length of the shRNA 
and the orientation of the guide strand.    
6.2.4 	RACE-Seq	 confirms	 the	 expected	 cleavage	 site	 for	 siRNA6	 and	
identifies	the	trigger	guide	strand	sequence	after	Dicer	cleavage	of	
shRNA6	
Both of the RACE-Seq samples for siRNA6 confirmed the expected RISC cleavage 
position as expected from the design of the synthetic siRNA6 molecule (Figure 6.1 C and 
D, Figure 6.2 B). Cleavage of the HCV replicon genome occurred at position T=282 with 
75.1% of 5’ ends obtained for siRNA6(1) and 73.4% of 5’ ends for siRNA6(2) (Table 6.4). 
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The sequence for the siRNA6 molecule was chosen based on the most common siRNA 
sequence observed when the small RNAs were sequenced after transfection of TT-034 to 
Huh7/con1b cells (Denise et al., 2014). However, the guide strand sequence of the 
synthetic siRNA6 molecule has at its 5’ end 1-nt from the shRNA6 hairpin loop structure 
and the 3’ end of the passenger stand has 3-nt of the loop structure (Figure 6.2 B), and the 
siRNA6 molecule is therefore not the same as the expected siRNA that would be generated 
by Dicer cleavage of shRNA6 (Figure 6.4 B).  
 
Since the shRNA6 molecule has the typical 21-bp stem-loop structure, the ‘loop counting 
rule’ could be applied when predicting Dicer cleavage activity (Gu et al., 2012).  The ‘loop 
counting rule’ states that for a duplex shRNA of 21-bp, Dicer recognises the single 
stranded region of the loop structure and cleaves the guide strand 2-nt from the start of the 
loop (Figure 6.4 B). RACE-Seq results for shRNA6 confirm the expected cleavage 
position (Figure 6.3 C and D) and obeyed the ‘loop counting rule’. Deriving further 
insights into shRNA6 analogue processing is restricted due to much lower number of total 
reads obtained for these two samples. Despite this low number of reads, particularly for 
shRNA6(1) which had only 5,182 reads in total (Table 6.2) and 590 reads at the expected 
cleavage position (Figure 6.3 C), RACE-Seq confirmed the expected cleavage position. 
Thus, well-designed and validated RACE-Seq assays have the potential to be utilized for 
targets with low expression.  
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Table 6.3   Percent aligned reads for siRNA22 and shRNA22 RACE-Seq assays 
 
RACE-Seq datasets were pre-filtered to specifically select for the target sequence 
and then trimmed to adapter+20-nt length. These short reads were input to the 
RACE-SEQ-lite analysis pipeline which performed the alignment reported the 5’ end 
counts as a percent of total aligned reads. Both siRNA22 and shRNA22 reported the 
highest percent of 5’ ends at position 9489 = T (in red), corresponding to a count of 
10 from the 5’ end of the siRNA or expected dicer processed shRNA22 guide strand.  
 
 
Hybridized	
guide	strand	
position
Nucleotide siRNA22(1) siRNA22(2) shRNA22(1) shRNA22(2)
3' 9478 C 0.0 0.2 0.0 0.2
9479 A 4.1 0.8 0.0 0.8
9480 A 0.3 0.1 0.0 0.1
9481 G 5.5 1.8 0.0 1.8
9482 C 0.0 0.2 0.0 0.2
9483 T 4.2 1.4 0.0 1.4
9484 C 0.0 0.0 0.0 0.0
9485 A 0.0 0.0 0.0 0.0
9486 A 0.4 0.2 0.0 0.2
9487 A 14.5 6.8 0.1 6.8
9488 C 0.7 1.8 1.9 1.8
9489 T 43.8 50.8 53.7 51.2
9490 C 14.2 25.7 37.3 25.3
9491 A 7.9 5.9 3.2 5.9
9492 C 0.7 1.6 1.8 1.6
9493 T 0.0 0.2 0.1 0.2
9494 C 3.6 1.2 1.4 1.2
9495 C 0.0 0.1 0.0 0.0
9496 A 0.0 0.0 0.0 0.0
9497 A 0.0 0.1 0.4 0.1
5' 9498 T 0.0 0.1 0.0 0.1
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Table 6.4   Percent aligned reads for siRNA6 and shRNA6 RACE-Seq assays 
 
For the RACE-Seq datasets of siRNA6 and shRNA6 that were trimmed to 
adapter+20-nt length and aligned to the HCV reference using the RACE-SEQ-lite 
analysis pipeline, two different cut sites on the target was indicated by 5’ end counts. 
While siRNA6 (left and) reported the highest number of aligned reads at 282 = T 
(red), the shRNA analogue reported the highest amount of reads at position 279 = C 
(red). In each case, this corresponded to canonical RISC-induced cleavage by the 
expected guide sequence.  
 
Hybridized	
guide	strand	
position
Nucleotide siRNA6(1) siRNA6(2)
Hybridized	
guide	strand	
position
Nucleotide shRNA6(1) shRNA6(2)
3’ 272 C 0.0 0.9 269 T 3.5 4.8
273 G 0.0 0.2 270 C 2.5 3.4
274 A 0.4 0.4 271 G 0.2 0.7
275 A 1.6 0.7 272 C 1.1 1.4
276 A 0.0 0.6 273 G 0.0 0.6
277 G 0.0 0.2 274 A 0.3 0.2
278 G 0.0 0.2 275 A 0.2 0.1
279 C 0.8 1.2 276 A 0.6 0.3
280 C 1.5 0.9 277 G 0.0 0.4
281 T 3.3 1.8 278 G 0.0 1.0
282 T 75.1 73.4 279 C 36.2 40.1
283 G 0.9 0.6 280 C 9.1 6.0
284 T 0.0 1.0 281 T 3.1 1.3
285 G 0.0 0.6 282 T 1.9 1.3
286 G 0.0 0.6 283 G 0.0 0.1
287 T 0.0 0.7 284 T 0.0 0.7
288 A 0.0 0.4 285 G 0.0 0.4
289 C 2.7 1.0 286 G 0.0 1.1
290 T 0.0 0.1 287 T 0.4 1.5
5’ 291 G 0.0 0.2 288 A 0.0 1.0
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Table 6.5   Percent aligned reads for siRNA19 and shRNA19 RACE-Seq assays 
 
The RACE-Seq datasets of siRNA19 and shRNA619 were trimmed to adapter+20-nt 
length and aligned to the HCV reference using the RACE-SEQ-lite analysis pipeline.   
The shRNA19 analogue reported four positions with high amount of aligned 5’ ends. 
The fist corresponded to a count of 10 from the 5’ end of the hybridized guide strand at 
position 9108 = T (red). Other 5’ end aligned counts corresponded to 9107 = C, 9155 = 
G and 9107 = T (red). For a canonical RISC cleavage mechanism to be maintained, this 
would necessitate that the siRNA19 analogue was processed in vivo to the appropriate 
5’ start site. The shRNA19 analogue generated two positions of 5’ aligned reads at 9105 
= G and 9104 = T (red).  
Hybridized	
guide	strand	
position
Nucleotide siRNA19(1) siRNA19(2) siRNA19(3) shRNA19(1) shRNA19(2*) shRNA19(2)
3' 9095 G 0.0 0.0 0.0 0.0 0.0 0.1
9096 T 0.0 0.0 0.0 0.1 0.0 0.2
9097 C 0.2 0.0 0.0 0.6 0.1 0.3
9098 A 0.0 0.0 0.0 0.2 0.0 0.1
9099 A 0.0 0.0 0.0 0.0 0.0 0.0
9100 T 0.0 0.0 0.0 0.0 0.0 0.1
9101 T 0.0 0.0 0.0 0.0 0.0 0.1
9102 C 0.0 0.0 0.0 0.0 0.0 0.1
9103 C 0.0 0.1 0.0 0.5 0.1 0.2
9104 T 14.5 17.3 10.9 17.4 19.4 12.0
9105 G 15.7 37.8 15.0 35.4 55.8 28.9
9106 G 1.8 3.0 1.7 1.0 1.7 0.9
9107 C 18.8 12.2 11.6 6.8 10.4 3.8
9108 T 18.8 15.0 10.6 0.1 1.2 1.4
9109 A 11.6 6.4 3.9 3.1 1.1 1.2
9110 G 5.4 2.2 5.2 2.4 0.8 0.9
9111 G 0.9 0.5 1.6 5.7 0.4 0.4
9112 C 1.5 0.1 1.6 2.3 0.2 0.3
9113 A 0.3 0.2 0.0 1.1 0.3 0.2
9114 A 0.2 0.1 0.0 1.8 0.3 0.2
9115 C 0.8 0.3 0.0 2.2 0.6 0.4
9116 A 0.0 0.1 0.0 0.7 0.1 0.2
5' 9117 T 0.0 0.1 0.0 0.0 0.3 0.2
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Figure 6.1   RACE-Seq detection of 5' end peaks for siRNA-mediated cleavage of HCV replicon RNA presented 
as percentage of total aligned reads. 
For two independent RACE-Seq assays, the expected cleavage site –light coloured bar- was identified with the highest 
number of 5’ ends for the siRNA22 samples (A) and (B). For siRNA6 (C and D), RACE-Seq reported the expected 
cleavage site based on canonical RISC cleavage. For siRNA19, RACE-Seq for three independent samples reported a 
peak pattern consisting of two pairs of peaks (E, F and G). The light-coloured peaks are the expected cleavage positions 
based on an unprocessed siRNA19 and classic ‘loop’ counting rule Dicer processed siRNA guide strand-mediate 
cleavage. The black peaks at +1 of the light-coloured peaks are postulated to be novel 5’ ends generated from additional 
siRNA19 Dicer processed species. 
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Figure 6.2   Illustration of duplex siRNA Illustration of predicted and RACE-Seq 
observed cleavage positions for three siRNAs targeting the sense strand of HCV 
replicon genome.    
(A) illustrates the hybridization of the guide and passenger RNA strands for siRNA22, 
siRNA6 (B) and siRNA19 (C). In each case, the black triangle indicated the expected 
AGO2 cleavage position. For siRNA19, the black triangles represent the proposed 
AGO2 cleavage sites based on the results from RACE-Seq data analysis and correspond 
to positions (I) and (II) as the start of the siRNA guide strands. The open triangles 
represent additional proposed AGO2 cleavage sites based on RACE-Seq data analysis 
with proposed corresponding start sites for guide strands at the dotted lines. The 
nucleotides are counted from the 5’ end of the guide strand or proposed end of cleaved 
strand. Lowercase letters = sequences that alogn to the loop the shRNA partner. 
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6.2.5 RACE-Seq	reports	two	active	siRNAs	processed	from	shRNA19		
The sequence for shRNA19 is the same as the shRNA sequence that is expected to be 
expressed from TT-034. In three separate experiments, RACE-Seq reported two distinct 
5’ end peaks around the expected cleavage site (Figure 6.3 E, F and G). The primary peak 
was found at position G=9105, with 35.4%, 55.8% and 28.9% of 5’ ends aligning to this 
expected cleavage site for each of the respective samples (Table 6.5). For all samples, a 
second peak at T=9104 with 17.4%, 19.4% and 12.0% of aligned reads for the respective 
samples was also identified (Table 6.5). This confirms the previous result for 5’ RACE-
PCR and Sanger sequencing when the cleavage products of TT-034 were assessed (Denise 
et al., 2014). The same two 5’ ends were identified from cleavage products.   
 
Since the second peak is positioned upstream of the primary peak, RACE-Seq data 
analysis led to the idea that at least two, highly active siRNAs must be processed from 
shRNA19 by Dicer cleavage. The sequence for shRNA19 was put into the UNAFold Web 
Server (http://unafold.rna.albany.edu/) to generate the predicted folded hairpin structure 
for shRNA19 and revealed an interesting characteristic regarding the hairpin loop 
sequence. The loop sequence of shRNA19 analogue is (uuuguguag) and is different from 
the shRNA22 and shRNA6 loop sequence which is (gaagcuug) (Figure 6.4). The predicted 
structure for shRNA19 indicated that the loop structure could be collapsed (McIntyre and 
Fanning, 2006), such that instead of the expected 9-nt shRNA loop based on the design of 
the molecule, a 5-nt loop occurs (Figure 6.4 B). Since the second cleavage product is 
extended by just 1 nucleotide, this must have been generated from a shRNA19 molecule 
with 7 nucleotides (Figure 6.4 C).  
 
The ‘loop counting’ rule can be used to predict the siRNA guide strand sequences and the 
expected cleavage products that would be generated from Dicer cleavage of shRNA19 
when the two possible loop configurations of shRNA19 are considered. The collapsed loop 
would generate the primary cleavage product (highest number of read), while the second 
structure accounts for the second peak (Figure 6.3 E, F, G and Figure 6.4 C). It is thus 
likely that shRNA19 exists as a mix of two species in the biological habitat, with some 
molecules having a 5-nt loop and others with a 7-nt loop.  
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Four primary conclusions may be drawn from the RACE-Seq analysis of shRNA19; (1) 
that RACE-Seq reliably detects the expected AGO2-RISC cleaved site, (2) that RACE-
Seq detects a second cleavage product, (3) RACE-Seq drives the prediction of the 
sequence of a second active siRNA19 species that was generated by Dicer cleavage of 
shRN19 and (4) analysis of the loop structure supported the notion of a dual structure for 
shRNA19.  
6.2.6 RACE-Seq	reports	multiple	active	siRNA	species	from	siRNA19		
In three independent RACE-Seq assays to assess AGO2-mediated cleavage of HCV 
replicon genome triggered by siRNA19, two distinct clusters of peaks, consisting of two 
peaks each was observed. The peaks occurred at nucleotide positions T = 9104/G = 9105 
and C = 9107/T = 9108 (Figure 6.1 E, F and G). Although the rank order of the 5’ end 
peaks varied for the three samples, these four peaks consistently ranked as the top 
percentage of aligned 5’ ends for each of the samples (Table 6.5). This observation of a 
pattern across all three siRNA19 samples led to closer examining of the siRNA19 
sequence.  
 
The siRNA19 sequence was compared to the shRNA19 sequence and the sequence of its 
target site. In doing so, siRNA19 was identified as a 23-mer siRNA that differed in 
sequence from the siRNAs that are expected to be processed from shRNA19 by Dicer 
cleavage. The sequence for siRNA19 was chosen as the most prominent siRNA19 
sequence after TT-034 transfection to Huh7/con1b cells and sequencing of the small RNAs 
(Denise et al., 2014). Additionally, the siRNA19 molecule has 3 nucleotides from the 
shRNA19 hairpin loop on the 5’ end of the guide strand (uuuguguag, underlined) and 
opposite this end, the passenger strand also has 5 nucleotides of the loop structure sequence 
(uuuguguag, in bold) at the 3’ end of the passenger strand (Figure 6.4 C).  
 
Since siRNA19 is a 23-mer siRNA, and has one end of undefined structure, this siRNA is 
a possible substrate for Dicer (Kim et al., 2005) However, care should be taken not to over-
interpret what looks like a hairpin structure at the 5’ end of the guide strand as this may be 
an artefact of the UNAFold software. In order to view the potential active siRNA19 
sequences that generated the observed RACE-Seq peaks, the peak information was 
overlaid onto the siRNA19 guide strand. The RACE-Seq peak profiles indicate that there 
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are four possible active siRNA guide sequences, which correspond to 23-mer, 22-mer, 19-
mer and 18-mer siRNAs (Figure 6.2 C). It remains to be determined whether active 
siRNAs are being generated from this siRNA19 molecule by either Dicer recognition and 
cleavage or not cleavage or some other cellular cleavage activity.
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Figure 6.3 RACE-Seq detection of 5' end peaks for siRNA-mediated cleavage of HCV replicon RNA presented as 
percentage of total aligned reads. 
For two independent RACE-Seq assays, the expected cleavage site –light coloured bars- was identified with the highest number of 
5’ ends for the shRNA22 samples (A) and (B). For siRNA6 (C and D), RACE-Seq reported the expected cleavage site based on the 
expected Dicer processed guide strand sequence. For shRNA19, RACE-Seq for three independent samples reported a peak pattern 
consisting of two distinct peaks (E, F and G). The light-coloured peaks are the expected cleavage position based on the ‘loop’ 
counting rule of Dicer processed shRNA19 with a 5-nucleotide loop structure, while the black bar at +1(T) of the expected cleavage 
site corresponds to a guide strand that was Dicer processed from a shRNA19 with a 7-nucleotide loop structure.  
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Figure 6.4   Illustration of shRNAs and RACE-Seq observed cleavage positions.    
(A) illustrates the expected cleavage position for the shRNA22 analogue targeting HCV. 
Regardless of Dicer processing imprecision, due to the orientation of the guide strand, the 
expected RISC cleavage site is expected to remain unaltered. (B) indicates the expected 
cleavage position for shRNA6 (black triangle), with the numbers counting from the expected 
5’ end of the guide strand expected to be processed out of Dicer. For siRNA19, the black 
triangle represents the expected cleavage position of a shRNA19 analogue with a collapsed 5-
nucleotide loop structure while the open triangle corresponds to a RACE-Seq confirmed 
cleavge position for a shRNA19 analogue with a 7-nucleotide loop structure. Lowercase letters 
= sequences that alogn to the loop the shRNA partner. 
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6.3 Discussion		
For two groups of independently prepared and sequenced RACE-Seq samples, the total 
number of reads per sample generated on the Ion Torrent PGM was sufficient to identify 
the expected RISC cleavage site and in addition, proved sufficient to derive new insights 
from the RACE-Seq datasets. Pre-filtering of datasets prior to mapping of reads to the 
reference gene retained a sufficient amount of data for the read alignment and counting of 
5’ ends. Variability in the number of reads obtained for each sample did not impair 
identifying the expected cleavage site. A number of additional 5’ peaks were observed 
around the expected peak site and within the expected siRNA hybridization site. Some of 
these were designated as degradation products, but in some instances, these additional 
peaks could be correlated to novel siRNA guide strands.  
 
In this chapter, the RACE-Seq data was presented at the linear scale as well as percentage 
of aligned 5’ ends. Graphically, the data is presented as bar graphs. RACE-Seq remains 
underutilized for confirming RISC cleavage, a small number of publications have with 
varied levels of success, applied the method. In most cases, the data is presented as 
percentage of aligned reads, without further reporting of total read number (Tabernero et 
al., 2013; Ganesh et al., 2016) and is used exclusively to report the expected RISC cleaved 
site. All current published RACE-Seq datasets show additional 5’ end peaks within the 
guide strand hybridization site and for those publications that show a wider view, RACE-
Seq is shown to report 5’ ends well beyond the guide strand hybridization site (Tabernero 
et al., 2013; Barve et al., 2015).  
 
Currently, there are no defined parameters for designing and executing RACE-Seq 
protocols or analysing and reporting the data. The assay itself remains challenging, 
requiring multiple manual handling operations that risk cross contamination of samples. 
Certainly, improvements to the RACE-Seq assay that eliminate the risk of cross 
contamination would be highly relevant if the assay is to be applied to clinical samples. 
For example, using barcoded RNA adapters at the RNA adapter ligation stage, would 
ensure that each sample is uniquely coded from the first sample handling stage (Peng et 
al., 2015; Kou et al., 2016).  
 
		
146	
When viewing the RACE-Seq peak profiles, it is assumed that the relative amounts 
presented at each position reflect the cleaved/ captured products of the original samples. 
RNA-ligase is known to show bias in RNA-RNA adapter ligation (Hafner et al., 2011). T4 
RNA ligase mediated adapter ligation has been shown to have preference for certain end 
sequences that allow stable secondary structures between RNA ends (Raabe et al., 2014; 
Sorefan et al., 2012). The impact of adapter ligation bias for identifying and interpreting 
diverse RACE-Seq cleavage products remains to be investigated.  
 
The shRNA6 samples produced the lowest number of NGS reads in both of the sequencing 
runs, with 5,812 reads for siRNA6(1) and an improved 29,934 reads for siRNA6(2) 
(though this was still 5 times below the next lowest read count). The dose response assays 
for siRNA6 and shRNA6 was calculated to have the same EC50 value, but the knockdown 
assays for RACE-Seq used 0.5 nmol/l for shRNA6(1) and 1.0 nmol/l for shRNA6(2). It 
seems that the number of reads obtained for shRNA6(1) therefore reflects the much lower 
amount of 5’ cleavage product that would have been generated. The increased dose would 
have resulted in an increase in cleavage products and therefore an increase in the amount 
of 5’ ends available for capture in the RLM RACE assay. Thus, in this case, the lower read 
depth does not constitute a failed assay, but rather correlates to the biological activity.  
 
In this chapter, experiment pairs were critical for deriving and confirming novel 
observations for siRNA and shRNA design and activity. Most noteworthy has been the 
RACE-Seq analysis and accompanying theory for multiple RNAi triggers generated from 
siRNA19. Although the pattern of clustered 5’ ends varied across three independent 
samples, a distinct pattern emerged. Although only a very limited number of studies have 
been conducted that include a 23-mer siRNA, they have been shown to be substrates of 
Dicer (Kim et al., 2005). Additionally, the unusual mismatched duplex structure at the’ 
end of siRNA19 may interact in altered conformations with Dicer, resulting in different 
cleavages and a mix of active siRNA19 molecules. The proposed stem lengths that would 
generate the four RACE-Seq peak incidence are still all within the size range for AGO2 
interaction. This hypothesis ties in with the current dogma of RISC cleavage specificity 
and variability of siRNA products from Dicer cleavage and seems more plausible than the 
proposal raised in Denise et al., (2014) of alternative/or imprecise slicer activity for AGO2. 
Their RACE-Seq assay generated a very similar peak profile.  
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One of the main risks of RNAi is the potential for off-target effects. There has been a long 
held concern that imprecise Dicer processing could lead to off-target effects by generating 
undesirable active siRNA (Dallas et al., 2012; Langenberger et al., 2013). These studies 
were largely based on the expression of short hairpin Dicer substrates with the sequence 
of these hairpins influenced by alterations in transcription start positions (Gu et al., 2012; 
Denise et al., 2014). For delivered Dicer substrate RNAi triggers such as synthetic shRNAs 
or long siRNA duplexes, RACE-Seq analysis (with confirmation of trigger sequence) has 
the potential to now provide evidence for an on-target mechanism of action of diverse 
RNAi triggers processed by Dicer. Modification of these Dicer substrates can then be 
investigated at an early stage to improve Dicer processing and drive the development of 
potent, clinically relevant RNAi drugs with well characterised RNAi mechanisms of 
action.  
 
In conclusion, experience from this RACE-Seq work proposes that multiple independent 
samples are of greater value than read depth when determining novel insights from RACE-
Seq data. Thus, low throughput sequencing instruments such as the Ion Torrent PGM and 
Illumina MiSeq are sufficient for multiplexing RACE-Seq samples. Here, RACE-Seq 
sample analysis defines a new role fort his assay, beyond confirming an expected RISC 
cleavage behaviour, RACE-Seq can define the sequence of the active siRNA.  
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, ADDITIONAL	FINDINGS	FROM	
RACE-SEQ	ASSAYS	AND	RACE-SEQ	
DATA	ANALYSIS	
7.1 Introduction		
Beyond identifying the genetic sequence of living organisms, NGS technologies are 
increasingly being employed, together with novel capture assays, to detect and measure 
biological events. These new assays are often accompanied by or generate a need for 
bioinformatics tools. While access to NGS technology has largely been overcome with 
numerous commercial enterprises accepting various sample types, NGS data analysis 
remains a bottleneck. Additionally, most of the software packages that have been 
developed for NGS are executed in the Unix/Linux environment, and while there are 
commercial packages such as the CLC Genomics Workbench, these tools may be costly. 
In some instances, researchers may not have access to a bioinformatics core or a dedicated 
bioinformatician and may even lack sufficient knowledge of NGS to identify the necessary 
tools for analysing their data.  
 
Traditionally, the 5’ RACE assay accompanied by Sanger sequencing has been used to 
confirm an expected outcome of AGO2-RISC cleavage activity. However, transitioning 
these assays to NGS offers the unique opportunity to continue to expand our understanding 
of the complexity of the RNAi pathway. Additionally, this is an opportune time for the 
uptake of the RACE-Seq assay within the RNAi field, as the recent news of a successful 
Phase III clinical trial is set to spur the RNAi therapeutic field to new successes in 2018.  
 
To this end, critical evaluation of current practise, establishing validated RACE-Seq assay 
protocols and appropriate data analysis practises will be helpful in persuading the RNAi 
therapeutic community of the added value that an NGS approach can provide. This chapter 
focuses on how standard and non-standard practises may impact RACE-Seq data output.  
		
149	
7.2 Results	
7.2.1 RLM	RACE	assays	for	non-target	control	samples	
It is standard practice to include a negative control in scientific experiments. However, 
attempting to sequence, by NGS, the negative (non-transfected control) sample from 
RNAi-based knockdown experiments may prove tricky. In order to perform RACE-Seq 
on the non-transfected cells from a knockdown assay, the RNA extracted from these cells 
must undergo all of the same operations as the treated sample.  
 
In this example, RLM RACE assays were carried out for non-transfected controls for site 
6, site 19, site 22 and the scrambled control for the TTR assays using the reverse primers 
and amplification primers in the same manner as the treated samples. All the samples had 
failed to produce a specific band at the expected 5’ RACE position (see Figure 4.5 and 
Figure 5.1 A, control lane of gels). In all cases the control 5’ RACE PCR samples were 
progressed directly to library preparation by first cleaning the samples using magnetic 
beads and quantifying the purified DNA using the Qubit High Sensitivity DNA assay. 
Qubit quantification yielded 29 ng/µl, 23 ng/µl, 14.4 ng/µl and 7 ng/µl, and allowed for 
493 ng, 391 ng, 245 ng and 119 ng of purified DNA to be used as input to the end repair 
reactions for control 6, control 19, control 22 and control TTR samples respectively. After 
adapter ligation, the reactions were cleaned with 0.8X bead volume and the cleaned DNA 
amplified in 7 cycles of PCR. Samples were again cleaned using 0.8X bead volume and 
the final cleaned NGS libraries eluted in nuclease-free water. Samples were quantified by 
the Qubit assay and then analysed on the Bioanalyzer.  
 
Unfortunately, in examining the fragment profiles of the control NGS samples, all samples 
were found to have fragment sizes that went well above 300 bp (Figure 7.1). For 200 bp 
sequencing on the Ion Torrent PGM, the maximum recommended size for library input is 
around 300 bp. The site 6 control sample had fragment size range from 323 bp to >2,000 
bp, (Figure 7.1 A) while control 19 had fragment sizes ranging from 230 bp to 1,505 bp 
(Figure 7.1 B). Control 22 and the TTR scrambled control also have fragment sizes well 
outside of the acceptable range for sequencing on the Ion Torrent PGM (Figure 7.1 C and 
D). Since all the library preparations were well outside of the recommended input size for 
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Ion Torrent sequencing, these samples were not suitable for sequencing on the Ion Torrent 
PGM.  
 
 
 
Figure 7.1  RACE-Seq library preparation for non-transfected control samples.  
(A) Control 6 sample, (B) Control 19 sample, (C) Control 22 sample and (D) Control 
TTR scrambled sample. All samples show DNA fragment sizes >300 bp in size and 
thus these libraries are not suitable for sequencing on the Ion Torrent PGM.  
 
7.2.2 Read	quality	analysis	of	adapter+20-nt	filtered	datasets	
A number of data pre-processing options for the long (>100 bp) amplicon RACE-Seq 
datasets was trialled before eventually opting for the adapter+20 nt approach.  Since the 
reads had been trimmed to very short sequences (expected to be ~50 bases), quality 
filtering of reads was not implemented. Since quality filtering of reads removes low quality 
bases from the 3’ end of reads, the expectation was that the short reads would be of 
generally good quality. The FASTQC tool (Babraham Bioinformatics, 
https://www.bioinformatics.babraham.ac.uk/projects/download.html) which is a simple 
Java executed pipeline that allows read quality analysis to be carried out. In examining the 
per base read quality and the read length analysis outputs for each of the samples pre-and 
post-adapter+20 nt clipping of reads, some unexpected observations were made.  
 
In comparing the profiles for read length, overall, a pattern regarding fragment size 
emerged. The majority of the time point 2 samples failed to be clipped to the ~50 bases 
A.																																																									 B.																																																																																																																											
C.																																																																																							D.																																																																																																																												
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stipulated by the adapter+20nt filtering criteria. The siRNA22(2) sample had at least 
110,000 reads that were clipped to the short length, but more than 120,000 reads failed to 
be trimmed and were of length approximately 120 bases (Figure 7.2 B). Sample 
shRNA22(2) and sample siRNA6(2) were the only samples of time point 2 that were 
trimmed primarily to the expected ~50 bases (Figure 7.2 D and Figure 7.4 B) but the 
shRNA6(2), siRNA19(2) and shRNA19(2) samples each reported a second read length of 
approximately 110 bases (Figure 7.4 D, Figure 7.5 E and F respectively). Interestingly, the 
time point 2 samples were the ones that were size selected post library preparation and had 
been progressed directly to pooling for emulsion PCR without any cleanup. Further 
evidence that size selection post library preparation is likely to be the impacting activity, 
is that sample siRNA19(2*) and shRNA19(2*) were samples that had been size selected 
prior to library preparation but had undergone the NGS library preparation and sequencing 
operations of the time point 2 samples but these samples did not show inhibited length 
trimming when processing the data (Figure 7.5 C and D). This indicates that agarose gel 
size selection (including the E-gel size selection) imparted some ‘contaminating element’ 
to the DNA, and this had an impact on the sequences generated.  
 
In analysing the per base quality of the processed RACE-Seq datasets, FASTQC analysis 
generated quite varied per base quality profiles for the siRNA22(1), siRNA22(2), 
shRNA22(1) and shRNA22(2) samples (Figure 7.2 A, B, C and D). Site 22 had already 
been identified as having greater sequence variability compared to site 6 and site 19 (Table 
6.1 and 6.2; site 22 had higher percent unaligned filtered reads). For siRNA22(2), which 
had a mix of long and short reads, when the short reads and the longer reads were separated 
and the quality profiles analysed, the short reads length (~50 bases) of both size fractions 
showed improved per base quality profiles but the average per base quality scores across 
the length did vary (Figure 7.3).  
 
It must also be remembered that, for this set of data, the GeneRacer RNA adapter sequence 
constitutes the first ~25 bases at the 5’ end of reads. Additionally, having reverse 
complemented reads that held the RNA adapter at the 3’ end, and pooled with the correct 
orientation adapter sequence, this may have placed possible poorer quality bases at the 5’ 
end of the dataset. This would account for the observed high variability of the per base 
quality scores observed in FASTQC profiles.  
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RACE-Seq samples siRNA6(1), siRNA6(2), shRNA6(1) and shRNA6(2) generally 
showed a much better per base quality profile compared to the site 22 samples. In general, 
the average per base quality values were above a score of 26 (Figures 7.4). Site 6 seemed 
to have less sequence variability as evidenced by >80% of filtered reads aligning to the 
HCV replicon reference (Table 6.1, Table 6.2). Again, with samples siRNA19(1), 
siRNA19(2*), siRNA19(2), shRNA19(1), shRNA19(2*) and shRNA19(2), FASTQC 
analysis identified a per base quality score generally above 26, particularly for nucleotide 
positions 1-50 (Figure 7.5).  
 
In conclusion, using the freely accessible FASTQC tool has brought new insights to the 
impact of isolating DNA from agarose gels and the need for DNA clean-up after DNA 
isolation. RACE-Seq data analysis is likely to tolerate a lower threshold level of read 
quality as very short reads are being used in the final alignment and the data is aligned to 
a known sequence, however, it remains good practise to validate the quality of reads prior 
to implementing data analysis.
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Figure 7.2   FASTQC analysis of RACE-Seq samples for site 22 samples for siRNA22 and shRNA22 samples 
The per base quality plot and read length profiles (red peaks) for the filtered (adapter+20-nt) RACE-Seq datasets of (A) siRNA22(1), (B) siRNA22(2), 
(C) shRNA22(1) and (D) shRNA22(2) The average quality score = blue line 
A.																																																																																		B.	
C.																																																																																		D.	
shRNA22(1)
siRNA22(1)
shRNA22(2)
siRNA22(2)
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Figure 7.3 Per base quality plot for two different read lengths for RACE-Seq 
sample siRNA22(2).  
For sample siRNA22(2), reads less than 60 bases were separated from reads greater 
than 60 bases from the filtered dataset (adapter+20-nt). The quality analysis for the 
short reads is presented in (A) and the quality analysis of the longs is presented in 
(B).  The short reads has good quality scores, while that of the long reads varied.  
 
 
A.																							 B.	
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Figure 7.4   FASTQC analysis of RACE-Seq samples for site 6 samples for siRNA6 and shRNA6 samples.  
The per base quality plot and the read length profiles for the filtered (adapter+20-nt) RACE-Seq datasets of (A) siRNA6(1), (B) siRNA6(2), (C) 
shRNA6 (1) and (D) shRNA6. The average quality score was above 26 (blue line) for all samples.  
 
A.																																																																																 B.
C.																																																																																 D.
siRNA6(1)
shRNA6(2)
siRNA6(2)
shRNA6(1)
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A.																																																															
siRNA19(1)
shRNA19(1)
shRNA19(2*)
siRNA19(2*)
60
60
60
60
B.																																																															
C.																																																															
D.																																																															
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Figure 7.5   FASTQC analysis of RACE-Seq samples for site 19 samples for 
siRNA19 and shRNA19 samples.  
Images on the left show the per base quality plot for each sample, and on the right 
the read length profiles for the filtered (adapter+20-nt) RACE-Seq datasets. The 
average quality score (blue line) was above 26 for all samples  
 
7.2.3 Analysis	and	insights	from	failed	TTR	RACE-Seq	datasets	
PCR is widely used for targeted amplification of nucleic acid sequences and relies on 
well-designed primers, optimised PCR conditions and quality reagents. A set of 5’ 
RACE samples from knockdown of TTR mRNA was analysed on 2% agarose gel. The 
expected DNA size bands of ~169 bp was not identified, but a smaller band was 
identified on the gel (Figure 7.6 A). Only a faint blurred region could be identified at 
169 bp, but these samples were still progressed to library preparation. The 5’ RACE 
PCR products for siRNA-TTR and DsiRNA-TTR were bead cleaned, end repaired and 
adapter ligated. After 7 cycles of PCR and a further round of bead cleaning, the samples 
shRNA19(2)
siRNA19(2)
E.																																																															
F.																																																															
shRNA19(2)
siRNA19(2)
60
60
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were quantified, diluted and pooled with other NGS samples for emulsion PCR and 
sequencing on the Ion Torrent PGM. Data filtering and read alignment to the TTR 
mRNA reference found that this siRNA-TTR samples had only 15.7% of all reads that 
aligned to the TTR gene, while the DsiRNA-TTR sample had only 1.1% of total reads 
that aligned to the reference (Table 7.1). For siRNA-TTR the RACE-Seq dataset still 
reported the expected RISC cleaved position as the primary peak (Figure 7.6 B). Two 
other peaks were reported at T=480 and G=475 as12.1% and 24.6% (Table 7.2). On 
closer inspections, it was noteworthy that these positions corresponded to the expected 
cleavage products of DsiRNA-TTR. It may be that the siRNA-TTR sample was cross 
contaminated with the DsiRNA-TTR sample prior to NGS library preparation.  
 
For the DsiRNA-TTR sample, although the expected RISC cleaved product was 
reported, it was not reported as the primary peak (Figure 7.6 C) and was reported as 
only 4.3% of aligned reads. Two other 5’ peaks were identified. One peak corresponded 
to a cleaved product that indicated that a non-Dicer processed guide strand was bound 
to AGO2, as reported in Chapter 6. However, the peak at G=473 was reported as 45.7% 
of aligned reads. In this poorly executed RACE-Seq assay, this peak may falsely gain 
attention as a possible RISC derived product.  
 
While these two examples have been pointedly examined as poor data it is noteworthy 
to observe that, if only the percent of 5’ aligned reads were to be reported (Table 7.2), 
it would be much more challenging to determine that the expected cleavage positions 
were derived from a poor dataset. The siRNA-TTR sample reported the expected 
cleavage position as 51.2% of all aligned reads, and the DsiRNA-TTR sample reported 
the expected cleavage position as 10.4% aligned reads.  
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Figure 7.6   Analysis of failed TTR RACE-Seq sample 
(A) Agarose gel analysis of failed sample showing prominent bands for siRNA-TTR and 
DsiRNA-TTR smaller than the expected cleavage site and no 5’ RACE PCR band for the 
scrambled control sample. (B) RACE-Seq result for siRNA-TTR sample showing the 
expected cleavage position as the primary peak, as well as two additional prominent 5’ end 
peaks. (C) RACE-Seq result for DsiRNA-TTR sample where the expected cleavage position 
is under reported.  
 
 
 
Table 7.1   RACE-Seq read analysis of failed TTR sample 
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Table 7.2   Table indicating the percentage of aligned reads for siRNA-TTR 
and DsiRNA-TTR failed RACE-Seq samples. 
 
 
 
 
 
 
 
 
Hybridized	
guide	strand	
position
Nucleotide siRNA-TTR	(%	aligned)
Hybridized	
guide	strand	
position
Nucleotide DsiRNA-TTR			(%	aligned)
474 T 0.0 3’ 463 G 0.0
475 G 24.6 464 C 0.0
476 G 0.0 465 A 0.0
477 T 0.0 466 T 0.0
478 A 0.0 467 G 0.0
479 T 0.0 468 C 0.0
480 T 12.1 469 A 0.0
481 C 0.0 470 G 0.0
482 A 0.1 471 A 0.0
483 C 51.2 472 G 0.0
484 A 0.3 473 G 45.7
485 G 0.0 474 T 0.0
486 C 0.0 475 G 10.4
487 C 0.0 476 G 0.0
488 A 0.0 477 T 0.0
489 A 0.0 478 A 0.0
490 C 0.0 479 T 0.0
491 G 0.0 480 T 42.6
492 A 0.0 481 C 0.0
482 A 0.0
483 C 0.1
484 A 0.0
485 G 0.0
486 C 0.0
487 C 0.0
488 A 0.0
5’ 489 A 0.0
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7.3 Discussion	
In order for RACE-Seq to be used beyond reporting an expected outcome, numerous 
challenges in assay design, sample validation, NGS preparation, data analysis and data 
presentation are yet to be overcome. The four RACE-Seq assays currently in 
publication shed some light on these challenges (as discussed in Chapter 5). The 
challenges may be split into three; (1) preparing the RLM RACE assays (from RNA to 
PCR amplicon), (2) preparing the NGS libraries and (3) data analysis. However, since 
these three operations are in most instances likely to be carried out by three separate 
individuals/organisations, particularly in industry or large research institutes, and 
therefore, assessing and/or mitigating the impacts of the different operations may be 
more challenging.  
 
Interestingly, it was found here, that certain sample preparation operations can impact 
data analysis in an unexpected manner. It seems that samples that had been size selected 
after library preparation had some inhibitory characteristic that prevented some of the 
NGS reads from being clipped to shorter reads by the fast-clipper programme from the 
FASTX toolkit. Access to such simple to use but powerful tools is vital in being able 
to analyse datasets prior to alignment. Since the 5’ RACE assay is not specific for RISC 
cleaved products, fragmented target RNA derived by other means can be captured and 
amplified in the 5’ RACE assay. Additionally, reverse transcription can generate non-
target templates that hold the RNA adapter. Thus, 5’ RACE is a ‘dirty’ assay, with 
spurious bands or background amplification often observed on agarose gels (Soutschek 
et al., 2004; Judge et al., 2009; Davis et al., 2010). For NGS, sample preparation 
methods that eliminate such material from the final library preparation help to enhance 
the amount of relevant data.   
 
In conclusion, this analysis of failed RACE-Seq analysis highlights the need to validate 
each stage of the RACE-Seq assay and also highlights that even poorly conducted 
RACE-Seq assays, may provide sufficient data for confirming an expected proof of 
MOA for a given RNAi bioactive. In this light, it becomes imperative that a mechanism 
for qualifying good vs poor RACE-Seq assays is derived if RACE-Seq is to be utilised 
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as an unbiased means for defining the active guide strand sequence based on an 
observed 5’ RACE-Seq peak.  
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@ 		CONCLUSIONS	 AND	 FUTURE	
WORK	
 
RNAi-based therapeutics represent an innovative class of medicines that harness a 
natural pathway to target and cut disease relevant mRNA. Many of the initial 
difficulties that related to toxic side effects, poor efficacy and drug delivery have now 
been overcome and resulted in a resurgence in RNAi-based clinical trials from 2012, 
such that current development of clinically relevant drugs is based on over 15 years of 
technology and research development. An important part of RNAi research has been to 
understand the rules governing small RNA interactions with two important components 
within the RNAi pathway. These two components are Dicer and AGO2. Much of the 
research investigating and characterising the catalytic activity of Dicer and AGO2 
substrates was undertaken from 2001 to 2006. Assays such as in vitro 32P-radiolabeled 
synthetic mRNA cleavage and analysis on agarose gels (Elbashir et al., 2001; Schwarz 
et al., 2004; Rand et al., 2005b), northern blotting (Gu et al., 2012) and in vitro dicing 
assays analysed by gel electrophoresis and Electro-spray ionization liquid 
chromatography mass-spectroscopy (Kim et al., 2005; Rose et al., 2005) were used. 
The first publications using the 5’ RACE assay to confirm the RISC-mediated cleavage 
product also began to emerge at this time (Soutschek et al., 2004; Zimmermann et al., 
2006), however, the expectation for a particular outcome based on the design of the 
RNAi bioactive had already been established using the assays mentioned.  
 
The 5’ RACE assay with Sanger sequencing quickly arose as the gold standard for 
confirming direct RNAi-induced activity, with two rounds of PCR being performed to 
enrich for the desired target sequence. The second round PCR often employed a diluted 
volume of the first round PCR reaction (Rao et al., 2010), potentially selecting for only 
the most prominent RISC cleaved product, and therefore masking the presence of other 
potentially real RISC-derived products. Additionally, reporting of 5’ RACE Sanger 
sequencing results has been limited to either a simple statement that the expected 
cleaved sequence was identified after sequencing a few clones or presenting an example 
sequencing chromatogram.  
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This thesis was concerned with designing and conducting RACE-Seq assays for the Ion 
Torrent PGM. The main aims of the project were to investigate robust methods for 
preparing NGS libraries for 5’ RACE amplicons, to implement a user-friendly data 
analysis pipeline and to determine the potential for RACE-Seq to provide information 
regarding siRNA-induced AGO-driven MOA beyond the expected behaviour. The 
project succeeded in all three outcomes, but also raised a number of challenges for 
advancing the uptake of RACE-Seq assays within the RNAi field. 
 
Some of the challenges in performing the assay include long incubation stages and 
substantial manual handling when processing the samples. These activities greatly 
reduce the number of samples that can be processed per day, or as a single batch. 
Additionally, manual handling operations increase the risk of cross-contamination as 
identified in at least two of the RACE-Seq samples presented in this thesis. Other than 
manual handling error, contamination may arise from repeat amplification of a 
particular sequence which leads to accumulation of amplification products in the lab 
environment. One proposal is to utilise a set of validated, barcoded RNA adapters, 
therefore tagging each RNA sample at the very first manipulation of the RNA.  
 
In order for the RACE-Seq assay to be used to provide new information and deliver 
new insights regarding Dicer substrate impacts and RISC activity, more quantitative 
information regarding key aspects of the assay is required. T4 RNA ligase mediated 
bias has been extensively researched for small RNA NGS preparation (Hafner et al., 
2011; Raabe et al., 2014). In particular, the work of Sorefan, et al., (2012) 
comprehensively investigated the ligation preference T4 Rnl1. Although RACE-Seq 
has much lower diversity of target sequence compared to preparing a microRNA 
library, looking forward, an increase in the uptake of the assay would generate 
‘sequence diversity’ and thus T4 RNA ligase-mediated bias may well impact RACE-
Seq assays.  
 
In this project, agarose gels were used to size select for NGS libraries. Exclusion of low 
molecular weight bands proved successful but exclusion of high molecular weight 
unwanted fragments was less successful. Although a number of electronic fragment 
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separation systems are available, such equipment may not be readily available in all 
labs. The E-gel system is much more economical.  However, this work identified that 
when the E-gel system was used to size select NGS libraries which were then diluted 
and progressed directly to emulsion PCR, it generated some contaminants that impacted 
the final datasets. When the PCR samples were size selected prior to library preparation, 
the bead clean operations are likely to have removed the contaminates, and as such, no 
inhibitory effects in trimming was observed for these samples. One of the difficulties 
in size selecting fragments prior to library preparation is that the amount of sample 
eluted may not be sufficient for NGS library preparation. This may be particularly 
impactful if using a commercial sequencing facility which would require a particular 
amount of high quality DNA. Alternative low cost size selection methods such as 
purification by denaturing polyacrylamide gel electrophoresis using the crush and soak 
extraction method (Alon et al., 2011) may be more successful in obtaining a discreet 
fragment size. Noteworthy is that the method used ethanol precipitation post gel 
extraction and highlighted that the use of Glycoblue during DNA precipitation is likely 
to interfere with Qubit-based quantification.  
 
One of the biggest barriers to the uptake of the RACE-Seq assay is the lack of 
bioinformatics tools for analysing the data. We developed a simple to execute pipeline 
to analyse our RACE-Seq data, but some knowledge of Unix is required to execute the 
pipeline. The stand-alone pre-filtering command line code allows simple copy paste 
utility.  
 
Moving forward, the novel insights regarding an on-target MOA for multiple guide 
strands derived from a single siRNA, Dicer substrate siRNA or shRNA needs to be 
investigated further.  
RACE-Seq analysis may prove to be a useful tool for looking back at previous 
investigations of siRNA or shRNA design strategies. For example, overlaying RACE-
Seq to an investigation of shRNA loop structure or sequence selection or positioning 
of a mismatch in the stem region has the potential to further enhance our understanding 
of Dicer and AGO2 processing preferences at the biological level. RACE-Seq also has 
the potential to be integrated into the design and validation of therapeutic oligos pre-
and post clinical trial development.   
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